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Abstract 
Antigen presentation and recognition are key processes of the immune system 
necessary to initiate the adaptive immune response. Longstanding goals of these 
fields have been to understand the molecular mechanism of MHC II-peptide 
binding, the way in which dysregulation of this process can lead to disease, and 
determining how γδTCRs recognize their ligands. To examine some of these 
outstanding questions, I designed photocleavable peptides that could bind HLA-
DR1 and could be used to facilitate peptide exchange. I also performed studies to 
understand whether peptide exchange on HLA-DR1 can be affected by glycation 
modifications, which occur in hyperglycemic conditions such as diabetes. I 
observed that while glycation modifications on HLA-DR1 did not affect peptide 
exchange, these modifications decreased the catalytic effect of HLA-DM on this 
reaction, which could affect antigen presentation in diabetic patients. For studies 
on antigen recognition by γδTCRs, I focused on γδNKT cells, a subset of γδT cells 
known to play a role during Listeria infection. I used four different variants of the 
γδNKT TCR to study the restrictions on Vγ junctional region usage by this TCR for 
ligand recognition. I found that all the TCR variants I examined could recognize 
cells infected with Listeria, indicating that this TCR is not restricted by γ-chain 
usage in order to recognize ligand. My research generated reagents that could 
serve in future studies of HLA-DR1 peptide binding and contributed to 
understanding the effect of hyperglycemic conditions on antigen presentation, as 
well as provided greater understanding of γδTCR restriction for ligand recognition.  
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Preface 
The work presented in this thesis is ready for publication, submitted to a journal, 
or already published. In Chapter II, I present work done in most part by myself, and 
it has been recently accepted for publication in PlosOne under the title: “The N-
terminal region of photocleavable peptides that bind HLA-DR1 determines the 
kinetics of fragment release”. In Chapter III, I presented work done in collaboration 
with Laura Santambrogio’s laboratory and it has been submitted to iScience. In 
Chapter IV, I presented work done in most part by myself. This work is ready for 
submission. Appendix I, shows the data I generated for control experiments done 
for a collaboration with a former member of the laboratory, Corrie Painter.  This 
work has been published in PNAS: Painter CA, Negroni MP, Kellersberger KA, 
Zavala-Ruiz Z, Evans JE, Stern LJ. (2011) Conformational lability in the class II 
MHC 310 helix and adjacent extended strand dictated HLA-DM susceptibility and 
peptide exchange. Proc Natl Acad Sci. Nov 29;108(48):19329-34. 
Each of these chapters and appendix have a brief author contributions section at 
the beginning to highlight my contributions, and a introduction specific for each 
research problem addressed.  
 
 
 19 
 
CHAPTER I 
Introduction 
Overview of the immune system 
The function of the immune system is to protect host organisms from invading 
infectious agents and the damage they cause. The response generated against a 
foreign pathogen is called the immune response, which is comprised of four main 
tasks. The first is immunological recognition, which involves detection of the 
infectious agent by several different types of immune cells. These include cells of 
the innate immune system, which provide a rapid response, and lymphocytes of 
the adaptive immune system, which provide a later but more precise and effective 
response. The second task is to control and clear the infection. For this purpose, 
several immune effector functions come into play, some of which are performed 
by proteins and some by cells. During this process of controlling and clearing the 
infection, the third task becomes essential, which is to self-regulate the magnitude 
of the immune response in order to avoid damage to the body. Failure to perform 
this last task can result in autoimmune diseases or allergic responses. The fourth 
task is to develop immunological memory in order to avoid recurring disease 
caused by the same pathogen. This means that once an organism has been 
exposed to an infectious agent, it can build an immediate and stronger immune 
response during subsequent exposures to the same agent (1).   
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Innate immune system 
Innate immunity is an evolutionary ancient defense mechanism present in 
different forms in all plants and animals. The innate immune system is the first line 
of defense that protects the host from pathogens that cross the physical and 
chemical barriers of the epithelial surface. When microorganisms enter the host 
and begin to replicate in the host tissues, these pathogens are immediately 
recognized and phagocytosed by macrophages that reside in these tissues. This 
response is followed by recruitment of a second family of phagocytic cells called 
neutrophils, which reside in the blood. In the case of intracellular pathogens, 
natural killer (NK) cells, which are cytotoxic lymphocytes, play an important role in 
recognizing infected cells through a system of activating and inhibitory receptors 
that induce apoptosis of the infected cells. Together, macrophages, neutrophils 
and NK cells play a key role in the innate immune system’s recognition and 
destruction of many pathogens, thereby preventing an established infection (1).  
In order to initiate the immune response, macrophages and neutrophils 
recognize pathogens using different receptors that can distinguish pathogen 
molecules from self-molecules present on the surface of the host cells. To allow 
such discrimination, innate immune cells take advantage of the fact that 
microorganisms bear repeating patterns of molecular structure, known as 
pathogen-associated molecular patterns (PAMPs) which they specifically 
recognize by several germline-encoded pattern recognition receptors (PRRs). 
Among these receptors, there are phagocytic receptors, which once they 
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recognize a PAMP induce phagocytosis followed by death of the pathogen inside 
the phagocyte via acidification of the phagosome, by fusion of the phagosome with 
lysosomes containing enzymes, proteins and peptides that can attack the microbe, 
or by activating different cellular pathways that produce oxygen reactive species 
and antimicrobial peptides that are toxic to the engulfed microorganism.  
Other types of PRRs include signaling receptors that upon recognition of their 
ligand trigger different signaling pathways that lead to production of pro-
inflammatory cytokines and chemokines. These receptors include the toll-like 
receptors (TLRs), C-type lectin receptors (CLRs), the nucleotide oligomerization 
domain (NOD)-like receptors (NLRs) and RIG-I-like receptors (RLRs) (2,3).  TLRs 
are the most studied of all these receptors and are comprised of a family of 
evolutionary conserved type-1 transmembrane glycoproteins. Some TLRs are 
localized to the cell surface and some to the endosomal compartment membrane, 
allowing them to recognize ligands in both the extracellular and intracellular 
compartments. There are 10 expressed TLR genes in humans, and each of them 
can recognize a distinct set of PAMPs present in most pathogenic microbes, such 
as bacterial lipopolysaccharide  (4–6) and lipoproteins present in Gram-negative 
bacteria (7,8), lipoteichoic acid  from Gram-positive bacteria (9), virus-derived 
double-stranded RNA (10), and nucleic acid from virus and bacteria (11). Other 
PAMPs, such as carbohydrate structures present in mannose, fructose and 
glucans, can be recognized by CLRs, which can either be soluble or membrane 
proteins (12,13). This family of receptors is characterized by a carbohydrate-
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binding domain that recognizes carbohydrates present in fungi, viruses and 
bacteria (14,15). In addition to triggering different signaling pathways that can 
induce pro-inflammatory cytokine production, activated CLRs can also modulate 
TLR-induced responses. Some PRR families are exclusively cytoplasmic 
receptors, such as NLRs and RLRs. The most studied NLRs, NOD1 and NOD2, 
have a caspase recruitment domain (CARD) at their N-terminus followed by a 
central NOD and C-terminal leucine-rich repeats that mediate ligand recognition. 
Both NOD1 and NOD2 recognize bacterial peptidoglycan structures (16,17). 
Similar to NOD1 and NOD2, RLRs also have CARDs in their N-terminal region. In 
RLRs, the CARDs are followed by a central DEAD box helicase/ATPase domain 
and a C-terminal regulatory domain that recognize viral RNA (18). NLRs and RLRs 
can activate signaling pathways that lead to increased expression of pro-
inflammatory molecules (2,3).   
The pro-inflammatory cytokines and chemokines secreted as a result of the 
induction of signaling pathways triggered by activation of PRRs on macrophages 
can initiate the process of inflammation in the tissue. The inflammatory response 
helps to combat the infection via several mechanisms. One such mechanism 
causes changes in local blood vessels including vasodilation, increase in 
permeability, and induction of cell adhesion molecule expression by the endothelial 
cells lining the blood vessels, thus favoring the recruitment of cells initiated by 
chemokines and the extravasation of those cells into the tissue. Initially, 
neutrophils are recruited in large numbers and are the principal cells to engulf and 
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kill the invading microorganism. Then, monocytes are recruited to the inflamed 
tissue and can differentiate into macrophages or immature dendritic cells 
depending on the precise signals received by the environment. Immature dendritic 
cells are a third type of phagocytic cell, but their primary role is not to clear the 
invading microorganism, but to activate a particular group of cells that belong to 
the adaptive immune system, T lymphocytes. Later in the inflammatory response, 
a different type of innate cell called eosinophils are also recruited to the inflamed 
tissue and contribute to destruction of the pathogen (1).  
The innate immune system also has an important non-cellular component 
called the complement system. The complement system is composed of more than 
30 plasma proteins. Some of these proteins act as PRRs and once they recognize 
a PAMP they activate another complement protein, which are synthesized as 
inactive pro-enzymes and become enzymatically active after proteolytic cleavage, 
gaining protease activity. In this way, after the first complement protein becomes 
activated, a cascade of proteolysis is initiated in which complement proteins are 
activated sequentially, each becoming and active protease that cleaves and 
activates many molecules of the next protein in the pathway. Finally, an effector 
complement component is activated, which aids the removal of the pathogen, by 
either assisting phagocytosis by macrophages, promoting inflammation or by 
disrupting the pathogen cell membrane causing cell lysis (1).  
In cases in which the innate immune response is insufficient, and the response 
is overwhelmed by the infecting agent, the adaptive immune response is initiated. 
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In such scenarios, innate immunity has an important function in delaying the 
infection process and keeping pathogen numbers in check, while the adaptive 
immune system prepares to mount a response. 
 
Adaptive immune system 
The adaptive immune response is only present in vertebrates and depends on 
the ability of adaptive immune lymphocytes to specifically recognize a particular 
pathogen and mount a stronger and more specific response, allowing for clearance 
of infections that may have evaded the innate immune system (1). There are two 
main lineages of lymphocytes that mediate the adaptive immune response, B and 
T lymphocytes (19). Both of these cell types express antigen-specific receptors 
that are the product of gene rearrangement, allowing each cell to express a 
receptor of a single specificity. On B cells, these are immunoglobulin molecules 
that can be secreted as antibodies or expressed on the cell surface as B cell 
receptors (BCRs), whereas T cell receptors (TCRs) are exclusively expressed at 
the cell surface. Both of these cell types share a common lymphoid progenitor 
located in the bone marrow, and expression of lineage-specific transcription factors 
drive differentiation of these two main lymphocyte lineages (20–22). B cells mature 
in the bone marrow, while T cell precursors migrate to the thymus for further 
differentiation, in which they can become two functionally distinct sublineages, αβT 
cells that express a TCR comprised of an α and a β chain, and γδT cells that 
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express a TCR comprised of a γ and a δ chain (23). αβT cells can further 
differentiate into two main subsets of cells, CD4+ or CD8+, depending on which co-
receptor they express. Once lymphocytes have differentiated and completed 
maturation, they enter the bloodstream and are considered mature naïve 
lymphocytes. They circulate through the peripheral lymphoid organs where, if their 
antigen receptor recognizes the corresponding antigen, an adaptive immune 
response is initiated (1,24).  
Dendritic cells (DCs) play a key role initiating the adaptive immune response 
through their role as antigen-presenting cells (APCs). They are found in an 
immature stage (immature DCs, or iDCs) in strategic sites where there is more 
exposure to the environment, such as the skin and mucosal tissues, and they can 
be recruited by macrophages to the site of infection. These cells can sample the 
environment by micropinocytosis, in which large volumes of surrounding fluid are 
engulfed, and they can also perform receptor-mediated phagocytosis of 
pathogens. Internalized pathogens are processed in endocytic compartments and 
proteolyzed into small peptides that can be loaded and presented on Class II major 
histocompatibility molecules (MHC II). MHC II proteins can then travel to the cell 
surface where an antigen-specific naïve CD4+ T cell can recognize the specific 
MHC II-peptide complex through its unique TCR. In the case of naïve CD8+ T cells, 
their TCR recognizes peptides presented in the context of MHC Class I (MHC I) 
molecules that sample different cellular compartments from MHC II. MHC I 
molecules bind peptides derived from cytosolic proteins processed by the 
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proteasome, which can include viral proteins synthesized in the cytosol of infected 
DCs (1,25). More detail about antigen presentation pathways is included in a 
subsequent section.  
In order to present antigens encountered in the periphery, iDCs need to 
become mature DCs (mDCs) and travel to local lymph nodes, where naïve 
lymphocytes reside. This process is initiated by the activation of PRRs in iDCs 
when they encounter a pathogen in the periphery. iDCs express several PRRs, 
including phagocytic receptors and signaling receptors such as TLRs. When TLRs 
become activated in iDCs, not only do they trigger the secretion of cytokines that 
mediate the innate response, but they also induce significant alterations in the 
chemokine receptors expressed by DCs. These chemokine receptors, particularly 
CCR7, recognize chemokines expressed in lymphoid tissue such as CCL21, which 
induces migration of DCs through the lymphatics and into the local lymphoid 
tissues (26,27). CCL21 recognition by CCR7 also plays an important role in the 
maturation of DCs. Ligation of CCR7 by CCL21 induces changes in DCs that 
include reducing their ability to engulf antigens by phagocytosis or 
micropinocytosis, as well as increasing expression of MHC I and MHC II to favor 
antigen presentation (28). Expression of costimulatory proteins is also increased 
on the surface of DCs, including B7.1 (CD80) and B7.2 (CD86), which interact with 
the CD28 receptor on naïve T cells. The B7/CD28 interaction is necessary for 
naïve T cells to become active if their TCR recognizes the appropriate MHC-
peptide complex on DCs (29,30). mDCs also express high levels of adhesion 
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molecules and secrete chemokines to attract naïve T cells and facilitate T cell  
entry into the lymph nodes (1,28).  
Once naïve T cells have entered the lymph node, they begin scanning with their 
unique TCRs for the corresponding MHC-peptide complex expressed on mDCs. T 
cells require three signals to be activated, to proliferate and to differentiate into 
effector T cells. The first signal is provided by TCR interaction with the MHC-
peptide complex expressed on the mDC surface. As described above, CD4+ T cells 
only recognize MHC II-peptide complexes due to the interaction of their CD4 
coreceptor with MHC II proteins, whereas CD8+ T cells only recognize MHC I-
peptide complexes because their CD8 coreceptor interacts with MHC I proteins. 
The second signal is provided by the interaction of costimulatory proteins 
expressed on mDCs with costimulatory receptors on naïve T cells (29). Together, 
these two signals orchestrate the secretion of IL-2 and the expression of an IL-2 
receptor subunit that increases the affinity of this receptor for its ligand. IL-2 
induces T cell proliferation, allowing for expansion of the specific T cell clone(s) 
able to recognize the antigen presented by the mDC (29–32).  
The third signal is supplied by the environment, specifically by the APCs, and 
is provided by the cytokines present when a particular naïve T cell has received 
signal 1 and 2, and is thus differentiating into an effector T cell. Interaction of these 
cytokines with their prospective receptors on T cells is what determines their 
effector fate. CD4+ T cells can differentiate into T helper 1 (TH1), T helper 2 (TH2), 
T helper 17  (TH17), T follicular helper (TFH) and T regulatory (Treg) effector cells 
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(33,34). Each of these effector cells have different roles. TH1 cells produce 
cytokines such as interferon-γ (IFN-γ) that activate macrophages, enabling them 
to destroy intracellular microorganisms more efficiently (35). TH2 cells produce IL-
4, IL-5 and IL-13, which recruit and activate eosinophils, mast cells and basophils 
to help control parasitic infections. TH2 cells also induce B cells to secrete a specific 
type of antibodies that play an important role in fighting parasites (36–38). TH17 
cells produce IL-17 and play a pro-inflammatory role by activating neutrophils and 
macrophages to combat extracellular pathogens (39,40). TFH secrete IFN-γ and 
IL-4 and localize to the lymphoid B cell follicles. These effector cells play an 
important role in helping naïve B cells to survive, proliferate and become effector 
cells called plasma cells that secrete antibodies (41). These secreted antibodies 
help clear extracellular infections by several mechanisms such as neutralization, 
which involves binding to key molecules on the pathogen to block them from 
binding with their ligands; opsonization, a mechanism by which the antibody coats 
the surface of the pathogen to enhance phagocytosis by cells expressing antibody 
receptors called Fc receptors; and also, activation of the complement system 
following coating of a pathogen by antibodies, which allows opsonization or directly 
lyses microorganisms. While all CD4+ effector cells described above activate 
different immune cells to favor the immune response against a pathogen, the role 
of the Treg subpopulation is to suppress T cell responses in order to control the 
magnitude of the immune response. Treg function is also of primary importance in 
prevention of  autoimmune disease (42).   
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Unlike CD4+ naïve T cells that can differentiate into different effector cells, CD8+ 
naïve T cells differentiate into cytotoxic T cells (CTLs). These cells kill their target 
cells, which are usually virus-infected cells. CTLs require stronger costimulatory 
signaling in order to become activated effector cells than do naïve CD4+ T cells. In 
some cases, virus-infected mDCs can express sufficient costimulatory molecules 
to directly activate CD8+ T cells. However, CD8+ T cell activation most often 
requires the interaction of CD4+ effector T cells with the same APC that presents 
antigen to the CD8+ T cell. CD4+ effector T cells become activated by costimulatory 
molecules on the mDCs, which drives them to secrete IL-2 and express CD40 
ligand. CD40 ligand then interacts with CD40 on the surface of the mDCs, 
delivering an additional signal that increases the expression of costimulatory 
molecules needed for CD8+ T cell activation. IL-2 secreted by the CD4+ effector T 
cells also acts as a growth factor to promote CD8+ T cell proliferation and 
differentiation (43). 
Once naïve lymphocytes become effector cells, they express a modified cell-
adhesion molecule profile on their surface that allows them to leave the lymph 
node and travel to their specific site of action. Effector cells also differ from naïve 
cells in that they no longer need costimulation in order to be activated. Interaction 
of their antigen receptors with the corresponding ligand on their target cells is 
enough to trigger their activation and induce a response. The fact that naïve cell 
proliferation and differentiation into effector cells is a 4-5-day process is the reason 
why the primary adaptive immune response to a given pathogen usually begins 
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approximately a week after the infection starts. Most lymphocytes generated 
during the adaptive immune response will eventually die. However, a significant 
number of them will differentiate into memory cells, which can be reactivated more 
rapidly in the case of a secondary infection, thereby providing lasting protective 
immunity (1). 
As mentioned above, a naïve lymphocyte begins the process of differentiation 
into effector cells only if their antigen receptor encounters the corresponding ligand 
on the APC. Each individual lymphocyte expresses an antigen receptor with a 
different specificity due to the fact that these receptors are the products of gene 
rearrangement. According to the focus of this thesis, I will describe T cell antigen 
receptors, their structure and the gene rearrangement process that drives their 
generation, as an example of the lymphocyte receptors.  
The TCRs are formed by two chains, an α-chain paired with a β-chain, or a γ- 
chain paired with a δ-chain. The structure and gene rearrangement process that 
forms αβTCRs and γδTCRs are very similar, so I will describe the αβTCR as an 
example. Each chain is formed by two extracellular domains followed by a stalk 
segment containing a cysteine that forms the interchain disulfide bond, a 
transmembrane domain and a short cytoplasmic domain. These two extracellular 
domains are immunoglobulin domains, which have a specific folding motif in which 
antiparallel β-strands form two β-sheets held together by a disulfide bond. The N-
terminal extracellular domain is called the variable domain. This domain is formed 
by the variable region of the TCR sequence that confers antigen specificity to each 
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TCR. The second extracellular domain, closer to the transmembrane span, is 
formed by the constant region of the TCR. The three flexible loops between the β-
strands at the tip of the variable domains is where most of the variability is 
concentrated, and these α- and the β-chain loops together form the antigen-
binding site of the receptor. These three loops are called complementarity 
determining region (CDR)1, CDR2 and CDR3. The high level of variability in these 
regions can be explained by the mechanism by which TCRs are generated. 
Both chains of the TCR are generated by recombination of different genes. In 
humans, the TCRα locus contains 70-80 variable (Vα) gene segments and a 
cluster of 61 joining (Jα) gene segments followed by a single constant (Cα) gene, 
which contains the sequence for the constant domain, the stalk, the 
transmembrane and the cytosolic domains. The TCRβ locus is organized 
differently, with a cluster of 52 variable (Vβ) gene segments and two clusters of 
genes, each containing a single diversity (Dβ) gene segment, six or seven joining 
(Jβ) gene segments, and a single Cβ gene. These TCR gene segments are 
rearranged by somatic recombination during T cell development to form a 
functional TCR. In the case of the α-chain, a Vα gene segment rearranges with a 
Jα gene segment to form a functional variable region exon. In the case of the β-
chain, rearrangement of the three gene segments (Vβ, Dβ and Jβ) generates the 
functional variable exon. The newly generated functional α and β variable exons 
are transcribed and joined by splicing to the Cα or a Cβ sequence, respectively. In 
this way, an mRNA transcript is generated that will be translated into the TCRα 
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and TCRβ chain proteins, respectively. The substantial number of V genes in each 
locus explains the variability at the CDR1 and CDR2, which are both encoded by 
this gene segment. The CDR3 loop is encoded by the V(D)J recombination region, 
illustrating why this loop has the greatest level of diversity among the three loops. 
In addition, further variability is added to this loop, due to the fact that during the 
process of gene recombination, different enzymes can remove or add nucleotides, 
referred as P and N nucleotides, to the DNA corresponding to the CDR3 region, 
increasing the levels of diversity in these regions (1). In the case of the B 
lymphocytes, a similar recombination process occurs to generate diversity of 
antigen receptors, but the end-product is a larger protein with two antigen-binding 
sites.  
From this description of the mechanism by which lymphocyte receptors are 
generated, we can now understand why each T cell expresses a unique receptor 
sequence that can recognize a specific ligand presented by the APC and then 
differentiates into effector cells with different functions. It is important to note that 
in addition to DCs, macrophages and B cells can also act as APCs, since they 
express both MHC and costimulatory molecules.  
So far, I have only described conventional αβT cells, how they are activated 
and differentiate into effector cells, and the different roles they can play in the 
adaptive immune system. However, another subset of T cells exists called innate-
like T cells. These cells include γδT cells as well as two αβ T cell families, mucosal-
associated invariant T (MAIT) cells and invariant natural killer T (iNKT) cells. All 
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the innate-like lymphocytes share several characteristics. They all express a TCR 
that is the product of gene recombination, which classifies them as an adaptive 
immune lymphocyte. However, they differ from conventional T cells, in that their 
TCR repertoire is restricted and is not limited to classical MHC-peptide recognition. 
They do not require a costimulation signal from APCs to be activated; instead, they 
are endowed with an activated phenotype that allows them to respond early in the 
immune response, similarly to innate immune cells (44). Each of these innate-like 
T cells has been described as having a specific ligand and function in the immune 
system. 
MAIT cells, as indicated by their name, are localized mainly to the mucosal 
tissue. They express a restricted TCR formed by a Vα1-2Jα33/12/20, which pairs 
with a more diverse array of β-chains, but with bias towards Vβ6/20. Their TCR 
recognizes MHC I-related protein (MR1), which is ubiquitously expressed in all 
cells. MR1 is expressed in the endoplasmic reticulum (ER), where it is retained 
due to incomplete folding. It is only in the presence of its ligand that MR1 can fully 
fold and traffick to the cell surface through the secretory pathway (45). MR1 
presents small-molecule precursors, derived from microbial biosynthesis of 
riboflavin (46,47), allowing MAIT cells to recognize and kill microbially infected cells 
(48). 
iNKT cells, so named due to the expression of cell markers characteristic of NK 
cells, express the transcription factor promyelocytic leukemia zinc-finger (PLZF), 
which drives their phenotype. They are characterized by expression of a restricted 
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TCR formed by Vα24Jα18 paired almost exclusively with a Vβ11 chain, which 
recognizes the MHC I-like molecule CD1d, shown to bind self and foreign lipids. 
CD1d is expressed in the ER, where it binds self-lipids that help stabilize its protein 
structure. Then, CD1d trafficks to the cell membrane to be internalized in early and 
late endosomes where it can exchange lipid for self or foreign lipids (49). The lipids 
that can be recognized by iNKT TCRs are either microbially-derived and thus not 
found in mammals, or they are self-lipids that are usually only synthesized under 
inflammatory conditions. iNKT activation with CD1d bound to self-lipids is 
important in cases in which the target cell is not infected by a pathogen, such as 
in cancer, autoimmune diseases or in viral infections. Activation of iNKT cells 
requires the TCR signal as well as a cytokine signal, such as IL-12 binding to the 
IL-12 receptor highly expressed on iNKT cells. Depending on the mechanism of 
activation, iNKT cells can have different effector functions including those of  TH1, 
TH2 or TH17 cells (50).  
The third group of innate-like lymphocytes, γδT cells, represents a small subset 
of the total T cell population. In adult human peripheral blood, they constitute 
between 0.5-16% of total T cells (51) and in adult mice, they make up 1-4% of total 
T cells in the thymus and secondary lymphoid organs. However, they are more 
numerous in some mucosal tissues that become populated by these cells during 
specific times of embryonic development (52–55). γδT cells are the first T cells to 
be generated in the fetal thymus, before αβT cells are differentiated. They undergo 
programmed rearrangement of distinct sets of TCR V(D)J segments at different 
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time points during fetal development, causing temporal waves of developing 
thymocytes that express different invariant γδTCRs (56,57). In the fetal thymus, 
enzymes that catalyze the addition and removal of nucleotides during V(D)J 
recombination are not yet expressed,  thereby explaining the canonical junctional 
sequences, also called germline sequences, observed in these early γδTCRs. 
TCR engagement, signal strength, and the temporal and cellular context during 
intrathymic development of the γδT cells is likely to determine the set of chemokine 
receptors expressed in each cell, which drives γδT cell tropism for specific organs 
and also induces the expression of certain transcription factors that affect their 
effector function in the periphery. For example, in mouse, between embryonic days 
12 and 16, there is a wave of γδT cells that express the Vγ5Vδ1 TCR, which then 
interacts with thymic epithelial cells and triggers the expression of skin homing 
receptors and the activation of transcription factors such as T-bet, conferring TH1-
like effector function to these cells (58,59). These skin-associated γδT cells are 
known as dendritic epidermal T cells (DETCs). Following this wave, on day 14 of 
embryonic development until birth, a set of γδT cells expressing a Vγ6Vδ1 is 
generated. Lack of TCR engagement in these cells leads to acquisition of TH17-like 
properties, under the control of the transcription factor retinoic acid receptor-
related orphan receptor (RORγt) (60–62). Finally, on day 18 of embryonic 
development and onwards, a last wave of cells expressing a Vγ1Vδ6.3 TCR 
interacts with thymic hematopoietic cells, and this interaction in conjunction with 
TCR engagement upregulates the expression of PLZF (63,64). These Vγ1Vδ6.3 T 
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cells home to liver and spleen and share similarities with iNKT cells with regard to 
cell markers and cytokine production upon activation (63,65). The development of 
γδT cells with invariant TCRs that home to specific tissues allows large numbers 
of T cells to be rapidly activated without the need for clonal expansion, which would 
cause a delay in the response.  
γδT cells can also be generated postnatally, in which case their TCRs are 
formed by various Vγs and Vδs combinations and display greater CDR3 diversity 
than fetal-derived γδT cells. These postnatally-generated γδT cells are found in all 
secondary lymphoid organs as well as beneath the epithelium or mucosal surfaces 
of several tissues such as small intestine and lung (52,66).  
γδT cells are not MHC-peptide-restricted, and their TCRs can recognize ligands 
of a different nature. Some of the few identified γδTCR ligands are the mouse T10 
and T22 non-classical MHC molecules recognized by G8 and KN6 TCRs (67,68), 
the herpes simplex virus glycoprotein gI (69), the MHC II proteins IEbks and IAd 
recognized by the LBK5 and LKD1 TCR clones, respectively, in a peptide-
independent manner (70,71), and the CD1d molecule that presents cardiolipin 
(72). The CD1d-lipid complex contains the only known ligand shared by mice and 
human γδ T cells. In humans, γδTCR clones that bind to CD1d-sulfatide and CD1d-
αGalCer have been identified (73,74). Other γδTCR ligands found in humans are 
phosphoantigens, which are recognized by the abundant Vγ9Vδ2 T cells in blood 
(75–78), ATP synthase and apolipoprotein A-1 recognized by the G115 TCR clone 
(79), and the endothelial protein C receptor (EPCR) recognized by the LES TCR 
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clone (80). Most of these ligands are self-ligands, which are increased in their 
expression during infection and/or cellular dysregulation or are recognized under 
specific pathogenic conditions. That is, T10 and T22 are expressed only in 
activated lymphocytes (81), cardiolipin presented by CD1d is a lipid present in 
gram-negative bacteria and is thus presented during infection, phosphoantigens 
can be produced endogenously and accumulate intracellularly during 
tumorigenesis or can be produced by microbes that infect the cells, and EPCR is 
only recognized by the γδTCR in CMV-infected cells or transformed cell lines.  
It is important to note that none of the ligands described above have been 
shown to be a ligand for fetal-derived γδ T cells. Identifying the ligands for these 
cells will help understand several unresolved questions about γδ T cells. Such 
information could help in studying their γδ T cell intrathymic development and how 
the presence of their ligands and engagement of their TCRs affects their 
development and effector function. Identifying γδ ligands will also help to 
understand if localization of γδ T cells with a specific TCR depends on the 
presence of their ligand in the tissue.  
 
Antigen presentation pathways 
Antigen presentation is the process by which different cells generate peptides 
from proteins present in their major subcellular compartments, where pathogens 
can be hidden, after which they are bound to MHC proteins that travel to the cell 
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surface to be recognized by a specific TCR. As mentioned in a previous section, 
there are two main classes of MHC proteins, Class I and Class II, that are 
recognized by the TCR expressed on CD8+ and CD4+ T cells respectively. The 
MHC I proteins consist of one heavy chain called the α-chain, which is non-
covalently associated with a smaller chain, β2-microglobulin (β2m). The MHC II 
proteins are formed by an α- and a β-chain, both of which have a transmembrane 
domain. The expression pattern of these proteins is correlated with the effector 
function of the T cells that recognize them. Since CD8+ T cells have cytotoxic 
effector function and play an important role in the immune response to viral 
infections, MHC I proteins are expressed in almost every nucleated cell presenting 
peptides from the cytosolic compartment, where viral proteins are synthesized. 
CD4+ T cells, instead, can display different helper effector functions and are 
generally activated by dendritic cells. CD4+ T cells then help B cells and 
macrophages to initiate their responses (82). These three subsets of APCs 
express MHC II and present peptides predominantly from endosomal 
compartments. It is important to note that for an adaptive immune response to be 
generated, pathogens cannot evade antigen presentation pathways (1).  
The MHC proteins have two major properties that make it difficult for pathogens 
to evade presentation of foreign peptides. One is that MHC proteins are polygenic, 
so that each individual expresses several different MHC I and MHC II with different 
peptide-binding specificities. The second property is that MHCs are highly 
polymorphic, so most individuals will be heterozygous for the genes encoding MHC 
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I and MHC II, which have a codominant expression. Together, these two properties 
ensure the expression of several different MHC proteins in the cells increasing the 
repertoire of MHC-peptide complexes that can be presented to T cells.  
In humans, the MHC gene locus is located on chromosome 6, and the MHC 
genes are called human leukocyte antigens (HLA). The HLA loci can be separated 
into different regions. The Class I region contains three classical MHC I α-chain 
genes called HLA-A, -B and -C, and three non-classical Class I, HLA-E, F, and -
G, which have limited polymorphism and restricted tissue expression. The Class II 
region contains the α- and β-chain genes that encode the three classical MHC II 
proteins HLA-DR, -DP and -DQ, and two pairs of non-classical Class II α- and the 
β-chain genes called HLA-DM (DM) and HLA-DO. The HLA-DR α-chain is 
invariant, while some degree of polymorphism exists in the α-chains of HLA-DP 
and HLA-DQ, with HLA-DQ being the most polymorphic. There is also a Class III 
region located between the Class I and the Class II regions, which encodes no 
known MHC I- or MHC II-like genes. Instead, it contains some complement factor 
genes, cytokine genes and many other genes with no obvious relationship to 
immune function or inflammation (82,83).  
Antigen presentation by MHC I 
MHC I molecules present peptides derived from cytosolic proteins that are 
degraded by the proteasome. In healthy cells, these proteins are self-proteins that 
generate MHC I-peptide complexes that tolerize CD8+ T cells. However, if the cell 
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expresses mutant sequences during tumorigenesis, viral genes during infection, 
or foreign polymorphic genes from a transplant, then the antigenic peptides 
originating from such proteins are added to the peptidome presented by MHC I 
and can be recognized by CD8+ T cells that can then destroy the target cells. This 
pathway of generating peptides from cytosolic proteins and loading them onto 
MHC I is initiated by proteasome-mediated protein degradation into peptide 
fragments (84,85). These fragments can be further trimmed or completely 
destroyed by cytosolic peptidases, but those that remain are translocated to the 
ER through a peptide transporter called transporter associated with antigen 
processing (TAP). TAP is embedded in the ER membrane and is the core of the 
peptide-loading complex that includes a chaperone called tapasin, empty MHC I 
molecules with no peptide in their peptide-binding groove, and two common 
chaperones, calreticulin and the protein disulfide isomerase ERp57 (86). TAP 
translocates peptides that can bind to the empty MHC I, while tapasin maintains 
the empty MHC I in the peptide-receptive conformation and promotes binding of 
peptides with a slow off-rate, thereby helping to define the repertoire of peptides 
presented by MHC I (87). In this reaction, the MHC I molecules test the binding of 
many peptides until a proper peptide, with a low off-rate, is bound (88). Peptides 
that are too long to fit into the MHC I peptide-binding groove can be trimmed by 
ER-resident aminopeptidases, ERAP 1 and ERAP 2 (89,90), before binding to an 
MHC I present either in the peptide-loading complex or associated with another 
tapasin look-alike chaperone in the ER called TAPBPR. Like tapasin, TAPBPR can 
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also have a role in defining the peptide repertoire presented by MHC I (91). Finally, 
the peptides that bind to form the MHC I-peptide complex are those that are of the 
correct length and have escaped further hydrolysis, which would render them too 
short to stabilize the MHC I molecule (92,93). Once a peptide binds to MHC I with 
a low off-rate, it stabilizes the structure of the MHC I, which is then released from 
the peptide-loading complex and from ER quality control systems for transport to 
the cell surface, where the MHC I-peptide complex can be recognized by CD8+ T 
cells (94). This system of low off-rate peptide selection may help prevent peptide 
release and exchange on the cell surface (95) (Figure 1.1A, filled arrows).   
Another well-studied mechanism of peptide loading on MHC I is called cross-
presentation. Through this process, APCs can present peptides on MHC I that are 
derived from phagosomal or endocytic compartments (96). In order for this to 
occur, the antigens in the phagosomal compartment need to be transferred to the 
cytosol for proteasomal degradation and then can follow the pathway described 
above, in which they are loaded onto MHC I in the ER (97). In another cross-
presentation mechanism, some antigens are degraded in the lysosomal 
compartments and loaded onto recycling MHC I molecules in a pathway similar to 
the MHC II pathway (98,99), which is described below (Figure 1.1A, dashed 
arrows).  
The peptides that bind MHC I do so via the peptide-binding groove of the MHC 
I protein, distant from the transmembrane domain. The MHC I structure is 
comprised of an α-chain called the heavy chain associated with β2m. The heavy 
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chain contains the α1 and α2 domains that form the peptide-binding region, and 
the α3 domain that has an Ig-like structure and lies beneath the peptide-binding 
region. Adjacent to the α3 domain and below the α1 domain is where the β2m 
molecule is located. The peptide-binding region consists of a β-sheet topped by 
two semiparallel α-helices separate enough to accommodate the peptide between 
them (Figure 1.1B) (100). Peptides in the MHC I-binding region adopt an elongated 
conformation, and their length is limited by the size of the cleft to 8 to 10 amino 
acids long (Figure 1.1C) (101). However, some MHC I complexes with longer 
peptides have been described, in which the peptide bulges out of the peptide-
binding groove in the middle (102).   
The major interactions between peptides and MHC I are between the free N- 
and C-termini of the peptide with conserved residues among different MHC I alleles 
located at the ends of the MHC I-binding groove. These conserved residues 
include a cluster of tyrosines that form hydrogen bonds with the amino-terminus of 
the bound peptide, and a cluster of residues that forms hydrogen bonds and ionic 
interactions with the peptide carboxy-terminus. These interactions allow for a 
broad peptide-binding specificity for MHC I proteins. In addition, the major sites of 
polymorphism among MHC I alleles are found at certain sites of the peptide-
binding groove, resulting in binding of different peptide motifs. In general, the 
different peptide motifs contain two anchor positions occupied by a fixed residue 
or by one of a few residues with closely-related side chains. Those anchor residues 
interact with pockets in the peptide-binding groove that are lined by polymorphic 
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amino acids. In general, most peptides that bind MHC I have a hydrophobic anchor 
residue at the C-terminus, while the second anchor residue position is more 
variable. While residues at other non-anchor positions can be relatively variable, 
some positions seem to be  
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Figure 1.1: MHC I antigen presentation pathways and MHC I structure. (A) 
The classical presentation pathway is shown using arrows with solid lines. In this 
pathway, proteins synthesized in the cytosol are degraded by the proteasome into 
peptides that enter the endoplasmic reticulum (ER) through TAP. Once in the ER, 
these peptides can be loaded onto the MHC I, assisted by the peptide-loading 
complex or can be further trimmed by ERAP 1 or ERAP 2. MHC I in the ER can 
also be associated with TAPBPR until it binds a peptide with a low off-rate. Stable 
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MHC I-peptide complexes traffic to the membrane through the Golgi. Cross-
presentation pathways are shown using arrows with dashed lines. A pathogen that 
is internalized through phagocytosis can be transported to the cytosol, where it is 
degraded by the proteasome. Peptides generated from proteolysis of the pathogen 
can be transported into the ER by TAP and follow the same path as peptides 
derived from cytosolic proteins (described above). The other cross-presentation 
mechanism shown here involves recycling MHC I that can be loaded with 
pathogen-derived antigenic peptides originating in lysosomal compartments. (B) 
MHC I (HLA-A2) structure shown as a cartoon. The heavy chain is shown in 
different tones of blue where α1 is cyan, α2 is dark blue and α3 is lavender. β2m is 
shown in green, and the peptide is represented as sticks in yellow with oxygen 
atoms shown in red and nitrogen atoms in blue. (C) Top view of the MHC I peptide-
binding groove surface shown in grey. The peptide is shown in yellow with oxygen 
atoms shown in red and nitrogen atoms in blue. (PDB: 2VLL). 
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preferentially occupied by a particular amino acid or by one of a few related 
amino acids, and other residues appear to abrogate peptide binding (103).  
Antigen presentation by MHC II 
The protein structure of MHC II is very similar to that of MHC I, as it is also a 
membrane protein that is folded in the ER and presents peptides on the cell 
surface. However, differently from MHC I, MHC II is formed by an α- and a β-chain, 
is loaded with peptides in endosomal compartments, and presents peptides to 
CD4+ T cells.  
The MHC II antigen presentation pathway is initiated by expression and folding 
of the α- and β-chains in the ER. This heterodimer assembles with a third protein, 
the invariant chain (Ii) (104,105). The Ii occupies the MHC II peptide-binding 
groove with a small segment called Class II-associated invariant chain peptide 
(CLIP), which acts as a low affinity pseudopeptide that helps prevent binding of 
peptides present in the ER (106). Ii also plays an important role in MHC II trafficking 
(107,108) by promoting its exit from the ER, through the Golgi into a late 
endosomal or lysosomal acidic compartment called the MHC II compartment 
(MIIC) (109,110). Once MHC II-Ii complexes enter the endosomal route, Ii is 
sequentially degraded by cysteine proteases (111), leaving a CLIP segment that 
is protected from proteases when bound to the MHC II peptide-binding groove 
(112). In the MIIC, CLIP is exchanged for antigenic peptides in a reaction catalyzed 
by a non-classical MHC II, DM (113–116) (Figure 1.2 A).  
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Figure 1.2: The MHC II antigen presentation pathway and MHC II structure. 
(A) MHC II is assembled in the endoplasmic reticulum (ER) together with the 
invariant chain (Ii) that occupies the MHC II peptide-binding groove. This complex 
traffics through the Golgi into the MIIC compartment, where the Ii is degraded by 
proteases active at low pH. A residual fragment of Ii protein, called CLIP peptide, 
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remains bound to the MHC II peptide-binding groove. CLIP can be exchanged for 
peptides present in the MIIC in a process catalyzed by a non-classical MHC II 
protein, HLA-DM (DM). Peptides in the MIIC compartments are derived from 
extracellular components internalized by endocytosis and degraded by different 
proteases in late endosomes, or from autophagosomes with peptides derived from 
cytosolic or nuclear proteins. (B) Structure of MHC II (HLA-DR1) represented as a 
cartoon. The α-chain is shown in green and the β-chain in orange. The peptide is 
represented as sticks in yellow with nitrogen and oxygen atoms in blue and red 
respectively. The α1 and β1 domain form the peptide-binding groove, while the α2 
and β2 domains are Ig-like domains on the bottom of the peptide-binding domain. 
(C) Top view of the MHC II peptide-binding groove surface shown in grey. The 
peptide is shown in yellow with nitrogen and oxygen atoms shown in blue and red 
respectively. (PDB: 1DLH). 
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As described earlier in this section, MIIC is a late endosomal compartment, and 
the peptides present here are products of protein degradation catalyzed by 
different proteases active at the low pH characteristic of those organelles. The 
source of those proteins can be extracellular pathogens or proteins that enter the 
cell through endocytosis. However, it is also possible for endosomes to have 
peptides derived from cytosolic and nuclear proteins or damaged organelles due 
to autophagy (117) (Figure 1.2 A). Different forms of autophagy have been 
described, including macroautophagy or canonical autophagy, in which proteins, 
protein aggregates and nuclear material, as well as entire organelles, are 
surrounded by a double membrane in an LC3/ubiquitin-dependent manner to form 
an autophagosome. This autophagosome can fuse with late endosomes or 
lysosomes, where its contents are degraded (117–119). Macroautophagy occurs 
in all cells, but it increases under cellular stress conditions, such as starvation. The 
other forms of autophagy, microautophagy and chaperone-mediated autophagy, 
do not have a clear function in the MHC II antigen presentation pathway.  
The peptides that bind to MHC II interact with a peptide-binding groove located 
on top of two Ig-like domains. The structure of MHC II resembles the structure of 
MHC I, but is formed by two chains, α and β, of similar size with a transmembrane 
domain and a short cytoplasmic domain. Each α- and β- chain forms one of the Ig-
like domains located closer to the membrane, and each of these domains is called 
α2 and β2, respectively. On top of those Ig-like domains, both chains interact to 
form the peptide-binding region with the α1 and β1 domains. This region is formed 
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by a β-sheet on the bottom and two semiparallel α-helices on top that 
accommodate the peptide between them (120), similar to the peptide-binding 
region of MHC I (Figure 1.2 B). However, the peptide-binding groove of MHC II is 
open at both ends, allowing longer peptides to bind and extend out of the main 
groove (121) (Figure 1.2 C).  
Peptides bound to MHC II can be approximately 13-20 amino acids long 
(122,123) and adopt an elongated type II polyproline conformation (120,124), 
where some amino acid side chains are solvent-exposed, as potential TCR 
contacts, and some face the peptide-binding groove (120,125). The canonical 
conformation of peptides bound to MHC II seems to be maintained by an extensive 
hydrogen bond network between the peptide backbone and conserved MHC II 
residues (120,124) (Figure 1.3 A). Another type of interaction involves the peptide 
side chains and pockets present in the MHC II peptide-binding groove, which are 
lined by MHC II polymorphic residues. In different alleles, these pockets can have 
different shapes and charges, resulting in different peptide-binding motifs (126). 
Four pockets exist in MHC II proteins, P1, P4, P6 and P9 (120,124,126–128), 
which interact with the peptide anchor residues. The residues that occupy the 
peptide-binding groove from P1 to P9 are considered the core of the peptide.  
The peptide-binding motif of HLA-DRB1 01:01 (DR1), which is the focus of one 
of the research projects presented in this thesis, has been extensively studied. 
Several crystal structures of DR1 with a mix of endogenous peptides or with 
specific peptides, as well as sequencing studies of peptides bound to DR1, 
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revealed the side chain preferences of DR1 at different peptide positions (Figure 
1.3 B). The P1 pocket is a large hydrophobic pocket that accommodates bulky 
hydrophobic residues, preferably Phe, Tyr, Trp, Leu and Ile (120,121). The 
interaction of the peptide side chain with P1 is the major determinant for DR1 
peptide binding (129,130). The P4 pocket is large and shallow and prefers large 
aliphatic side chains like Met, Leu or Val. Conversely, residues with a positive 
charge are disadvantageous at this position, possibly due to unfavorable 
electrostatic interactions with Arg at β71. The P6 pocket is a small shallow pocket 
that can only fit small residues such as Ala and Gly. The last pocket, P9, is a small 
hydrophobic pocket that shows preference for hydrophobic residues such as Leu, 
Val or Ala (120,124,127,128). These interactions contribute to the peptide affinity 
for DR1 in a cooperative way (131).  
The reaction of peptide binding to DR1 involves several steps and stabilizes 
the structure of DR1 (132). Several in vitro studies using the soluble DR1 
ectodomain showed that DR1 with no peptide bound (DR1 empty) is in equilibrium 
between a peptide-averse and inactive conformation that cannot bind peptide 
(DR1i), and a peptide-receptive and active conformation that can bind peptide 
(DR1a) (133,134). DR1a appears to be an unstable form that converts into DR1i 
within minutes at 37 °C (135). Conversion of DR1i into DR1a is a slow step in the 
reaction, followed by rapid binding of DR1a with free peptide, which  
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Figure 1.3: Determinants of HLA-DR1-peptide interactions. (A) Hydrogen bond 
network between the peptide backbone and conserved residues among MHC II 
proteins. View of the HLA-DR1 peptide-binding domain from the top with the 
peptide N-terminus at the left and the HLA-DR1 α-chain on top. The peptide shown 
is the well-characterized antigenic peptide HA306-318, derived from influenza virus 
hemagglutinin (129).  HLA-DR1 is shown as a cartoon in gray, with sidechains of 
the residues involved in hydrogen bonds with the peptide shown as cyan sticks. 
The peptide main chain is represented as green sticks. Nitrogen and oxygen atoms 
are shown in blue and red, respectively. The hydrogen bonds are represented as 
black dashed lines between the atoms involved in the interaction. The residues 
from HLA-DR1 that form hydrogen bonds with the peptide are labeled. (B) HLA-
DR1 pockets that determine the peptide-binding motif. The surface of HLA-DR1 is 
shown in gray, and the HA306-318 peptide is represented as green sticks with 
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nitrogen and oxygen atoms shown in blue and red, respectively. The top panel 
shows the same view of HLA-DR1 as panel A. The pockets that show preferences 
for particular amino acid side chains are circled and labeled (P1, P4, P6 and P9). 
The bottom panel shows a 90° rotation of the surface representation shown in the 
top panel, cut away to show a side view of the P1, P4, P6 and P9 pockets. (PDB 
1DLH) 
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generates an intermediate (DR1-peptide’) that slowly converts into the final DR1-
peptide complex (DR1-peptide) (134).  
The conversion of DR1i to DR1a involves conformational changes in the 
structure of this molecule. Despite the fact that multiple crystal structures have 
been solved for DR1 in complex with different peptides, there is no 3D structural 
work published for DR1 empty in either of its conformations. One reason is that 
DR1 empty is unstable and prone to aggregation (132), which makes it difficult to 
produce the high concentrations of soluble protein needed for crystallography. 
Through molecular dynamic simulation studies, a model of the DR1 empty 
conformation has been obtained (136). This simulation was done using the X-ray 
coordinates of DR1 in complex with an HIV capsid peptide, for which the peptide 
was removed before starting the simulation. Most of the changes observed in the 
structure once the peptide was removed occurred in the first 5-10 ns, and only 
smaller fluctuations occur thereafter, indicating that the molecule adopted a stable 
DR1 empty conformation during the first 10 ns of simulation. Significant 
movements were observed in the α-helices of the peptide-binding site, being the 
motion of the α50-59 region the major conformational alteration observed. This 
region is located at the N-terminal side of the peptide-binding groove and during 
this simulation, it moved to fill the amino-terminal end of the peptide-binding site, 
taking the place of a bound peptide between the P1 to P4 pockets. This 
conformation appears to be locked by the αF54 residue that occupies the P1 
pocket in the same orientation as the tyrosine of the HIV peptide that was bound 
 55 
 
to DR1 in the crystal structure used to run the simulation. The final location of the 
α50-59 region can also make most of the hydrogen bonds that a peptide would 
with DR1. This motion occurred early in the simulation and persisted through the 
entire 60 ns time course, suggesting that this adopted conformation stabilized the 
DR1 empty structure. We interpreted this DR1 empty conformation obtained from 
the molecular dynamic simulation as the DR1i conformation, since no peptide can 
bind if the peptide-binding groove is occupied. The α50-59 thus needs to move out 
of the binding site in order to become DR1a and allow a peptide to bind.  
The fact that DR1 empty is in equilibrium between DR1i and DR1a complicates 
DR1-peptide-binding kinetic studies, given that a high percentage of the soluble 
DR1 empty used for in vitro assays is in the inactive conformation (134). When the 
DR1-peptide-binding rate is measured, this is determined by the binding rate of 
DR1a to the peptide and by the rate of conversion of DR1i to DR1a. Therefore, it 
would be useful to find tools to isolate the different steps of the reaction and 
measure each of their rates independently. This would be especially useful in 
cases where DR1 mutants with different peptide-binding rates are identified, and 
it is necessary to understand whether that difference in overall rates is due to the 
rate of conversion from DR1i to DR1a or to the rate of DR1a binding to peptide.   
  
 56 
 
Structural view of TCR-MHC interactions 
In order to initiate an adaptive immune response, T cells must recognize a 
specific antigen through their TCR. Different subsets of T cells recognize different 
antigens in the context of MHC molecules. The structural determination of more 
than 50 TCR-antigen-MHC complexes has led to a better understanding of the 
mechanism of antigen recognition through the TCR.  
The αβTCR from CD8+ T cells recognizes MHC I-peptide complexes. All crystal 
structures of these ternary complexes have shown that the TCR docks above the 
MHC I peptide-binding groove in a perpendicular mode with an approximately 
diagonal orientation. The TCR Vα chain sits over the MHC I α2-helix, whereas the 
TCR Vβ chain sits on top of the α1-helix of the peptide-binding groove. The highly 
variable CDR3 loops of both TCR chains usually interact with the exposed regions 
of the peptide, while the germline-encoded CDR1 and CDR2 interact with MHC I 
(125,137) (Figure 1.4 A). The interface of the TCR and the MHC I-peptide lacks 
good shape complementarity, which explains the low affinity of the TCRs for the 
MHC I-peptide complexes they recognize (137).  
Recognition of MHC II-peptide complexes by the αβTCR in CD4+ T cells follows 
a similar pattern as is observed in CD8+ T cell αβTCR recognition of MHC I-peptide 
complexes. From the various TCR-MHC II-peptide structures solved to date, we 
have learned that the TCR also docks above the MHC II peptide-binding groove 
with a diagonal orientation, with the CDR3 loops mainly contacting the peptide and 
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the CDR1 and CDR2 forming contacts with the MHC II. The TCR Vα chain sits 
over the MHC II α-helix of the β-chain, whereas the TCR Vβ chain sits on top of 
the α-helix of the α-chain (125) (Figure 1.4 B).  
The recognition of MHC-like molecules by αβTCRs in innate-like T cells follows 
different patterns than recognition of classical MHC molecules described above. 
In the case of iNKT TCRs recognizing CD1d-presenting lipids, all known structures 
of the ternary TCR-CD1d-lipid complexes have demonstrated that the TCR docks 
at a tilted angle on top of the antigen-binding cleft over the F’ pocket of CD1d, 
located where the C-terminus of a peptide would be on a classical MHC (125). The 
TCR CDR1α and CDR3α loops contact the sugar moiety of the lipid, providing a 
possible mechanism of iNKT TCR specificity of lipid recognition. The TCR β-chain 
interactions occurred mainly through the CDR2β loop, which interacts with the F’ 
roof of CD1d (138) (Figure 1.4 C). The CDR3β loop appeared only to interact with 
the CD1d α2 domain in the structures of iNKT TCRs recognizing self-lipids (139). 
MAIT cells utilize a different recognition pattern, in which their TCRs recognizing 
MR1 bound to vitamin B-based metabolites dock centrally and orthogonally on top 
of the MR1 antigen-binding domain. The TCR Vα primarily contacts MR1 together 
with the CDR3β loop, whereas the CDR1β and CDR2β loops participated in fewer 
contacts with MR1. The CDR3α and CDR3β loops also make contacts with MAIT-
stimulatory metabolites loaded on MR1 (47,125) (Figure 1.4 D). 
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Figure 1.4: Structural determination of different αβTCRs recognizing their 
antigens. Structure of an αβTCR recognizing (A) HLA-A-peptide (PDB: 3VXR), 
(B) HLA-DR1-peptide (PDB: 4E41), (C) CD1d-lipid (PDB: 2PO6), and (D) MR1-
metabolite (PDB: 4NQC). In the top panels, ternary complexes are shown with the 
TCR and the MHCs or MHC I-like molecules represented as cartoons, and the 
antigens as yellow sticks with nitrogen and oxygen atoms in blue and red, 
respectively. The TCR α-chains are shown in red and the β-chains in blue. The 
MHC I protein is shown in white, the MHC II α-chain is shown in green and the β-
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chain in wheat, CD1d and MR1 are shown in gray, and β2m is shown in green. The 
two channels of CD1d that accommodate the long fatty acids, A’ and F’, are 
labeled. The bottom panels show the TCR footprint onto MHC molecules. The 
surface of different MHCs and MHC I-like molecules are represented in white, and 
the antigens in their pockets in gray. The MHC atoms in contact with CDR1α, 2α 
and 3α are teal, green and purple, respectively, whereas the atoms contacted by 
CDR1β, 2β and 3β are red, orange and yellow, respectively. The red and blue 
spheres indicate the centers of mass for the α and β variable domains, 
respectively. 
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In the case of γδTCRs recognizing MHC I-like molecules, there are currently 
only three deposited crystal structures of γδTCRs in complex with the 
corresponding MHC I-like molecule (Figure 1.5). The first structure to be solved 
was from a murine γδTCR clone, the G8 TCR, recognizing T22 (140), which has 
a very similar structure to classical MHC I molecules but does not bind any antigen 
in the peptide-binding groove. The G8 TCR binds T22 with a tilted angle at one 
side of the T22 cleft, making most of the contacts through the Vδ domain. The 
CDR3δ loop extends as a hairpin and binds in a cavity formed by the T22 exposed 
β-sheet platform and the α1-helix, contributing with 67% of the buried surface area 
(BSA) between the TCR and T22. The CDR1δ, CDR2δ and CDR3γ also contact 
T22 but make only small contributions to the interaction (Figure 1.5 A). In the 
crystal structure of a human Vδ1+ γδTCR recognizing CD1d presenting α-
Galactosylceramide (α-Gal-Cer), it was also observed that most of the contacts 
between the TCR and CD1d-lipid were made by the Vδ domain (Figure 1.5 B) (73). 
Differently from the TCR-T22 complex, the TCR docks orthogonally over the 
extreme end of the CD1d A’ pocket, with the TCR Vδ domain positioned over the 
CD1d α1-helix and the center of the lipid-binding groove, whereas the Vγ domain 
is located on the periphery of the α2-domain of CD1d. Most of the interactions 
between TCR and CD1d-lipid are given by the CDR1δ loop (41% of the BSA) 
contacting both α1- and α2-helices, followed by the CDR3δ loop, which extends 
as a hairpin in the antigen-binding site of CD1d. The only region of the Vγ domain 
that interacts with CD1d is the CDR3γ loop, while the rest of this domain seems to 
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favor the interaction with CD1d by helping maintain the conformation of the CDR3δ 
loop. The third structure of a γδTCR in complex with its ligand also involved a 
human Vδ1+ γδTCR recognizing CD1d, but in this complex CD1d was presenting 
a sulfatide lipid instead of α-Gal-Cer (Figure 1.5 C) (74). This is the most extreme 
case of all three available structures, where all the interactions between the TCR 
and CD1d-sulfatide are made exclusively by the Vδ domain, while the Vγ makes 
no contribution to the interaction. This TCR docks with a tilted angle above the A’ 
pocket, with the CDR3δ contacting the α1-helix and the sulfatide head group, and 
the CDR1δ and CDR2δ contacting almost exclusively the CD1d α2-domain.  
In general, the three crystal structures show that γδTCRs recognize their 
ligands through the predicted antigen-binding domain formed by the CDR loops at 
the tip of the Vδ and the Vγ domains. The three γδTCRs docked on top of the 
antigen-binding cleft of the MHC I-like protein, but each γδTCR docked at different 
sites of the cleft and at different angles, indicating that γδTCRs may not have a 
distinct docking pattern as was observed for αβTCRs. However, all three γδTCR-
ligand structures showed that γδTCRs appear to have a bias toward the Vδ domain 
over the Vγ domain for MHC I-like molecule recognition, as the CDR3δ is a key 
player in the interaction, although not always the major contact between the TCR 
and the ligand.  
The limited structural work of γδTCRs in complex with their ligands makes it 
difficult to predict a molecular mechanism of ligand recognition by these TCRs. 
Despite observing a common pattern, in which all of the three γδTCR-ligand crystal 
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structures showed a bias toward using the Vδ domain for recognition, it is still not 
known whether this will be the rule, or the exception to the rule, when more 
structural work becomes available. In addition, there is no structural work of 
γδTCRs recognizing non-MHC related ligands, so it remains unclear what drives 
the ligand restriction of these γδTCRs. As a consequence, investigating γδTCR-
ligand recognition and understanding what regions of these TCRs drive their ability 
to recognize their ligands is of key importance in the γδT cell field. This may help 
us to resolve different aspects of γδT cells, such as determining particular ligands 
recognized by different γδT cell subsets and the mode of recognition, as well as 
why these cells display a bias toward certain combinations of Vγ and Vδ chains. 
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Figure 1.5: Structural determination of different γδTCRs recognizing MHC I-
like molecules. Structure of (A) a mouse γδTCR recognizing T22 (PDB: 1YPZ), 
(B) a human γδTCR recognizing CD1d loaded with α-Gal-Cer (PDB: 4LHJ), and 
(C) a human γδTCR recognizing CD1d loaded with a sulfatide lipid (PDB: 4MNG). 
The top panels show the γδTCRs and the MHC I-like molecules represented as 
cartoons, where the TCR δ-chain and γ-chain are violet and blue, respectively, and 
the MHC I-like molecules are gray. β2m is shown in green, and the lipids are 
represented as yellow sticks with nitrogen and oxygen atoms shown in blue and 
red, respectively. The CDR loops of the TCRs are shown in different colors: 
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CDR1δ in teal, CDR2δ in green, CDR3δ in pink, CDR1γ in red, CDR2γ in orange 
and CDR3γ in yellow. The bottom panels show the surface of the MHC I-like 
molecules in gray and the CDR loops as ribbons following the same color pattern 
as in the top panel.  
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Remaining questions in antigen presentation field 
In the antigen presentation field, there are outstanding remaining questions 
related to the processes that define the peptides presented on MHC molecules 
and how γδT cells recognize their ligands.  
In this thesis I present work done studying DR1-peptide-binding kinetics. I 
designed photocleavable peptides in search of a reagent that could allow 
measuring the rate of different steps of the DR1-peptide-binding reaction 
independently. Measuring these rates can help identify DR1 residues involved in 
DR1i to DR1a conformational change, and residues that directly interact with the 
peptide. I also present work studying how peptide binding to DR1 is affected by 
posttranslational modifications during pathological conditions. In particular, I 
studied how antigen presentation by DR1 can be affected by glycosylation in a 
diabetic patient. On the antigen recognition field, I focused on γδT cells and I 
present work studying the requirements of a specific γδTCR for its antigen 
recognition.   
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CHAPTER II 
The N-terminal region of photocleavable peptides that bind HLA-
DR1 determines the kinetics of fragment release. 
The work presented in this chapter corresponds to the following manuscript 
accepted for publication at PlosOne:  
Negroni M.P. and Stern L.J. (2018). The N-terminal region of photocleavable 
peptides that bind HLA-DR1 determines the kinetics of fragment release.  
 
Author contributions 
I conducted all the work presented in this chapter except for the mass 
spectrometry experiments that were performed at the Proteomics and Mass 
Spectrometry Facility at the University of Massachusetts.  
 
Abstract 
Major Histocompatibility Complex class II (MHC II) molecules bind peptides and 
present them to receptors on CD4+ T cells as part of the immune system’s 
surveillance of pathogens and malignancy. In the absence of peptide, MHC II 
equilibrates between peptide-receptive and peptide-averse conformations. The 
conversion between these forms has been postulated to be important in regulating 
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cellular antigen presentation but has been difficult to study. In order to generate 
the MHC II molecule HLA-DR1 in the peptide-receptive form, we designed and 
tested a series of photocleavable peptides that included the UV-sensitive 3-amino-
3-(2-nitrophenyl)-propionate amino acid analog. They were intended to bind tightly 
to the HLA-DR1 MHC molecule, but to generate low-affinity fragments after UV 
exposure that would be released to yield HLA-DR1 in the peptide-receptive 
conformation. We were able to identify photocleavable peptides that bound tightly 
to HLA-DR1 and generated the peptide-receptive conformation after UV exposure. 
However, slow release of photocleaved peptide fragments from the binding site 
limited the rate of binding of an incoming labeled peptide and complicated kinetic 
measurements of the individual steps of the overall peptide binding reaction. 
Modification of the N-terminal region of the photocleavable peptide to reduce MHC 
II pocket or H-bonding interactions allowed for generation of the peptide receptive 
form immediately after UV exposure with peptide fragments neither retained within 
the site nor interfering with binding of an incoming peptide. However this was 
achieved only at the expense of a substantial reduction in overall peptide binding 
affinity, and these peptides had such weak interaction with HLA-DR1 that they 
were easily exchanged by incoming peptide without UV exposure. These results 
show that photocleavable peptides can be used to generate peptide-receptive 
HLA-DR1 and to facilitate peptide exchange in generation of specific peptide-MHC 
II complexes, but that usage of these peptides for kinetic studies can be 
constrained by slow fragment release. 
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Introduction 
Major histocompatibility complex (MHC) molecules are membrane 
glycoproteins that bind short peptides and present them at the cell surface for 
interaction with receptors on T cells. This is part of the antigen presentation 
mechanism by which the immune system recognizes and clears pathogens and 
tumors. As T cells recognize peptide antigens only when bound to MHC proteins, 
studies of the MHC-peptide interaction are important for predicting and monitoring 
T cell-mediated immune responses. For more than a decade, extensive studies 
have been dedicated to understanding how peptides bind to MHC and how T cell 
receptors recognize the MHC-peptide complexes (141,142). 
A major obstacle in the field is the instability of most MHC proteins in the 
absence of peptide. Consequently, folding in vitro in the absence of peptide is 
efficient for some particular MHC proteins (143,144), but for many MHC proteins 
appropriate in vitro folding conditions have not been established. Thus, in most 
cases MHC-peptide complexes have to be generated by exchange of pre-bound 
peptide or by de novo folding in the presence of peptide. For the exchange 
methods it often is difficult to find a peptide that binds sufficiently tightly to stabilize 
the MHC structure but sufficiently weakly so as to be exchanged easily. Moreover, 
even for MHC proteins that are stable in the absence of peptide, such as HLA-
DRB1*01:01 (DR1) (132), the focus of this study, peptide binding reactions 
proceed slowly because of most of the preparation adopts a peptide-averse 
conformation (133,135,145). To alleviate these problems, photocleavable MHC-
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binding peptides were developed (146,147). These peptides incorporated the UV-
sensitive β-amino acid 3-amino-3-(2-nitrophenyl)-propionic acid (148), or the α-
amino acid(2-nitro)-phenylglycine (146,149), in place of a conventional α-amino 
acid. After photocleavage the peptide fragments bind more weakly to the MHC 
protein than the full-length peptide and can be easily exchanged for other peptides. 
This strategy allowed generation of many different MHC-peptide complexes for 
interrogation of T cells (147,150) and for study of molecular aspects of the MHC-
peptide interaction (151,152).  
The photocleavable peptide strategy was first developed for MHC class I 
proteins (MHC I) and later generalized to MHC class II proteins (MHC II). MHC I 
proteins bind peptides of restricted length (usually 8-11 residues) and generally 
require both amino and carboxyl termini for stable binding (153–155). Thus, a 
photocleavable group located at any site in the central region of a MHC I binding 
peptide should provide peptide fragments with low affinity after photoreaction. By 
contrast, MHC II proteins interact with peptide main chain and side chain groups 
all along the length of the peptide (Figure 2.1A) (120,124,128). Moreover, short 
peptides can be bound efficiently provided that they occupy several of the peptide 
side-chain binding pockets (156,157). To date, the photocleavable peptide strategy 
had been applied to MHC II protein only in a single case, using HLA-DRB1*15:01 
(DR2b) and a peptide derived from human myelin basic protein to investigate the 
role of DM in peptide association (151). 
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We wanted to adapt the photocleavable peptide strategy for use with DR1, a 
common human MHC II protein that has been the focus of work on MHC II 
conformational changes and their relationship to peptide binding events 
(134,145,156,158–160). DR1 has different binding constraints (161) than DR2b, 
previously used for development of photocleavable MHC II binding peptides. The 
myelin basic protein sequence previously used has been shown to bind poorly to 
DR1, with IC50 ~ 700-20,000 nM depending on peptide length (130) despite 
binding tightly to DR2b (IC50 2-5 nM) (162–165). Thus, we used a different peptide 
sequence optimized to bind to DR1 as a basis for development of a photocleavable 
peptide that could be used with DR1.  
We intended to understand kinetic aspects of conformational changes that 
MHC II proteins undergo in the absence of peptide, when it is considered “empty”. 
So far, it is known that DR1 adopts peptide-receptive and peptide-averse 
conformations in reversible equilibrium (133,134,145). Only the receptive form can 
bind peptide, limiting the overall rate of the MHC II peptide binding reaction. In 
order to perform studies on the kinetics of conversion between empty forms, we 
wanted to generate DR1 in the peptide-receptive, active conformation (DR1a) 
using DR1 loaded with a photocleavable peptide. Our strategy was to expose the 
DR1-photocleavable peptide complex to UV light, so the peptide is cleaved and 
the fragments are released from the peptide-binding grove, yielding empty DR1a. 
Two important caveats should be considered for this method to work as described. 
First, the fragments must have weak binding affinity so that they do not compete 
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efficiently with incoming peptides. Second, the rate of peptide release has to be 
substantially faster than the MHC inactivation rate in order to build up a substantial 
concentration of the DR1a form. Our initial attempts to design an effective 
photocleavable peptide resulted in fragments that were released very slowly from 
the peptide binding site. We found that weakening interactions between DR1 and 
peptide allowed faster fragment release but also allowed peptide exchange even 
without photocleavage. Thus, the photocleavable peptides we designed can be a 
good tool for investigation of DR1 peptide exchange, but fragment release kinetics 
must be taken into account and can limit the efficiency of generation of peptide-
receptive DR1a. 
 
Results 
Photocleavable peptide design 
In order to design a photocleavable peptide for DR1, we used the photolabile 
amino acid analog 3-amino-3-(2-nitrophenyl)-propionyl residue (Figure 2.1A) that 
under UV exposure rearranges so that an oxygen attacks the α-carbon cleaving 
the peptide backbone. This reaction yields an amide at the end of the N-terminal 
fragment and a nitrosophenyl ketone at the start of the C-terminal fragment (Figure 
2.1B). We incorporated the 3-amino-3-(2-nitrophenyl)-propionyl group into a 
peptide designed to bind to DR1, taking into account the positions of DR1-peptide 
side chain interactions previously described (Figure 2.1A) (120,128,166). MHC II 
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proteins have four major peptide side-chain binding pockets, P1, P4, P6 and P9, 
named for the positions of the peptide side chains accommodated, counting from 
a large hydrophobic pocket (P1) that binds an aliphatic or aromatic side chain near 
the N-terminus of the peptide. In a study of the ability of peptides with different 
lengths to bind DR1 it was shown that peptides as short as four residues could still 
bind if they had side chains that interacted well with the P1 and P4 pockets (156). 
Therefore, we decided to incorporate the photocleavable group at position P4, so 
that after UV exposure the N-terminal fragment ends at P3, which we expected 
would not have sufficient interaction with DR1 to remain bound. Other important 
MHC II-peptide interactions include hydrogen bonds between the peptide 
backbone and MHC II alpha and beta chain, which are distributed along the entire 
peptide length (124,166–169). Some of these hydrogen bonds involve conserved 
glutamines and asparagines from the MHC II molecules that form rings involving 9 
to 11 atoms and help holding the peptide in a polyproline type II helix (124). The 
hydrogen bond formed between DR1 αQ9 and the amine and carboxyl group of 
the peptide residue at P4 (Figure 2.1B), forms a ring with 9 atoms. If a β-amino 
acid like 3-amino-3-(2-nitrophenyl)-propionyl residue were incorporated at the P4 
position, the ring will be formed by 10 atoms, which most likely will still 
accommodate the polyproline type II helix of the peptide. With the photocleavable 
amino acid analog thus at the P4 position, we placed at the other pocket-interacting 
positions tyrosine at P1, alanine at P6, and leucine at P9.  In each case the side 
chains of these residues are optimal for interaction with DR1 (127). At the 
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intervening residues located at P2 (Gln), P3 (Met), P7 (Leu), and P8 (Ala), where 
peptide side chains make minor contacts with DR1 (120), we included residues 
with favorable side chains (127) without potentially reactive functional groups that 
might interfere with the desired photochemistry. At position 5, where the side chain 
does not interact with DR1, we included an asparagine group to increase solubility. 
We did not include any residues flanking the key MHC-interacting P1-P9 region, 
although we did include a N-acetyl group at the N-terminus to retain hydrogen 
bonds to the αS53 main chain and βH81 side chain.  We refer to this peptide as 
Y1MxN (Figure 2.1C). 
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Figure 2.1: Photocleavable peptide design. (A) DR1-peptide interactions. View 
of DR1 peptide binding groove, shown as a light-pink surface, occupied by a 
peptide shown as yellow sticks (blue: Nitrogen atoms, red: Oxygen atoms, yellow 
spheres: peptide side chains). DR1 peptide binding groove pockets are indicated 
as P1, P4, P6 and P9. The hydrogen bonds between the peptide backbone and 
conserved MHC II residues are shown as yellow dotted lines and DR1 residues 
involve in the hydrogen bonds are represented in sticks and labeled. (B) The 
photo-reactive group, 3-amino-3-(2-nitrophenyl)-propionyl (highlighted with a black 
dashed box) is incorporated as a residue in the peptide. When peptides with this 
group are exposed to UV light, the photo-reactive group is cleaved generating two 
peptide fragments. The N-terminal fragment will have an amide group and the C-
terminal fragment will have a nitrosophenyl ketone (highlighted with a gray dashed 
box) on the site of the reaction. (C) Peptides used along this study. Peptide 
nomenclature, sequences, residue occupying the P1 pocket and N-terminal 
hydrogen bonds between the peptide and DR1 are shown.   
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We tested the ability of the Y1MxN peptide to bind to DR1 using a competition 
binding assay. DR1 was incubated with increasing concentrations of the 
photocleavable Y1MxN peptide and a constant concentration of a fluorescently-
labeled non-photocleavable peptide (HA) based on a well-studied 
immunodominant HA306-318 viral epitope from influenza virus hemagglutinin, which 
binds tightly to DR1 with Kd estimated at 13 nM (170,171). The fraction of 
fluorescent HA bound to DR1 in the presence of varying concentrations of Y1MxN 
was measured by fluorescence polarization assay (172) (Figure 2.2). The Y1MxN 
peptide was able to compete with the labeled peptide for DR1 binding, but had 
reduced affinity, with an IC50 of 323 ± 23 nM as compared to 40 nM for HA (Table 
2.1).  This IC50 value, while higher than for the HA peptide, is in the range 
commonly observed for self- and foreign peptides bound to DR1 (173), and is 
similar to that observed for a photocleavable myelin basic protein peptide binding 
to DR2b (151). The reduced affinity did not interfere with the ability to isolate DR1-
Y1MxN complex by gel filtration. 
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Figure 2.2: Y1MxN peptide can bind DR1. The ability of Y1MxN photocleavable 
peptide to bind DR1 was measured in a competition binding assay using a 
fluorescent high affinity binding peptide, HA (Ac-PRFVK*QNTLRLAT, where K* is 
lysine labeled with Alexa488). Different concentrations of Y1MxN or unlabeled HA 
were incubated for 3 days with a 100 nM DR1 and 25 nM Alexa488-labeled HA. 
Binding of the labeled peptide to DR1 was quantified by fluorescence polarization 
and the fraction of binding that was inhibited by the unlabeled peptide was 
calculated and plotted against unlabeled peptide concentration. Squares and 
circles show the mean and the error bars the standard deviation of two 
experiments done in triplicate.  
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To test whether the photocleavable Y1MxN peptide was cleaved to generate 
the expected fragments, we performed mass spectroscopy of the peptide before 
and after UV treatment. The mass spectra before UV exposure showed a major 
peak with an m/z corresponding to the intact peptide MNa+ ion. After UV exposure, 
MNa+ ions corresponding to the N-terminal or C-terminal expected fragments were 
detected (Table 2.1). 
 
Slow Y1MxN fragment release limits peptide binding to DR1 
To test the ability of the photocleavable Y1MxN peptide to generate peptide-
receptive DR1a, we compared the effect of UV treatment on DR1-Y1MxN, DR1 in 
complex with a non-photocleavable peptide HA, and peptide-free “DR1 empty”.  
For this purpose we used purified DR1-Y1MxN, DR1-HA and DR1 empty and 
exposed them to UV light at 4 °C. The UV exposure was done using a long 
wavelength UV light (365 nm) to prevent potential protein damage from short-
wavelength UV exposure. We kept the sample at 4 °C during exposure to long-
wavelength UV light, in order to stabilize the peptide-receptive DR1a form. At 
elevated temperatures the conversion of DR1 to the peptide averse conformation 
is fast (τ=8 min. at 37 °C) but at 4 °C the DR1a can be stable for several days (135). 
In this way, we can preserve the newly generated DR1a in that conformation 
avoiding conversion to the peptide-averse form.  
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After UV light exposure, we measured DR1 binding to fluorescently labeled HA 
at 37 °C using fluorescence polarization assay. We observed that DR1 empty 
binds labeled HA at the same rate before (Figure 2.3A, black trace) and after 20 
or 60 minutes of UV treatment (Figure 2.3A, blue and purple traces respectively) 
indicating that UV exposure does not modify the ability of DR1 to bind peptide. 
Similar results were shown for DR1-HA, for which binding to labeled HA behaves 
the same way for the sample not treated or treated 20 or 60 minutes with UV light 
(Figure 2.3B). We observed that DR1-HA binds labeled peptide slower than DR1 
empty due to the slow off rate of the prebound HA. In contrast to DR1 empty or 
DR1-HA, DR1-Y1MxN bound peptide more efficiently after exposure to UV light 
(Figure 2.3C). After 5 min of exposure, DR1-Y1MxN exhibited increased binding 
of labeled HA (Figure 2.3C, red trace) as compared to a non-illuminated sample 
(Figure 2.3C, black trace), with additional illumination time (15 to 60 minutes) 
leading to increase rates of binding (Figure 2.3C). Initial rates of the peptide 
binding reaction after the different UV exposure times are shown in Figure 2.3D 
and Table 2.1. The observed increase in the initial rate of peptide binding after 
illumination indicates that after UV treatment, more DR1a was present in the 
sample. 
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Figure 2.3: DR1-Y1MxN photocleavage generates DR1a. (A) 150 nM DR1 
empty was not exposed (0 minutes, black trace) or exposed to UV light for different 
periods of time (20 minutes, blue trace or 60 minutes purple trace), finishing all 
exposures simultaneously. After UV exposure, samples were mixed with 25 nM 
labeled HA and binding to DR1 was measured by fluorescence polarization. The 
concentration of labeled HA bound to DR1 is plotted vs. time. (B) Same as in panel 
A, but using DR1 bound to unlabeled HA. (C) Same as in panel A and B, but using 
DR1-Y1MxN and exposing the sample to UV light for different periods of time (5 
minutes: red trace, 15 minutes: green trace, 20 minutes: blue trace, 30 minutes: 
orange trace, and 60 minutes: purple trace) or not exposed to UV (black trace). 
Panels A-C show the mean of one representative experiment performed with 
duplicate or triplicate samples out of three independent experiments. (D) Initial 
peptide binding rates were calculated as the slope of a linear fit to the initial time 
points of the peptide binding data shown in panel A, B and C. Black bars show the 
values for DR1 empty, DR1-HA or DR1-Y1MxN binding to labeled HA without 
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being exposed to UV light (0 min.). In red, green, blue, orange and purple bars are 
shown the binding rates of DR1 empty, DR1-HA or DR1-Y1MxN to labeled HA 
after being exposed 5, 15, 20, 30 or 60 minutes to UV light respectively. Bars 
represent the mean and the error bars the standard deviation of the initial rates 
calculated from three independent experiments done with triplicate samples. 
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Peptide photocleavage is expected to be a relatively fast reaction, and it was 
surprising that the maximum peptide-binding rate for DR1-Y1MxN was not 
achieved with 5 minutes of UV treatment. Five minutes of UV treatment yielded an 
intermediate rate (Figure 2.3C and 2.3D, red trace or bar), with the maximum rate 
achieved only with 15 minutes or longer UV treatment. In order to understand why 
15 minutes or longer irradiation was needed to achieve the highest peptide binding 
rate, we considered which steps of the overall reaction pathway affect the 
accumulation of peptide-receptive, active DR1a (Figure 2.4). The reaction starts 
with DR1 in complex with photocleavable peptide which holds the protein in the 
peptide-receptive conformation (DR1-pep Figure 2.4). During UV exposure, 
photocleavage yields DR1 bound to the low affinity peptide fragments (DR1-
pepcleaved Figure 2.4), which are released to generate empty DR1a (DR1a+ pep 
fragments Figure 2.4). This form, which can bind labeled peptide, is in equilibrium 
with peptide-averse DR1 inactive form that cannot bind peptide (DR1i, Figure 2.4). 
Thus, accumulation of DR1a could be affected by many steps, including 
photocleavage of the photocleavable peptide bound to DR1, release of the 
photocleavable peptide fragments from the peptide binding groove and the 
conversion of DR1a into DR1i. We evaluated the role of these processes in 
generation of peptide-receptive DR1a to understand why extended illumination was 
necessary for maximum binding rates.  
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Figure 2.4: Generation of DR1 empty in its active conformation using a 
photocleavable peptide. DR1 is in its peptide receptive conformation when is 
bound to a peptide, in this case, a photocleavable peptide (DR1-pep). During UV 
exposure, photocleavage yields DR1 bound to two peptide fragments (DR1-
pepcleaved). These fragments can get released from the peptide binding grove 
leaving DR1 in an active peptide receptive form (DR1a + pep fragments) that can 
bind peptide. DR1a can either inactivate, producing DR1 in its inactive peptide 
averse conformation (DR1i), or it can bind an incoming peptide, in this case a 
labeled peptide (Pep-Alexa488) used to track DR1-pep formation by fluorescence 
polarization.  
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First we measured the rate of photocleavage of the Y1MxN peptide free in 
solution, or bound to DR1, to ensure that it was rapid as expected. We used mass 
spectrometry of Y1MxN free and bound samples before and after different lengths 
of UV exposure to measure the relative abundance of the ion that corresponds to 
the intact peptide (Figure 2.5). After 1 minute of UV exposure, the ion 
corresponding to the intact peptide was no longer detected in the Y1MxN free 
sample. For the Y1MxN loaded on DR1, photocleavage was slower than for the 
free peptide. After 3 minutes or 5 minutes of UV exposure, 90% and 93% of the 
peptide was cleaved, and after 10 minutes of UV treatment we could not detect 
ions corresponding to the intact peptide. This indicates that slow photocleavage of 
Y1MxN loaded on DR1 is not the reason why 15 minutes UV exposures was 
needed to achieve the maximum binding rate.  
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Figure 2.5: Y1MxN fragmentation occurs during short UV exposures.  Y1MxN 
peptide free in solution (Y1MxN Free, black) or Y1MxN loaded on DR1 (Y1MxN –
DR1, grey) were exposed to UV light for different periods of time and then each 
sample was analyzed by mass spectrometry using MALDI-TOFF. The relative 
abundance of the ion corresponding to the Y1MxN intact peptide present in each 
sample exposed 1, 3, 5, 10 and 20 minutes to UV light is plotted.   
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Next, we addressed the inactivation of DR1a, to test if inactivation during the 
photocleavage reaction was limiting the generation of peptide-receptive DR1a.   
DR1 in complex with Y1MxN peptide was exposed to UV illumination for 20 
minutes at 4 °C, and then incubated for different periods of time at 4 °C before 
addition of labeled peptide. We reasoned that if DR1a were becoming inactivated 
at 4 °C, we would observe a slower peptide binding rate after longer incubations 
at this temperature. In contrast we observed that the initial peptide binding rate of 
DR1 was not greatly affected by 15, 30 and 60 minutes of 4 °C incubation after 
irradiation (Figure 2.6A, green, red and purple respectively) compared to no 
incubation (Figure 2.6A, blue trace). Thus, under these conditions, conversion to 
an inactive form does not occur appreciably even after 60 minutes of 4 °C, 
consistent with a results from an earlier study using a different method of 
generation of peptide-receptive DR1a (135). As an additional test we performed 
the photocleavage step in the presence of labeled peptide, instead of adding 
labeled peptide after photocleavage as in previous experiments. We compared 
binding rates in these reactions to reactions where labeled peptide was added after 
photocleavage, reasoning that if DR1a were becoming inactivated at 4 °C, the 
presence of labeled peptide during irradiation would lead to additional labeled 
peptide binding. In contrast, we observed that binding rates were similar whether 
peptide was added during or after photocleavage (Figure 2.6B, compare -HA and 
+HA traces). Overall these results indicate that peptide-receptive DR1a is stable at 
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4 °C, and that inactivation during the photocleavage reaction is not likely to 
constrain generation of peptide-receptive DR1a. 
Having measured photocleavage and the inactivation kinetics, and observing 
that photocleavage is almost completed at 5 minutes of UV exposure and that 
inactivation is not detected at 4 °C, we suspected that the reason the peptide 
binding rate does not reach a maximum until 15 minutes or longer UV exposure 
was that peptide photofragments were retained in the DR1 peptide binding groove 
interfering with labeled HA binding. Because the major determinants of peptide 
binding to DR1 are side-chain binding pockets (128,156,169,174,175) and main-
chain hydrogen bonding interactions (128,167–169,176) at the N-terminal side of 
the peptide binding groove, we suspected that retention of the N-terminal 
photoproduct was responsible. Thus we designed additional photocleavable 
peptides with reduced MHC-peptide interaction sites and tested these for ability to 
generate peptide-receptive DR1a.  
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Figure 2.6: DR1a generated after photocleavage of Y1MxN is stable at 4 °C. 
(A) 150 nM DR1-Y1MxN was exposed to UV light on ice during 20 minutes and 
incubated on ice for different periods of time: not incubated (blue), 15 minutes 
(green), 30 minutes (red) and 60 minutes (pink). As a control, DR1-Y1MxN not 
exposed to UV light and kept always on ice was also tested (black trace). Then it 
was mixed with 25 nM labeled HA and binding to DR1 was measured by 
fluorescence polarization. The concentration of labeled HA bound to DR1 is plotted 
vs. time. Each data point shown in the plot is the mean of duplicate samples from 
one of two independent experiments. (B) 150 nM DR1 empty (left panel) or DR1-
Y1MxN (right panel) were not exposed (black trace) or exposed to UV light for 5 
(red and orange traces) or 20 minutes (green and blue traces) on ice. 25 nM 
labeled HA was either present during the UV exposure (“+HA” samples, orange 
and blue traces), or added after the exposure (“-HA” samples, red and green 
traces) and binding of labeled HA to DR1 was measured by fluorescence 
polarization. The concentration of labeled HA bound to DR1 is plotted versus time. 
Each data point shown in the plot is the mean of triplicate samples from one of 
three independent experiments. (C) The initial peptide binding rates were 
calculated as the slope of a linear fit to the initial time points of the peptide binding 
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data shown in panel B and plotted as a bar graph. The bars represent the mean 
and the error bars the standard deviation of the initial rates calculated from three 
independent experiments done with triplicate samples.  
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Y1MxN P1 Pocket substitution  
We attempted to promote fragment release by weakening the peptide 
interaction with the P1 pocket, which is the major determinant for peptide binding 
specificity for DR1 (and other HLA-DR1 allotypes) (156,166,175).  We replaced 
the tyrosine residue from the Y1MxN, expected to bind into the hydrophobic P1 
pocket, for a leucine (L1MxN) or a valine (V1MxN). These substitutions are 
expected to lead to weaker MHC-peptide interaction, based on previously reported 
effects of substitutions at this position in other peptides (174,177). We added a 
histidine on the N-terminal end of the peptide sequence to improve solubility and 
to allow an extra hydrogen bond with αS53N (Figure 2.1C). Both L1MxN and 
V1MxN exhibited the expected photocleavage after exposure to UV light, although 
C-terminal fragments were not detected (Table 2.1). 
We evaluated the effect of the P1 substitutions in DR1 binding affinity using the 
competition binding assay.  As expected, both L1MxN and V1MxN bound to DR1 
more weakly than did Y1MxN, with IC50 values of 4100 ± 300 nM and 5400 ± 340 
nM respectively (Figure 2.7A and Table 2.1). We used purified DR1-L1MxN and 
DR1-V1MxN complexes to test the ability of the newly designed peptides to 
generate DR1a. The DR1 complexes were exposed for 5 or 20 minutes to UV light, 
and binding to labeled HA was measured by fluorescence polarization (Figure 
2.7B). After 5 minutes of UV light treatment (Figure 2.7B left panel, light blue trace), 
DR1-L1MxN showed a binding curve that behaves the same as the binding curve 
of the complex treated 20 minutes with UV light (Figure 2.7B left panel, dark blue 
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trace). Similar results were observed for the V1MxN peptide, where labeled HA 
binding curves for the DR1-V1MxN exposed 5 or 20 minutes to UV light were 
similar to each other (Figure 2.7B right panel). In contrast to DR1-Y1MxN complex, 
which reached the maximum peptide binding rate with UV incubations of 15 
minutes or longer (Figure 2.3C), L1MxN and V1MxN were able to induce the 
fastest peptide binding rate with 5 minutes of UV treatment (Figure 2.7C and Table 
2.1). This indicates that these two peptides with weaker interaction with the DR1 
P1 pocket are cleaved, released, and yield DR1a within 5 minutes of UV treatment. 
However, we observed that DR1-L1MxN and DR1-V1MxN without UV treatment 
also had a fast peptide binding rate (Figure 2.7B, gray traces), indicating facile 
exchange of peptide even in the absence of photocleavage. The binding rate of 
DR1-L1MxN and DR1-V1MxN in the absence of irradiation (Figure 2.7C, grey 
bars) in fact was comparable to the binding rate of DR1-Y1MxN after 15 minutes 
of UV treatment (Figure 2.3D, green bar). This result shows that weakening the P1 
pocket interaction in L1MxN and V1MxN peptides made them bind so weakly to 
DR1 that even without being photocleaved, they were easily released from the 
peptide binding groove and replaced by labeled HA. Thus, by replacing the peptide 
residue that interacts with the P1 pocket, we were able to reduce photocleaved 
peptide fragment retention, however this also had the unexpected and undesired 
effect of increases spontaneous peptide exchange. 
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Figure 2.7: Photocleavable peptides with reduced interaction with DR1 P1 
pocket generate DR1a independently of UV exposure. (A) The ability of L1MxN 
and V1MxN peptides to bind DR1 was measured in a competition binding assay 
using labeled HA. Different concentrations of photocleavable peptides or 
unlabeled HA were incubated for 3 days with a 150 nM DR1 and 25 nM labeled 
HA. Binding of the labeled peptide to DR1 was quantified by fluorescence 
polarization and the fraction of binding that was inhibited by the unlabeled peptide 
was calculated and plotted against unlabeled peptide concentration. Squares, 
circles and triangles show the mean and the error bars represent the standard 
deviation of two independent experiments done with triplicate samples. (B) DR1-
L1MxN (left panel) and DR1-V1MxN (right panel) were not exposed (grey trace) or 
exposed 5 (light blue) and 20 minutes (blue trace) to UV light on ice. Then, a 150 
nM of each sample was mixed with 25 nM labeled HA and binding of the labeled 
HA to DR1 was quantified by fluorescence polarization. Concentration of the 
labeled peptide bound to DR1 is plotted against time. Each data point shown in the 
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plot is the mean of duplicate samples from one of two independent experiments. 
(C) Initial peptide binding rates were calculated as the slope of a linear fit to the 
initial time points of the peptide binding data shown in panel B and plotted as a bar 
graph. The bars represent the mean and the error bars the standard deviation of 
the initial rates calculated from two independent experiments done with duplicate 
samples.  
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Reducing Hydrogen bonds by N-terminal truncation 
Since reducing the strength of the interaction between the peptide and the DR1 
P1 pocket made the photocleavable peptide susceptible to exchange even in the 
absence of photocleavage, we explored modification of MHC-peptide hydrogen 
bonding in an effort to promote release of peptide photoproducts and facilitate UV-
driven production of peptide receptive DR1. We designed four additional 
photocleavable peptides with different capacity to form main chain hydrogen bonds 
with MHC at the N-terminal side of the peptide binding site (Figure 2.1C). For these 
peptides we switched to HA as a framework, because pocket and H-bonding 
contributions have been investigated in detail for this peptide in several studies 
(176,177). These four peptides maintained the same core sequence (position 1 to 
9) but differ in that they have sequential truncations at the N-terminal end 
preceding the residue that binds in the P1 pocket. Usually, the first two peptide 
residues preceding the P1 pocket form three main-chain hydrogen bonds with DR1 
alpha and beta chain residues (αF51, αS53 and βH81) (Figure 2.1B). The N-
terminal modifications on the different photocleavable peptides abrogate the 
formation of some or all of these hydrogen bonds (Figure 2.1C). The peptide 
photoHA can form all three bonds, Ac-photoHA cannot form the first hydrogen 
bond with αF51, Ac-photoHA1-2 cannot form the first two bonds with αF51 and 
αS53N, and photoHA1-2 peptide cannot form any of the first three hydrogen bonds 
with αF51, αS53N and βH81. We measured the binding affinity of these peptides 
in the fluorescence polarization completion assay (Figure 2.8A). Binding affinity 
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was decreased for the photocleavable peptides with reduced number of hydrogen 
bonds between their N-terminal end and DR1. The largest effect was observed 
with the photoHA1-2 peptide that shows an IC50 of 1043 ± 88 nM, followed by Ac-
photoHA’1-2 with an IC50 of 227 ± 23 nM. This result indicates that the hydrogen 
bond between the peptide and βH81 plays an important role in stabilizing the DR1-
peptide interaction consistent with previous studies that showed that peptides 
losing the hydrogen bond with βH81 had a bigger increase in their koff than when 
losing bonds with αF51 and αS53 (167–169,176,177). To test whether these 
peptides were cleaved to generate the expected fragments, we analyzed them by 
mass spectroscopy before and after UV treatment. After UV exposure, ions 
corresponding to the expected N-terminal fragments and related to the C-terminal 
fragments were detected (Table 2.1). 
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Figure 2.8: Photocleavable peptides with bigger N-terminal truncations 
generate DR1a more efficiently but independent of UV exposure. (A) The 
ability of photoHA, Ac-photoHA, Ac-photoHAΔ1-2 and photoHAΔ1-2 to bind DR1 
was measured in a competition binding assay. Different concentrations of 
photocleavable peptides or unlabeled HA were incubated for 3 days with a 150 nM 
DR1 and 25 nM labeled HA. Binding of the labeled peptide to DR1 was quantified 
by fluorescence polarization and the fraction of binding that was inhibited by the 
unlabeled peptide was calculated and plotted against unlabeled peptide 
concentration. Symbols show the mean and the error bars the standard deviation 
of three replicate samples from one representative experiment, out of two 
independent experiments. The mean IC50 from the two experiments is shown in 
table 1. (B) DR1 loaded with photoHA, Ac-photoHA, Ac-photoHAΔ1-2, photoHAΔ1-
2 or DR1 empty were not exposed (grey trace) or exposed 5 (light blue) and 20 
minutes (blue trace) to UV light on ice. Then, a 150 nM of each sample was mixed 
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with 25 nM labeled HA and binding of the labeled HA to DR1 was quantified by 
fluorescence polarization. Concentration of the labeled peptide bound to DR1 is 
plotted against time. Each data point shown in the plot is the mean of one 
representative experiment done with duplicate samples out of three independent 
experiments. (C) Initial peptide binding rates were calculated as the slope of a 
linear fit to the initial time points of the peptide binding data. The bars represent 
the mean and the error bars the standard deviation of the initial rates calculated 
from three independent experiments done with duplicate samples. 
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We evaluated the effects of photolabile peptide N-terminal truncation on the 
labeled peptide binding rate taking into consideration the particular MHC-peptide 
H-bonds disrupted by the truncations. All of the DR1 complexes with the N-terminal 
truncated photocleavable peptides showed increased binding of labeled HA after 
UV exposure (Figure 2.8B). In general, greater increases were observed for the 
shorter peptides, with initial rate of binding after both 5 and 20 minutes UV 
exposure increasing in the series Ac-photoHA < photoHA < Ac-photoHA1-2 < 
photoHA1-2 (Figure 2.8C and Table 2.1). Complexes with the two longest 
peptides, DR1-Ac-photoHA and DR1-photoHA, both showed small increases in 
labeled peptide binding rates after UV treatment. These peptides differ in that the 
Ac-photoHA cannot form the αF51 hydrogen bond. Larger increases in labeled 
peptide binding rate after 5 minutes or 20 minutes illumination were observed for 
Ac-photoHA1-2, which in addition cannot form the αS53N hydrogen bond.  Much 
larger increases in labeled peptide binding rates were observed for the photoHA1-
2 complex, which cannot form any of the αF51, αS53N, or βH81 hydrogen bonds. 
However, this complex exhibited substantial exchange of labeled peptide in the 
absence of illumination, similar to the complexes with V1MxN and L1MxN. Thus, 
N-terminal truncation of a photocleavable peptide can modulate retention of 
fragments after photocleavage, but as before optimum fragment release was 
linked to an increase in spontaneous peptide release. 
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Discussion 
We sought a photocleavable DR1-binding peptide that would generate peptide-
receptive DR1a after UV exposure. The first peptide that we designed and tested, 
Y1MxN, included the photocleavable amino acid analog 3-amino-3-(2-
nitrophenyl)-propionic acid at the P4 position to optimally disrupt MHC-peptide 
interaction. This peptide bound well to DR1 with IC50 ~300 nM, and underwent 
photocleavage with <5 minutes of long-wavelength irradiation to generate the 
expected fragments. Peptide exchange after photocleavage was much faster than 
for either peptide-free “empty” DR1 (25-fold) or for DR1 preloaded with a non-
photocleavable peptide (78-fold). Peptide exchange reactions after 15-60 minute 
UV exposures were complete within approximately ~100 min after photocleavage 
of DR1-Y1MxN, as compared to empty DR1 or preloaded DR1-HA for which 
complete exchange requires more than 24 hrs. Thus photocleaved Y1MxN 
generated DR1a that was able to bind incoming labeled peptide with a faster rate 
than DR1 empty, which is in equilibrium between DR1a and DR1i forms. For many 
applications of photocleavable peptides such as high-throughput generation of 
different peptide-MHC complexes (146,147), Y1MxN would be ideal.   
One application of the photocleavable peptides described here could be in 
generation of MHC-peptide tetramer staining reagents as previously done for MHC 
I (146,150). Tetramers of MHC-peptide complexes can be used to study their 
recognition by antigen receptors on T cells (TCRs) (147).One potential concern 
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with this approach might be that UV irradiation might cause protein damage that 
could interfere with recognition by TCRs. An advantage of the 3-amino-3-(2-
nitrophenyl)-photocleavable group used in this study is that it is cleaved by a 
relatively long wavelength (300-340 nm) irradiation (148). It was shown previously 
that MHC-I tetramers made using long-wavelength UV irradiation, as used here, 
were able to stain T cells as well as conventional MHC-peptide tetramers (146) 
indicating that the UV treatment did not damage the MHC protein or interfere with 
its ability to present peptides to the TCRs.  
We were interested in using photocleavable peptides to generate DR1 in a 
peptide-receptive form for studies of peptide binding kinetics. In initial experiments 
with Y1MxN, the rate of peptide binding depended on the length of time of UV 
exposure, despite the photocleavage reaction itself being essentially complete in 
<1 min. Further experimentation ruled out formation of non-receptive empty forms 
as a factor limiting peptide binding kinetics, and suggested that slow release of 
photogenerated peptide fragments might be responsible. To evaluate this 
possibility, we designed peptides with reduced MHC-peptide interaction.  
Substitution of the tyrosine in the key P1 pocket position by less-optimal side 
chains resulted in faster peptide binding after photocleavage as compared to 
Y1MxN, ~4.6-fold for L1MxN and ~1.8-fold for V1MxN, confirming retention of N-
terminal fragments after photocleavage as a factor limiting production of peptide-
receptive DR1. However, the P1 substituted peptides exhibited greatly increased 
rates of peptide binding in the absence of photocleavage (~36-fold for L1MxN and 
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~38-fold for V1MxN), limiting their use for controlled generation of peptide-
receptive DR1. We designed a second series of peptides with N-terminal 
truncations instead of P1 substitutions, reasoning that fragment binding after 
photocleavage could be reduced by removal of key MHC-peptide hydrogen bonds, 
as an alternative to P1 pocket substitutions. Hydrogen bonds at the N-terminal side 
of the DR1 peptide binding site have been shown in many previous studies by 
several groups to be important determinants of DR1 binding affinity (167–169,176), 
and sequential removal of these interactions indeed resulted in faster binding of 
labeled peptide after photocleavage. However, spontaneous peptide exchange in 
the absence of photocleavage also increased with sequential removal of N-
terminal hydrogen bonds, and as for the P1 substitutions, the maximal rate of 
peptide binding was observed only for a peptide that exhibited a high degree of 
spontaneous exchange. The best compromise for many applications would appear 
to be Ac-photoHA1-2, which bound peptide 1.2-fold faster after photocleavage 
than did Y1MxN, with only 4.1-fold increase in spontaneous binding. However, the 
initial rate of peptide binding after photocleavage for this peptide was substantially 
slower than for other peptides, (ex., 2.9-fold slower than DR1-photoHA1-2 and 3.7-
fold slower than L1MxN), indicating that for Ac-photoHA1-2, fragment retention still 
limited the kinetics of generation of peptide-receptive DR1. 
Our observations on the effects of weakening P1 pocket and N-terminal 
hydrogen bonding interactions are consistent with previous studies. Work done to 
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identify DR1-peptide motifs using a M13 phage library, showed a strong preference 
for big hydrophobic residues such as tyrosine, tryptophan or phenylalanine at P1 
pocket (127). Replacing the tyrosine for an alanine at the P1 pocket of viral HA 
peptide caused an increase in its IC50 value and impaired the ability of the peptide 
to induce DR1 conformational changes related to peptide binding (156). Replacing 
the tryptophan for a leucine or valine at the P1 pocket of the transplantation antigen 
HLA-A2(104-117) peptide, increased the IC50 of the peptide and increases its 
susceptibility to DM-mediated editing, indicating that the replacement weakens the 
affinity of the peptide for DR1 (174). Similarly to these previous findings, when we 
replaced the tyrosine of Y1MxN for a leucine in L1MxN, or a valine in V1MxN, we 
observed an increase in the IC50 and a faster peptide fragment release. Our 
observations of the effect of altering N-terminal hydrogen bonds also aligned with 
previous findings. Stratikos et al. used peptides based on the HA sequence and 
truncated the N-terminal end or modified the peptide sequence by adding methyl 
groups to interfere with different conserved hydrogen bonds between the peptide 
and DR1 (176). They observed that loss of hydrogen bonds involving αF51 and 
αS53N (corresponding to the first and second hydrogen bonds shown in Fig 1B) 
caused only a small increase on the peptide IC50, but the loss of the hydrogen 
bond with βH81 (corresponding to the third hydrogen bond in Fig 1B) had a 
dramatic effect (176). This hydrogen bond, between DR1 βH81 and the peptide 
carbonyl group of the residue preceding the P1, has been shown by several groups 
to be a key interaction between DR1 and the peptide. Mutation of βH81 to an 
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asparagine, caused a significant decrease in the dissociation time of pre-bound 
peptides compared to wild type DR1, indicating that the loss of a single hydrogen 
bond has a significant impact on DR1-peptide affinity (167–169,177). Consistent 
with these studies, we also observed that truncated photocleavable peptides that 
lost hydrogen bonds with αF51 and αS53N have a small increase in IC50 with 
somewhat faster release of their fragments, but dramatic effects on both IC50 and 
fragment release were observed when the βH81 hydrogen bond was removed in 
addition to loss of αF51 and αS53N hydrogen bonds. The photocleavable peptide 
with all the three hydrogen bonds removed was easily replaced by labeled HA even 
without photocleavage, indicating a substantial increase in its dissociation lifetime, 
along with 10.3-fold increase in IC50.  
Although the effect of P1 pocket and H-bonding interactions were expected 
based on previous studies, an unanticipated complication of photopeptide design 
in this system was that substitutions needed for efficient fragment release after 
photocleavage also weakened the overall DR1-peptide binding interaction to the 
point where spontaneous peptide release was observed. It is possible that a 
search of additional photocleavable peptide variants might identify one with a more 
optimal balance of peptide binding affinity sufficiently strong to prevent release in 
the absence of photocleavage with N-terminal fragment affinity sufficiently weak to 
allow for fast peptide fragment release. All of the peptides we tested had the 
photocleavable group at the P4 position, and it is possible that a full-length peptide 
with the photocleavable group at the P1 position, could generate a 2 residue N-
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terminal fragment and a C-terminal fragment that will be similar to the photoHAΔ1-
2 peptide which has a fast spontaneous release. If this were the case, the intact 
peptide will have all the key DR1 interactions and neither of the fragments will be 
retained after UV treatment. However, the photocleavable group has two features 
that may weaken peptide binding: it lacks a beta carbon, making it more rigid and 
potentially not able to adopt the right orientation for occupying the entire depth of 
the P1 pocket, and it has an additional methylene in the peptide main chain (-
amino acid), potentially altering the hydrogen bond network in the key region 
surrounding the P1 region (158). 
In the antigen presentation field, photocleavable peptides were first used by the 
Schumacher group to generate MHC I that could easily be loaded with peptides of 
interest after UV exposure (146). Several photosensitive peptides for binding to 
four different MHC I were designed and studied (147). Many peptides containing 
the photolabile 3-amino-3-(2-nitrophenyl)-propionic acid residue efficiently 
exchanged peptide after UV exposure, but many did not. Bakker et al. observed 
that some of the MHC I-peptide complexes containing photolabile groups did not 
unfold after UV exposure in the absence of exchange peptide, which is surprising 
considering that MHC I is unstable without a peptide. This may indicate that some 
of the MHC I-binding peptides carrying photolabile groups generated fragments 
that were not released after photoreaction, providing stability to the MHC I 
molecule against unfolding. However this issue was not addressed during that 
work (147). In general, photocleavable peptides have been used with MHC I 
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molecules to promote peptide binding efficiency (146,147,152,178,179), but 
neither kinetics of photoproduct release, kinetics of exchange peptide binding, nor 
rates of spontaneous release were measured in these studies. 
In the only previous report in which a photocleavable peptide was used with a 
MHC-II protein, the complex studied was DR2b (HLA-DRB1*15:01) with a peptide 
derived from human myelin basic protein (MBP85-99) with the photocleavable group 
replacing the residue at P4 position (ENPVVHFXKNIVTPR) (151). It was shown 
that after 2 minutes of UV exposure the parent peptide was almost undetectable 
while the peptide fragments could be identified and photogenerated DR2b bound 
peptide faster after 2 minutes than after 10 minutes of UV exposure. Thus in this 
case the peptide is cleaved efficiently and the fragments do not seem to interfere 
with peptide exchange. In contrast, we observed that for DR1 (HLA-DRB1*01:01), 
photocleaved peptide complexes bind peptide faster after 20 minutes than after 5 
minutes of UV exposure, and release of photocleaved fragment appears to limit 
the kinetics of peptide exchange. There are several differences between the 
system used by Grotenberg et al. 2007 (151), and the one described in this work 
that might help to explain the different behavior observed. First, the P1 pocket in 
the DR2b is not as deep as in DR1 due to substitution of Gly86 by Val (180), and 
the interaction between the valine from the MBP derived peptide and the DR2b P1 
pocket is likely to be weaker than the tyrosine from the HA derived peptides and 
the DR1 P1 pocket. Second, the P5 to P10 residues of the MBP derived peptide 
bound to DR2b are positioned higher in the groove than the corresponding HA 
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residues bound to DR1, with loss of a MHC-peptide hydrogen bond at the P5 
residue due to substitution of Arg71 by alanine. Thus both N-terminal and C-
terminal photolysis fragments of the MBP peptide would be expected to bind more 
weakly to DR2b than do the fragments of the HA peptide to DR1.  
Photocleavable peptides containing the 3-amino-3-(2-nitrophenyl)-propionyl 
residue are a powerful tool for generation of MHC proteins loaded with different 
peptides and for studying peptide sequence preferences of different MHC 
molecules. However, in the use of these reagents, we suggest that peptide 
exchange kinetics can be limited by release of photocleaved peptide products, 
even when such fragments are designed for minimal retention. We observed that 
binding of photocleaved peptide fragment did not interfere with the efficiency of 
peptide exchange, only the kinetics. Thus retention of peptide fragments would not 
be expected to interfere with use of photocleavable peptides to facilitate peptide 
loading, which has been the major application of these reagents to date. 
 
Materials and methods 
Equipment 
The equipment used for this study was Gilson preparative HPLC system, 
Shimadzu Biotech Axima TOF2 (Shimadzu Instruments), reverse HPLC (Agilent) 
and Victor X5 Multilabel plate reader (PerkinElmer, Shelton, CT). 
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Protein expression and purification 
 HLA-DR1 (DRA*01:01/DRB1*01:01) extracellular domain was expressed in 
Drosophila S2 cells  and purified as previously described by Sloan VS, et al. (181). 
For this purpose we used stable transformants of Drosophila S2 cells that express 
and secrete a soluble form of HLA-DR1, which were a gift from Dr. E. Mellins 
(Stanford University Medical College). These cells are cultured in SF900 II SFM 
media with penicillin-Steptomycin at 27 °C and are induced with 1 mM CuSO4 
when they are 8-10x106 cells/ml. After 6-7 days of induction, the supernatant is 
collected, filtered and HLA-DR1 is purified using an LB3.1 immuno-affinity column.  
Mass spectrometry 
Peptides Ac-YQMxNALAL, Ac-HLQMxNALAL, Ac-HVQMxNALAL, Ac-
PRYVKxNTLRLAT, PRYVKxNTLRLAT, Ac-YVKxNTLRLAT and YVKxNTLRLAT 
(21st Century Biochemicals, Marlboro, MA) where Ac represents a N-terminal 
acetyl group and x corresponds to the photocleavable group, were analyzed by 
mass spectrometry before and after they were exposed to UV light using matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOFF).  The peptides 
were deposited directly onto the MALDI sample target with 1-2 µl of 
acetonitrile:0.1% TFA (80:20) followed by addition of 0.5µl of matrix solution which 
consisted of 5 mg/ml of alpha cyano- 4-hydroxy cinnamic acid (recrystallized) in 
acetonitrile: 0.1% TFA (50:50). Samples were allowed to air dry prior to insertion 
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into the mass spectrometer. Peptides were analyzed in positive ion Reflectron 
mode. All spectra were processed with Mascot Distiller (Matrix Sciences, Ltd.).  
Peptide labeling 
 The HA306-318-derived peptide Ac-PRYVKQNTLRLAT, where Ac represents N-
terminal acetyl group, was labeled using the free amino group at position K5. For 
this purpose, 2 mgs of peptide were dissolved in 400 μl of 150 mM sodium 
bicarbonate pH 9.8 and mixed with 1 mg of Alexa488-tetrafluorophenyl ester 
(Molecular Probes). After one hour incubation at room temperature, labeled 
peptide was purified by reverse HPLC (Agilent) using a C18 column (Jupiter 300A 
00G-4053-E0) and a gradient of acetonitrile in 0.02% trifluoracetic acid.  
Determination of relative binding affinity (IC50) 
HA, Y1MxN, V1MxN, L1MxN, Ac-photoHA, photoHA, Ac-photoHAΔ1-2 and 
photoHAΔ1-2 peptides (Figure 1.1C) were diluted in binding buffer (100 mM sodium 
citrate, 50 mM sodium chloride, 0.1% octyl β-D-glucopyranoside, 5 mM 
ethylenediaminetetraacetic acid, 0.1% sodium azide, 0.1 μg/ml 
phenylmethanesulfonyl fluoride, 0.2 mM iodoacetic acid, 1 mM dithiothreitol). 
Serial dilutions of these peptides were prepared in binding buffer, as triplicates in 
wells of a black polypropylene 96 well plate (Bio-one, Grenier). Then DR1 and HA-
Alexa488 were added to each well to final concentrations of 100 nM and 25 nM, 
respectively, in a final volume of 200 μl. The plate was sealed with aluminum 
sealing foil (USA scientific 2998-7100), incubated at 37 C for 72 h, and 
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fluorescence polarization was measured using a Victor X5 Multilabel plate reader 
(PerkinElmer, Shelton, CT). The fractional inhibition was calculated as [1- 
((mPsample - mPfree) / (mPno inibitor - mPfree))], where “mPfree” is the mP value obtained 
from a sample were the only species present is labeled-HA (~30 mP), and “mPno 
inhibitor” is the mP value obtained from a sample were the competitor is not present 
(~350 mP).  
Determination of peptide association rate 
DR1 was loaded with different photocleavable peptides by incubating purified 
DR1 with five times molar excess of photocleavable peptide at 37 C for 3 days in 
binding buffer (described above). DR1-peptide complexes or DR1 peptide-free as 
isolated from insect cells, was purified by gel filtration using Sephadex-200 
column. The peak corresponding to the monomeric fraction was isolated and 
diluted in binding buffer to 300 nM, right before UV exposure begins. These 
samples were exposed to UV light for different periods of time in a pre-chilled low 
binding, polypropylene V-shape bottom 96 well plate (Bio-one, Grenier) on ice in 
a 4 C cold room with the long-wavelength UV lamp (Blak Ray B100AP/R, UVP), 
held 6 cm above of the plate. This lamp has emission spectrum that ranges from 
~310 nm-410 nm with λmax of 365 nm and a 40 nm full-width at half maximum. 
After exposure the plate was covered and incubated for 3 min at 37 C. Then 25 
μl of the samples were transferred to a black, polystyrene half well area 96 well 
plate (Corning) in duplicates or triplicates along with 25 μl/well of pre-warmed 
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labeled-HA (50 nM) in binding buffer. The final volume per well was 50 μl with final 
concentrations of 150 nM of DR1 and 25 nM of labeled-HA in binding buffer. The 
plate was immediately read in a Victor X5 Multilabel plate reader (PerkinElmer, 
Shelton, CT) once every 50 seconds during 3 h. The concentration of HA-
Alexa488 bound to DR1 was calculated as the fraction of peptide bound times the 
concentration of labeled peptide. The fraction of peptide bound was calculated as: 
[(mPsample - mP100% free) / (mP100% bound - mP100% free)], where “mP100% free” is the mP 
value obtained from a sample with no DR1 present to bind peptide (23 mP), and 
“mP100% bound ” is the mP value for fully bound DR-HA obtained from a sample with 
1 μM DR1 and 25 nM labeled-HA (342 mP).  
In cases where labeled HA was present during UV exposure, 30 μl of 300 nM 
DR1 were mixed with 30 μl of 50 nM labeled HA in the pre-chilled low binding, 
polypropylene V-shape bottom 96 well plate (Bio-one, Grenier). After UV exposure, 
50 μl were transferred to the black, polystyrene half well area plate, the plate was 
sealed and incubated at 37 °C for 3 minutes. Then the plate was read in a Victor 
X5 Multilabel plate reader once every 50 seconds during 3 hours. The 
concentration of labeled HA bound to DR1 was calculated as described above.  
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CHAPTER III 
Consequences of glycation of the MHC II antigen presentation 
pathway in diabetic humans and mice 
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Abstract 
Patients with obesity, metabolic syndrome, or type-2 diabetes often exhibit 
hyperglycemia and hyperlipidemia. One of the consequences of such altered 
metabolism is non-enzymatic coupling of reactive sugars and lipids with proteins 
and DNA inducing glycation and glycoxidation. Biochemically, these modifications 
can disrupt the cellular proteome by changing the protein chemical structure and 
inducing protein unfolding, cross-linking, aggregation and overall compromising 
biological activity. We investigated protein modifications induced by glycation and 
glycoxidation using peripheral blood mononuclear cells from non-diabetic, pre-
diabetic and diabetic individuals. We found that several cellular pathways were 
affected, including endosomal maturation and antigen presentation and 
processing pathways. Similar types of modifications were observed for CD11c+ 
dendritic cells from mice fed a high-fat diet, or from obese (Ob/Ob) mice. Using an 
in vitro antigen processing assay, we tested for the functional consequences of 
such glycation, and observed decreased processing of a model antigen for Ob/Ob 
as compared to control mice. MHC II proteins were prominent targets of 
modifications induced by elevated glucose in both humans and mice. In vitro 
glycation of the human MHC II protein HLA-DR resulted in impaired interaction 
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with the peptide exchange factor HLA-DM, suggesting altered peptide loading as 
a possible explanation for the observed antigen processing defects. Overall these 
results highlight a potential role for modification of components of the MHC II 
antigen processing pathway in inflammatory processes induced by elevated 
glucose levels. 
 
Introduction 
In hyperglycemic conditions, as present in patients with obesity, metabolic 
syndrome, or type-2 Diabetes, proteomic modifications associated with glycation 
and glycoxidation are often observed (182–196).  Since glucose and other blood 
sugars are electron acceptors, they can easily oxidize proteins in a concentration-
dependent manner. Protein glycation refers to the non-enzymatic covalent binding 
of carbohydrate moieties to reactive protein residues, whereas glycoxidation refers 
to the covalent binding of previously-oxidized carbohydrate with protein residues 
(196).  At the chemical level glycation is the nucleophilic addition reaction between 
the carbonyl group of a reducing sugar and the ɛ-amino groups of a lysine, 
hydroxylysine, arginine or the α-amino groups of the amino terminal residues of a 
protein (197). During glycoxidation monosaccharides such as glucose, aldose, 
fructose, or lipids are previously oxidized into dicarbonyl products known as α-
oxaldehydes, among which glyoxal, methylglyoxal, and 3-deoxyglucosone are the 
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most common. These oxidized sugars will then bind to reactive protein groups 
through the same nucleophilic reaction as described above (197).   
Since both glycation and glycoxidation are non-enzymatic reactions; the 
protein-sugar bond, generated through Schiff base formation (commonly known as 
Maillard reaction), is strictly dependent on the sugar concentration, is rapidly 
formed, and is freely reversible.  Indeed, protein glycation is found at low levels in 
physiological conditions as well, reflecting the fluctuation in serum glycaemia. 
However, the process is greatly enhanced during hyperglycemia, as observed in 
obesity, metabolic syndrome and Diabetes (198–201). That is why elevated protein 
glycation and glycoxidation is the best predictor of elevated blood sugar; as such 
glycated hemoglobin and albumin are commonly used as indicators of glycemic 
levels (189,195).  
Over time, the glycated protein will undergo a series of more stable 
rearrangements, mostly through generation of ketoamine or fructosamine known 
as initial Amadori products (182). Over one hundred Amadori products have been 
described, which encompass different chemical rearrangements of the glycated 
proteins: the acrylic, -pyranose, -furanose, β-pyranose and β-furanose bound 
with the amino group of lysines, or more rarely, with the thiol of cysteines as well 
as the free amino end of proteins, are among the best characterized (182,197).  
Albeit these initial reactions are reversible, following a series of chemical 
rearrangements, the modifications will become irreversible and are normally 
referred to as advanced glycation end-products (AGEs) (202–204). The AGEs are 
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more commonly detected in tissue proteins with a long half-life, including dermal 
collagens and extracellular matrix proteins as well as cartilage tissue (205). In 
these proteins Nϵcarboxymethyllysine (CML), pentosidins, and glucosepane are 
the more prevalent AGEs (187). 
AGEs, and glycation in general, are known to be a crucial risk factors for 
disease progression as well as exacerbation of many age-associated degenerative 
disorders (192,200,206,207). In diabetic individuals the increase in glycated 
proteins has important clinical implication as it is involved in disorders like 
nephropathy, neuropathy, retinopathy and coronary artery disease (187,208). 
Biochemically, these modifications can disrupt the cellular proteome by changing 
the protein primary amino acids structure and inducing protein unfolding, cross-
linking, aggregation and overall compromised biological activity (200,201,208–
211). Additionally, glucolipotoxicity stimulates NADPH oxidase and NF-kB-
mediated inflammatory pathway via receptor for advanced-glycation end products 
(RAGE) and Toll-like receptor 4 (212) further promoting chronic inflammation 
(213–215).  
Despite the positive association found between AGEs and several pathological 
conditions the molecular details of how AGEs contribute to the biochemistry of 
disease pathogenesis remain poorly characterized.  In our previous analysis we 
determined that several proteins associated with the antigen processing and 
presentation machinery were glycated during conditions associated with increased 
metabolic and oxidative stress (210,211). Herein we further characterize the 
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biological implications of the role played by glycation in antigen 
processing/presentation in general and MHC II peptide binding in particular. Our 
data underscore how MHC II glycation affects peptide binding/presentation for T 
cell recognition. 
 
Results 
Characterization of the glycated proteome in PBMC from healthy, pre-diabetic, 
and diabetic subjects  
Protein post-translational modifications by Maillard reaction, known as 
glycation, is thought to be the main cause of different pathophysiological conditions 
and complications, as observed in diabetes and age-related disorders (203).  
Based on the hypothesis that formation of amide-AGE modified proteins in immune 
cells could impact many cellular and molecular functions involved in the antigen 
presentation pathway and immune inflammatory responses, we purified PBMC 
from clinical samples of healthy, pre-diabetic, and diabetic patients to characterize 
the whole spectrum of AGE-PTM.  We evaluated these changes using western 
blot analysis and label-free mass spectrometry.  Western blot analysis was 
performed using antibodies against known hallmarks of diabetes-associated 
protein PTM: AGE, lipoxidation (4-hydroxynonenal (HNE) and total carbonylation 
(Figure 3.1A). A statistically significant difference in the accumulation of AGE and 
HNE in diabetics as compared with the pre-diabetics and control healthy subjects 
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was observed (Figure 3.1A).  Albeit some pre- and diabetics patients showed 
increased protein carbonylation, a less direct indicator of increased glycaemia, 
overall there was no significant difference in protein carbonylation among the three 
groups. 
It was recently showed that nanoLC/MS/MS-based proteomics 
technologies, applied to tryptic digests from complex protein mixtures, is 
sufficiently sensitive to detect protein-bound amide-AGE modifications without the 
need for AGE enrichment strategies (216–218). To establish a reliable label-free 
proteomic platform for identification of AGE-amide modified proteins, we first 
focused on testing the sensitivity of this analytical tool, using different starting 
amounts of total protein extracts from patients’ PBMC (20 to 60 g total protein).  
We tested samples isolated from healthy, pre-diabetic, and diabetic patients. 
Additionally, due to the selective AGE-targeted chemical modifications of lysines 
and arginines, we employed multiple enzymatic digestions using a combination of 
LysC/trypsin/Glu-C/Asp-N, which was previously shown to enable a higher 
sequence coverage and better accuracy for PTM site identification in complex 
cellular proteomes (205). Glycated peptides from each PBMC fraction from 
individual patients were analyzed using HCD MS/MS on a Q Exactive HF 
quadrupole orbitrap mass spectrometer in data dependent acquisition (DDA) 
mode. After at least three trials, we established that 25 g total protein extract of 
PBMC cell fraction purified from each individual donor was sufficient to generate a 
reproducible number of AGE-PTM in technical triplicates. 
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We first identified and annotated AGE-PTM in each proteome, using a 
conservative identification strategy with false discovery rate <1.5 % at the protein 
level and <1% at the peptide level (Figure 3.1B). We observed a difference in the 
total number of unique AGE sites (485 versus 22) in the pre-diabetic/diabetic 
versus healthy controls (Figure 3.1B). All reported AGE-PTM are characterized by 
“A scores” above 20 and at least 0.9 localization probability; as recommended for 
accurate PTM mapping (217–220).  
 In depth analysis of the type of unique amide-AGE and carbonylated proteome 
was further performed on proteins for which sequence coverage was > 48%. This 
criterion was selected so presence or absence of PTM in healthy and diabetic 
patients could be assigned on 50% protein coverage ensuring high confidence for 
statistical analysis. As is shown in Figure 3.1C there is almost a two-fold increase 
in the percentage of glycated or carbonylated proteins in the “diabetics” sample as 
compared with healthy controls (42.11% vs 24.4%, respectively). Comparative 
analysis of the type of AGE-PTM accumulated in the proteome from “diabetic” 
samples ranked the site-specific carboxymethylation of lysine (CML) as the most 
abundant AGE found in the glycated proteome, followed by formylation of lysine 
(Formyl K) and carboxymethylation of arginine (CMA) (Figure 3.1D).  
Glycated hemoglobin is a clinical standard used worldwide as readout of the 
blood level of glycaemia (221). Thus, we performed the quantification of CML 
residues of alpha and beta hemoglobin chains, by label-free mass spectrometry, 
as an internal standard to assess the extent of glycation in diabetics and pre-
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diabetics vs control samples (Figure 3.1E, 3.1F). A statistically significant increase 
was observed in the number of unique CML sites on hemoglobin from diabetics 
(p=0.006) vs healthy donors, but not for pre-diabetics (Figure 3.1E). Additionally, 
a positive correlation was observed between the number of unique CML sites 
identified on the total PBMC proteome as compared to the number of sites found 
on hemoglobin in each patient (Figure 3.1F).  
In conclusion, the label-free proteomic assay developed for mapping the AGE-
modified proteins in the protein extracts from PBMC was reliable in identifying site-
specific amide-AGE modifications and could be used to further analyze other AGE-
PTM on selected proteins of interest. 
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Figure 3.1: Analysis of the AGE, HNE and carbonyl-modified proteome in 
PBMC of healthy and pre/diabetics subjects. (A) Scatter dot plot graph of 
densitometric readings from western blotting of total PBMC cell lysates from 
healthy controls (Ctrs), pre-Diabetics and Diabetics subjects. Western blot analysis 
was performed to detect the AGEs, HNE and carbonyl-modified proteome in each 
group. Protein band intensities were normalized to the total loaded protein. The 
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mean and S.E. are shown for each Healthy (n=10), pre-diabetics (n =12) and 
diabetics (n=13) group. Data was analyzed by one-way ANOVA and Dunnett's 
multiple comparisons test; significance level: *P < 0.05; ****P < 0.001; ns= not 
significant (averaged values were calculated over three independent technical 
replicates). (B) Bar graph representing the average number of total AGE unique 
sites identified by the global proteomics profiling of protein extracts from PBMC of 
patients with glycemia above 120 mg/dL (Diabetic: red) (n=25) in comparison with 
control, healthy subjects (Ctrs: gray) (n=10). The identifications of PTM sites were 
performed by PEAKS 8.0 in combination with Scaffold PTM 3.1.0 which annotated 
the PTM sites derived from MS/MS sequencing using Scaffold (version 4.7.2). A 
MuDPIT setting was used to combine all patients and all technical and biological 
replicates. (C) Percent distribution of the AGE and carbonyl-modified proteome in 
healthy (Ctrs) and Diabetic subjects as mapped on proteins with at least a 50% 
sequence coverage by MS/MS. (D) Bar graphs representing the most abundant 
AGE unique sites identified by global proteomics profiling PBMC protein extracts 
from patients with glycemia above 120 mg/dL (Diabetic: red) in comparison with 
control healthy subjects (Ctrs: gray). MG-H1: methylglyoxal-derived 
hydroimidazolone of arginine; G-H1: glyoxal-derived hydroimidazolone of arginine. 
Presented data are a compilation from n=10 healthy and n=25 diabetic, biological 
replicates, each run in technical duplicates. (E) Scatter dot plot graph representing 
the total number of CML unique sites in the hemoglobin, alpha and beta chains, 
from control (n=10), pre- (n=12) and diabetics (n=13) patients. Statistical analysis 
was performed by one-way ANOVA and Dunnett's multiple comparison test. (F) 
Correlation between CML-modified hemoglobin and total CML-unique sites in the 
proteome of diabetics’ patients (Pearson coefficient r = 0.7377, ****P < 0.0001).   
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Results from the proteomic profiling of PBMC from healthy, and diabetics 
subjects were further processed through Ingenuity Pathway Analysis (IPA) to 
determine the full extent of the cellular functions potentially affected by the AGE-
modified proteome (Figure 3.2). IPA identified molecular functions associated with 
cellular movement, cellular maintenance, cellular trafficking and signaling, immune 
inflammatory response and protein, lipids and nucleic acid metabolism as being 
the top pathways affected by AGE-modified proteins (Figure 3.2A).  Additionally, 
endosomal maturation and antigen processing and presentation pathways where 
among the top canonical biochemical processes affected by the AGE-PTM (Figure 
3.2B and 3.2C).  We focused subsequent work on the effect on these pathways. 
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Figure 3.2: Gene ontology and functional annotations of the AGE and 
carbonyl-modified proteome mapped in the PBMC of diabetic patients. (A) 
IPA predicted major biochemical and cellular pathways affected by AGE and 
carbonylation in PBMC from diabetic patients. The protein accession numbers 
annotated in the proteomic experiments corresponding to the AGE-modified and 
carbonylated proteins were processed by IPA software and the percentage of 
experimentally identified molecules overlapped with the knowledge database of 
IPA. (B) IPA generated view of the endosomal maturation pathway highlighting the 
proteins affected by AGE and carbonylation. (C) IPA generated view of the antigen 
processing pathway highlighting the proteins affected by AGE and carbonylation.  
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Increased levels of carbonylated and AGE-modified proteins in dendritic cells 
from Ob/Ob mice 
To further analyze the effects of AGE-related modifications on the endosomal 
maturation and antigen processing and presentation pathways we used two animal 
models of diabetes/metabolic syndrome, Ob/Ob mice and C57BL/6 mice fed a 
high-fat diet (Figure 3.3A and 3.3B). Ob/Ob mice have a spontaneous mutation for 
the leptin gene (Lepob), which cause hyperphagia and rapid weight gain. These 
mice exhibit a diabetes-like syndrome with hyperglycemia, glucose intolerance, 
elevated plasma insulin, subfertility and impaired wound healing. The second 
model we used was C57BL/6 mice, which were served a high fat diet (HFD) for 6 
months. These mice also develop hyperlipidemia, hyperglycemia and a metabolic 
syndrome. To confirm presence of metabolic stress, mice were injected with the 
fluorescent probe CellROX® (excitation 640 nm / emission 664 nm), for which 
fluorescence is proportional to the amount of reactive oxygen species present 
(222). Five minutes after tail-vein injection, mice were imaged (Figure 3.3A), and 
then were sacrificed, followed by ex vivo imaging of spleen, intestine, kidney, heart 
and fat tissues (excitation 610 nm/ emission 700 nm (IVIS, Kodak Image Station 
400MM PRO). An increased level of oxidative/metabolic stress, as detected both 
in the whole body and individual organs, could be imaged in both Ob/Ob mice and 
HFD mice as compared to the C57BL/6 control group (Figure 3.3A and 3.3B).   
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Figure 3.3: Analysis of the AGE, HNE and carbonyl-modified proteome in 
Ob/Ob mice and high fat diet-feed mice as compared to healthy controls. (A) 
In vivo imaging of control C57Bl6 mice (CTR), mice on a high-fat diet (HFD) and 
Ob/Ob mice. The animals were intravenously injected with the oxidative stress 
reagent CellROX® (excitation 640 nm/emission 664 nm) and imaged using the in 
vivo F PRO imaging system. (B) Ex vivo imaging of spleen, gut, kidney, hart and 
fat tissue samples collected from intravenously injected animals with the oxidative 
stress reagent CellROX® and imaged with the in vivo F PRO imaging system. 
Samples were imaged for 3 minutes at excitation 610 nm/emission 700 nm using 
build-in cooled CCD camera. Fluorescence intensity scale ranges from pink 
(lowest level) to red (highest level). (C) Representative FACS analysis of CD11c+ 
DCs purified from the spleen of CTR, HFD and Ob/Ob mice, previously injected 
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with the oxidative stress reagent CellROX® as detailed in (A) and (B). (D) Bar graph 
of the mean fluorescence index (MFI) of CellROX® as detected in CD11c+ DCs 
purified from the spleen of CTR, HFD and Ob/Ob mice. The bars and the error 
bars represent the mean and the standard deviation from four experiments, 
respectively. (E, F) Bar graph of the densitometric analysis from western blotting 
of CD11c+ DC lysates from CTR and Ob/Ob mice. Western blot analysis was 
performed to detect the (E) AGEs and (F) carbonyl-modified proteome in each 
mouse group. Protein band intensities were normalized to the amount of total 
loaded protein. The mean and standard error are shown for each WT (n=3) and 
Ob/Ob group (n=3). Statistical analysis was performed by one-way ANOVA and 
Dunnett's multiple comparisons test; significance level: **P < 0.005; ns= not 
significant. (G, H) Bar graph of the densitometric analysis from western blotting of 
JAWS cells cultured in absence or presence of increasing glucose concentrations 
(5 mM, 7 mM, 15 mM and 20 mM) for 72 hours. Western blot analysis was 
performed to detect the (G) AGEs and (H) carbonyl-modified proteome. Protein 
band intensities were normalized to the amount of total loaded protein. The mean 
and standard error are shown for control (n=3) and glucose treated group (n=3). 
Statistical analysis was performed by one-way ANOVA and Dunnett's multiple 
comparisons test; significance level: *P < 0.05; **P < 0.005; ****P < 0.001; ns= not 
significant. 
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To begin to evaluate effects on antigen processing and presentation pathways, 
we purified CD11c+ DCs from spleen of these mice, and assayed for metabolic 
stress. DCs from both Ob/Ob and HFD mice showed increased oxidative/metabolic 
stress-related fluorescence relative to DCs from control C57BL/6 mice (Figure 
3.3C and 3.3D). We also assayed the CD11c+ DCs for AGE-PTM. Western blot 
analysis identified a significantly higher amount of AGE-modified proteins in DCs 
from Ob/Ob mice as compared to DCs from littermates control (Figure 3.3E). 
Likewise, an increased amount of carbonylation (Figure 3.3F) was also observed 
in DCs from Ob/Ob mice as compared with control mice, although as previously 
observed in diabetic patients the difference was not statistically significant (Figure 
3.3F). In addition, to evaluate whether there was a direct link between increased 
glucose concentration and the observed increased numbers of AGE-PTM and 
number of glycated proteins in relevant immune response pathways, we cultured 
a mouse DC line (JAWS) with increasing glucose concentrations (5 mM- 20 mM), 
mimicking the transition between pre-diabetic and diabetic (T2DM) conditions. A 
dose-dependent increase in the AGE-modified and carbonyl-modified proteome 
was observed in the in vitro treated DCs (Figure 3.3G and 3.3H), similarly to the 
modifications observed DCs isolated from Ob/Ob and HFD mice.  
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AGE-modified pathways in DCs from Ob/Ob mice 
To map at the molecular level the AGE-modified proteins identified by western 
blot of total cell extracts from DCs of Ob/Ob mice and littermate controls, we 
performed label-free mass spectrometry. The goal was to establish whether the 
proteomic profiling of AGE and carbonylation observed in primary DCs from Ob/Ob 
mice would recapitulate the pattern previously observed in PBMC from diabetic 
patients, and to have a reliable basis for analysis of the effects of AGE on the MHC 
II antigen processing/loading machinery in a mouse model. 
For quantitative proteomic analysis, the fold change in the amount of modified 
protein, for each AGE-modified protein, was calculated for biological triplicate 
Ob/Ob and control DC samples by the IPA algorithm using the rescaled log2 
transformation of each protein’s area ratios (ObOb/control) from MS1 analysis 
extracted by the LFQ method built in the PEAKS 8.0 software (as described in 
detail in the methods). The three-major cellular and biochemical pathways affected 
by increased amount of AGE-modified proteins were identified (Figure 3.4). Similar 
to what was observed in the PBMC proteomes from pre-diabetic and diabetic 
patients, IPA identified clathrin-mediated endocytosis, endosomal maturation and 
antigen processing and presentation as the top pathways bearing a higher number 
of proteins modified by AGE and carbonylation in DCs purified from Ob/Ob mice 
as compared with the corresponding proteins in DCs from control mice (Figure 
3.4A, 3.4B and 3.4C). 
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Figure 3.4: Gene ontology and functional annotations of the AGE and 
carbonyl-modified proteome mapped in Ob/Ob mice highlight the antigen 
processing pathway as a top cellular pathway affected by nonenzymatic 
glycation and carbonylation. IPA predicted major biochemical and cellular 
pathways affected by AGE and carbonylation in primary DCs from Ob/Ob mice.  
IPA generated view of (A) clathrin mediated endocytosis (B) endosomal 
maturation pathway and (C) antigen processing pathway. Up-regulated proteins 
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are displayed with different shades of red and down-regulated proteins are shown 
in different shades of green. The probability of having a relationship between each 
IPA indexed biological function and the experimentally determined genes was 
calculated by a right-tailed Fisher’s exact test. The level of significance was set to 
a P-value of <0.05. For quantitative analysis (n=3 for each Ob/Ob and control DC 
samples), the expression fold for each protein was calculated by the IPA algorithm 
using the rescaled log2 transformation of protein’s area ratios (ObOB/Control) from 
MS1 analysis extracted by the LFQ method built in the PEAKS 8.0 software. 
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The detected site-specific amide-AGE modifications were also accurately 
mapped to proteins involved in other cellular pathways related to response to 
inflammation, immune cell trafficking, actin and cytoskeleton signaling and cell 
movement and pathways involving carbohydrate, nucleic acids and protein 
metabolism (Figure 3.4A, 3.4B and 3.4C). 
Glycation of the Ob/Ob antigen processing machinery interferes with E 
presentation 
Many AGE-modified lysines and arginines identified by MS/MS in the DC 
proteome from Ob/Ob vs. control mice were annotated to the MHC proteins. To 
help evaluate possible effects of the AGE-PTM we mapped the sites of 
modification onto the crystal structure of I-Ab (223), the MHC II molecule present 
in Ob/Ob and C57Bl6 mice (Figure 3.5). The observed sites were distributed all 
over the surface of the protein, with several in position to alter peptide binding 
specificity and/or T cell recognition (Table 3.1, Figure 3.5A). Other modification 
sites were located on the lateral surface extending down from N-terminal end of 
the peptide-binding site (Table 3.1, Figure 3.5B), which is the major interaction site 
of catalytic peptide exchange and editing factor, DM (115,224,225).  
To analyze the implications of the AGE-modified proteome on the antigen 
processing machinery, we treated primary DC from Ob/Ob and control mice with 
the chimeric Ealpha-red fluorescent protein (Eα-RFP). The kinetics and efficiency 
of endosomal processing of Eα-RFP can be monitored by flow cytometry using 
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RFP fluorescence to follow endosomal uptake of the Eα-RFP, and Y-Ae 
fluorescent antibody to detect presentation of the Eα52-68 peptide, derived from Eα-
RFP degradation, loaded on I-Ab (Figure 3.5C). We challenged primary DC from 
Ob/Ob and control mice with Eα-RFP protein and chase it for different times (0, 2, 
6 and 12 hours) Two hours following incubation with Eα-RFP 16% of DC in control 
mice already expressed the Y-Ae epitope as compared to 10% in the Ob/Ob DC 
(p0.004). The gap in epitope presentation increased at 6 and 2 hours with 32% of 
Y-Ae+ DC in control mice and less than 20% in Ob/Ob DC (Figure 3.5C and 3.5D). 
These results indicate that AGE-modified proteins, associated with the antigen 
processing/loading machinery, could potentially affect the efficiency of antigen 
processing and presentation. 
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Figure 3.5:  Decreased Eα52-68peptide presentation on AGE-modified I-Ab. (A, 
B) Mapping of AGE PTM identified from MS/MS analysis on the crystal structure 
of I-Ab bound to a CLIP peptide (PDB: 1MUJ). Site specific AGEs were identified 
both in the (A) peptide binding site and (B) in the DM interaction site. I-Ab surface 
is shown in pink color, the peptide is represented as grey sticks with nitrogen and 
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oxygen atoms shown in blue and red, respectively. Glycated sites are shown in 
magenta, oxidated and carbonylated sites in yellow, and HNE and HNE derivatives 
of lipooxidation sites in green. PTM identification were performed by PEAKS 8.0 in 
combination with Scaffold PTM 3.1.0 which annotated the PTM sites derived from 
MS/MS sequencing using Scaffold (version 4.7.2). The type and the corresponding 
localization probability on each alpha and beta chains of MHC-II are presented in 
Table 3.1. (C) FACS analysis of CD11c+ DCs derived from C57bl6 (Ctr) and Ob/Ob 
spleen, treated for 1 hour with ERFP, and then chased for different time points: 
0, 2, 6 and 12 hours (T0, T2, T6 and T12, respectively). Dot plots show RFP 
fluorescence on the Y axis, and staining with FITC-labeled Y-A2 antibody that 
recognizes I-Ab loaded with Eα52-68 peptide, on the X-Axis. (D) Bar graph shows 
the mean fluorescence intensity (MFI) of CD11c+ DCs stained with the Y-Ae-FITC 
antibody. Statistical analysis was performed using paired-t test. Significance level 
correspond to *P < 0.05; **P < 0.005; ****P < 0.001. 
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Table 3.1: Post translational modifications mapped on I-Ab 
a.a.: amino acid  
  
PTM Peptide Peptide position
4-Oxononenal (ONE) K.VEH*WGLEEPVLK.H 3
GLAP K.HNLGVLTK*.R 8
Lysine oxidation to aminoadipic 
semialdehyde
K.LSYLTFIPSDDDIYDCK*.V 17
Tryptophan oxidation to 
hydroxykynurenin
K.VEHW*GLEEPVLK.H 4
Tyrosine oxidation to 2-
aminotyrosine
K.LSY*LTFIPSDDDIYDCK.V 3
Tyrosine oxidation to 2-
aminotyrosine
K.LSYLTFIPSDDDIY*DCK.V 14
LysTetrosyl E.APQATVFPK.S 9
Arg-MG-H R.LEQPNVVISLSR*.T 12
carboxyethyl CEA K.SPITVEWR*.A 8
Oxidation (HW) R.H*NYEGPETHTSLR.R 1
Oxidation (HW) R.HNYEGPETH*TSLR.R 9
Oxidation (HW) K.SPITVEW*R.A 7
Oxidation or Hydroxylation R.Y*DSDVGEHR.A 1
Oxidation or Hydroxylation R.HNY*EGPETHTSLR.R 3
Oxidation or Hydroxylation R.HNYEGP*ETHTSLR.R 6
Proline oxidation to 
pyroglutamic acid
R.HNYEGP*ETHTSLR.R 6
Proline oxidation to 
pyrrolidinone
R.HNYEGP*ETHTSLR.R 6
4-hydroxynonenal (HNE) R.H*NYEGPETHTSLR.R 1
methylglyoxal adduct (MGH1) R.AELDTVCR*.H 8
Oxidation or Hydroxylation K.SPITVEWR*.A 8
Tryptophan oxidation to 
oxolactone
K.SPITVEW*R.A 7HB2A_MOUSE 216
HB2A_MOUSE 108
HB2A_MOUSE 107
HB2A_MOUSE 217
HB2A_MOUSE 113
HB2A_MOUSE 113
HB2A_MOUSE 113
HB2A_MOUSE 216
HB2A_MOUSE 67
HB2A_MOUSE 110
HB2A_MOUSE 217
HB2A_MOUSE 108
HB2A_MOUSE 116
HA2B_MOUSE 188
HA2B_MOUSE 121
HB2A_MOUSE 133
HA2B_MOUSE 191
HA2B_MOUSE 195
HA2B_MOUSE 177
Protein Ob/Ob    a.a. position 
HA2B_MOUSE 194
HA2B_MOUSE 102
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DR1 glycation interferes with DM mediated peptide exchange 
We wanted to evaluate the effect of glycation on MHC II-peptide binding and 
peptide exchange catalysis by DM. For this purpose we glycated recombinant DR1 
in vitro. To simulate the effect of glucose exposure in vivo we incubated DR1 for 3 
days at 37 °C in the presence or absence of 5 mM or 20 mM glucose, together 
with the CLIP fragment of the invariant chain chaperone. After incubation, the DR1-
CLIP monomer fraction was purified by gel filtration in presence of the 
corresponding glucose concentration. Gel filtration traces indicated the absence of 
any substantial unfolding or aggregation as a result of the incubation with glucose 
(Figure 3.6A). Quantitative LFQ mass spectrometry analysis of the DR1 samples 
treated for 3 days with 5 and 20 mM glucose showed many amido-glycated 
arginine and lysine residues, at sites similar to those observed for I-Ab modified in 
vivo. We mapped the sites of DR1 modification onto the crystal structure (120) 
(Figure 3.6B and 3.6C) to compare with I-Ab modification sites (Figure 3.5A and 
3.5B). As previously observed for I-Ab, many of these residues were located at the 
interface with DM (Figure 3.6B and 3.6C, orange residues).   
To evaluate the effect of DR1 glycation on DM-catalyzed peptide exchange 
activity, we used a fluorescence polarization assay (172,226). DR1 treated as 
described above for 3 days in the presence of various concentrations of glucose 
was mixed with a fluorescent peptide in the absence or presence of DM, with 
binding followed over time by fluorescence polarization. In this experiment we 
maintained the glucose concentrations during the assay at the same concentration 
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as during the 3 day incubation. In the absence of DM (Figure 3.6D, top left panel), 
initial rates of peptide exchange were similar for DR1 incubated in the absence of 
glucose (black trace) or treated with 5 mM (red trace) or 20 mM glucose (blue 
trace). With longer incubation times (Figure 3.6D, top right panel), lower levels of 
peptide binding were observed for DR1 treated with either concentration of glucose 
than for the control mock-treated sample. In the presence of DM, peptide exchange 
rates were faster than in the absence of DM for all of the samples (Figure 3.6E). 
However, initial peptide binding rates for both of the glucose-treated samples were 
significantly lower than for the mock-treated sample (Figure 3.6E), indicating that 
glucose-mediated modifications interfere with the action of DM.  
To test if the glucose-mediated modifications on DR1 that interfere with DM 
action were reversible, we repeated the experiment described above, but this time 
we purified DR1 by gel filtration and assayed its peptide binding activity and 
sensitivity to DM in the absence of glucose. We expected that under these 
conditions reversible modifications would be lost. In the absence of DM, no 
significant differences were observed between the samples (Figure 3.6F and 3.6G, 
-DM samples), as observed for the samples assayed in the presence of glucose 
(Figure 3.6E, -DM samples). However, in contrast to what was observed in the 
previous experiment, treatment with glucose had no effect on DM-catalyzed 
peptide exchange (Figure 3.6F and 3.6G, +DM samples). This result indicates that 
DR1 modifications caused by 3-day incubation with glucose that interfered with 
DM catalysis were predominantly reversible.  
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Since the DR1 modification conditions that we used might not be sufficient to 
allow reversible Amadori products to undergo the chemical rearrangements 
necessary to become irreversible AGE products, we used a previously-described 
method to induce AGE modifications in vitro that involved incubation of the protein 
with high concentration of glucose for a longer period of time (227,228). Following 
this method, we incubated DR1 in the presence of 500 mM glucose for 50 days. 
After incubation we purified monomeric DR1 and removed glucose by gel filtration 
and assayed peptide-binding activity as before (Figure 3.6H and 3.6I). Under these 
conditions the samples behaved similarly to the samples incubated for 3 days and 
assayed in the presence of glucose (Figure 3.6D and 3.6E). Preincubation with 
glucose had no appreciable effect on peptide binding activity in the absence of DM 
(Figure 3.6H and 3.6I, -DM samples), but DM-catalyzed peptide exchange was 
significantly reduced for DR1 pretreated with glucose (Figure 3.6H and 3.6I, +DM 
samples). The reduction in the DM effect could not be overcome by increasing the 
DM concentration (Figure 3.6J), indicating that DR1 residues important in the DM-
mediated peptide exchange catalysis were modified by glucose treatment.  Overall 
these results indicate that DM-peptide exchange catalysis on MHC II molecules 
can be affected by both reversible and irreversible glucose-derived modifications.  
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Figure 3.6: DR1 glycation interferes with peptide exchange catalyzed by DM. 
(A) Gel filtration trace of the purified monomeric fraction of DR1 incubated with 0, 
5 or 20 mM glucose for 3 days in presence of CLIP. (B, C) Glucose-induced 
modifications identified by mass spectrometry mapped on DR1-HA peptide 
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structure (PDB: 1DLH). DR1 surface is shown in green and the peptide is 
represented as sticks in yellow, with oxygen and nitrogen atoms shown in red and 
blue, respectively. (B) View of the DR1 interface with DM. DR1 residues that were 
found to have glucose modifications are shown in magenta or orange if they are 
involved in DM interaction. (C) View of the DR1 peptide-binding groove. In cyan 
are shown residues with glucose modifications that are involved in peptide 
interaction. Residues that were modified but are not seen in the DR1 views shown 
in figure B or C are mentioned as “Not in view”. (D, E) DR1 was incubated with 
CLIP peptide for 3 days at 37 °C in absence (black traces) or presence of 5 mM 
glucose (blue traces) or 20 mM glucose (red traces), purified by gel filtration in PBS 
with the corresponding concentration of glucose, and mixed with labeled-HA 
peptide in the absence (top panels) or presence (lower panels) of 1 μM DM, 
keeping the concentration of glucose equal to the concentration during the 
incubation. Binding of labeled peptide was measured by fluorescence polarization 
over time. (D) Early time points used for initial rate determination (slope) are shown 
on the left, and longer time course is shown on the right. (E) The initial peptide 
binding rates for DR1 incubated with 0, 5 or 20 mM glucose in absence or presence 
of DM for 3 independent experiments each done in triplicate. (F, G) Same as in 
panels D and E but modified DR1 was purified by gel filtration in PBS and assayed 
in absence of glucose. (H, I) Same as in figure D and E, but DR1 was incubated in 
the absence (gray traces) or presence of 500 mM glucose (green traces) for 50 
days at 37 °C, and purified by gel filtration in PBS and assayed in absence of 
glucose. (J) The same samples as in panels H and I but assayed with different 
concentration of DM. Initial rate for each sample were plotted versus DM and fit to 
a hyperbolic equation. The indicated p value corresponds to significance of 
difference of fit values. Asterisks indicate significance of difference between 
samples for each DM concentration, were ** correspond to p<0.005, and *** to 
p<0.0005. 
  
 142 
 
Discussion 
A loss of metabolic control with hyperlipidemia and hyperglycemia is a hallmark 
of type II diabetes and metabolic syndrome (229–232). The high levels of blood 
glucose and lipids generate reactive molecular species such as carboxymethyl 
lysine or carboxymethyl arginine, following glucose/ribose oxidation, and 
malonaldehyde following lipid oxidation (220,233–236). Additionally, the 
hyperlipidemia and hyperglycemia favor the generation of both mitochondrial and 
cytosolic ROS and RNS, which also contribute to protein oxidative modifications 
(233,237).  Moreover, in addition to their endogenous formation these reactive 
lipids and sugars can also be directly ingested through dietary intake. Thus, 
altogether, a metabolic state of cellular/tissue oxidative stress is observed in both 
diabetes and metabolic syndrome characterized by the presence of highly reactive 
moieties which will bind and oxidize cellular macromolecules including nucleic 
acids and proteins (238,239). The binding is non-enzymatic, initially reversible, and 
the binding equilibrium depends on the concentration of the reactive moieties. 
Several studies have reported proteomics analyses of samples harvested from 
patients with diabetes and from a mice model for type II diabetes (203,219,220). 
These analyses indicate that the most commonly observed non-enzymatic PTM 
are glycation, nitrosylation and oxidation/reduction. Albeit, most amino acids are 
susceptible to oxidation by these reactive species, the most susceptible are lysine, 
arginine, methionine and cysteine due to the presence of free amino and sulfhydryl 
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groups on their side chains. Our proteomic analysis confirms that the most 
common AGEs observed in vivo are carboxymethyl lysine and arginine, followed 
by lysine formylation and arginine adducts of glucosone and deoxyglucosone 
(203,216,218,240).  
A very extensive literature has described the long-term consequences of an 
AGEs/carbonyl-modified proteome including cardiovascular, musculoskeletal, 
cataract and parenchymal organs pathologies and as a contributing factor in 
cancer cell transformation (172,229,233,236,238,239). Indeed inhibition of AGEs 
formation has been shown to improve both diabetes and arthrosclerosis 
(115,158,224,225). On a biochemical level, several major consequences may 
occur when a protein is AGEs/carbonyl modified, including degradation, 
aggregation, or changes in functionality. AGEs and carbonyl groups modify the 
protein chemical structure, which may hinder protein folding and induce protein 
aggregation. Aggregation can also be facilitated by cross-linking, through Schiff-
base formation between aldehyde and an amino group on the same protein or 
adjacent proteins (210). Unfolding and aggregation will activate a series of cellular 
chaperones to restore protein folding, among which hsc-70/hsp-70 are the best 
characterized.  Cells have also developed several detoxifying pathways against 
AGEs accumulation. Enzymes such as the glutathione-dependent glyoxalase 
system or fructosamine-3-kinase play important roles in the intracellular removal 
of Amadori products. Among these glyoxalase I and II use reduced glutathione to 
catalyze the conversion of glyoxal, methylglyoxal, and other α-oxoaldehydes to the 
 144 
 
less toxic D-lactate (241–243). Fructosamine kinases (243,244) phosphorylates 
and destabilizes Amadori products favoring their spontaneous breakdown (241). 
Ultimately these mechanisms can restore protein functionality.  
However, in conditions of prolonged oxidative and metabolic stress, when 
these protective mechanisms are unbalanced by the redox environment, modified 
proteins are targeted for degradation by either the proteasome, when the protein 
can still unfold to enter the proteasomal catalytic chamber, or through autophagy 
for protein aggregates (210,211). A full machinery associated with protein 
ubiquitination as well as macro-autophagy, micro-autophagy and chaperone 
mediated autophagy has been well characterized as a mean to dispose the 
AGEs/carbonyl-modified proteome (210,211,245–251).  
An important area of research that is currently developing relates to how the 
AGEs/carbonyl groups can modify protein functionality. Indeed it has been 
reported that glycation reduces the stability of Apo-AI and decreases HDL 
transport functionality (252), affects Hb oxygen delivery (253,254), and decreases 
the enzymatic activity of bisphosphoglycerate mutase, catalase, cysteine ligase, 
aspartate aminotransferase and kinases, among many other enzymes (255–259). 
Glycation induces cellular apoptosis through modifications of Hsp70, JNK, and NF-
kappaB (260) and changes histones and ribonucleases structure/function 
(261,262). In immune cells, glycation-type modifications have been shown to 
compromise the proteasome catalytic activity, immunoglobulin functions, NLRP3 
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inflammasome-mediated innate immune responses and phagocytic activity (263–
267).  
Following into this line of investigation we decided to take a further look at the 
immunoproteome of type II diabetes in general, and the antigen processing loading 
machinery in particular. We found that several proteins involved in antigen uptake, 
processing and MHC II peptide/loading were subject to both AGEs and carbonyl 
type modifications under conditions of elevated glucose, for both humans and 
mice, in vivo and in vitro. Some of these modifications were located on MHC II 
proteins at sites known to be involved in the interactions with peptides, with the 
peptide exchange factor DM, and with T cell antigen receptors. Residues within 
the MHC II peptide-binding groove were modified, including DR1 residues αArg76 
and βArg71 and I-Ab residues βArg80, βHis81, βAsn82, βPro85, and βHis88. For 
DR1 these substitutions appeared to cause only minor alterations in the peptide 
exchange kinetics, although it should be noted that effects on peptide specificity 
were not examined in these experiments. Large alterations in DM-mediated 
peptide exchange were observed to results from DR1 glycation, likely due to 
modifications of DR1 residues in the binding interface of DM: αArg34, αLys38, 
αLys39, αArg50, αLys98, αArg100, and αArg189 (Figure 3.6B and 3.6C), Many 
modifications at similar sites in I-Ab were observed (Figure 3.5A and 3.5B).   
For both DR1 and I-Ab, modification of residues on the “upper” surface of the 
protein adjacent to the peptide binding region was observed. These include DR1 
βArg71, at the center of the TCR interface for TCRs binding in a conventional 
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orientation, where it is often contacted by side chains of residues in the TCR 
CDR3α or CDR3β loops, and residues around the periphery of the interface:  I-Ab 
βHis81, often contacted by CDR1α residues, DR1 βLys65, sometimes contacted 
CDR2β residues, and αLys75, modified in both DR1 and I-Ab, which is occasionally 
contacted by residues adjacent to CDR2β (268). Glycation at these sites 
potentially could modify TCR binding by hindering TCR-MHCII interactions or 
providing sites for neoantigen-like reactivity.  
In conclusion our analysis indicates that one of the biochemical consequences 
of hyperglycemia, as observed in type-2 diabetes and animal models of obesity, is 
the glycation and glycoxidation of proteins involved in endosomal maturation and 
antigen processing and presentation pathways and the related immunological 
consequences were in vivo decreased presentation of a model antigen. MHC II 
proteins were prominent targets of modifications induced by elevated glucose in 
humans and mice and in vitro glycation of the human MHC II protein HLA-DR 
resulted in impaired interaction with the peptide exchange factor HLA-DM, 
suggesting altered peptide loading as a possible explanation for the observed 
antigen processing defects. Overall these results highlight a potential role for 
modification of components of the MHC II antigen processing pathway in 
pathological processes induced by elevated glucose levels. 
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Materials and Methods 
Chemicals 
Acetic acid (ULC/MS grade), acetonitrile, formic acid, methanol, trifluoroacetic 
acid (TFA), and ULC/MS-grade water (for nanoLC analysis, 99% purity) were 
purchased from Fisher Scientific. TCEP-HCL (Tris(2-carboxyethyl) phosphine 
hydrochloride), dithiothreitol (DTT), iodoacetamide, ammonium bicarbonate, 
glycine, urea, Coomassie Brilliant Blue R-250, KCl, KH2PO4, H3PO4, and Na2CO3 
were purchased from Sigma-Aldrich of the highest grade available.  Complete 
Proteinase inhibitor cocktail was also purchased from Sigma.  Porcine trypsin 
(specific activity > 5,000 units/mg seq. grade modified), Lys-C (sequencing grade) 
and Glu-C, sequencing grade, were purchased from Promega (Madison, WI). The 
Bradford assay was performed with the Biorad Braford assay kit (Biorad catalog # 
500006).  All solutions were prepared using MilliQ water purified by an Elix 3 UV 
Water Purification System (Millipore, Billerica, USA) and filtered through 0.2 μm 
pore membrane sterile filter units (SteritopTM, Millipore).  The gel silver staining kit 
for mass spectrometry was from Pierce (catalog 24600).  The Oxyblot Protein 
Detection Kit (catalog # S7150) was from EMD Millipore and SDS-PAGE pre-
casted gels (4%–15%) were from Bio-Rad (catalog # 456-8083). TMB substrate 
solution for ELISA (catalog # N301) was purchased from Thermo Fisher Scientific. 
Collagenase type I (catalog # 195109) was purchased from MP Biomedicals LLC. 
The Cell Proliferation ELISA BrdU (colorimetric) assay kit (catalog # 11647229001) 
was purchased from Roche.  The following primary antibodies were used: 
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polyclonal goat-anti AGE (catalog # AB9890, from EMD-Millipore); polyclonal goat-
anti 4-hydroxynonenal (HNE) (catalog #NB100-63093, from Novus Biologicals); 
mouse monoclonal anti-carboxymethyl lysine (CML) (catalog # MAB3247-SP, from 
R&D Systems). 
Human subjects 
Ten healthy, twelve pre-diabetics and thirteen diabetics age-matched subjects 
were recruited from the Geriatric Department at Perugia University. All pre- and 
diabetics patients met criteria for glycemia as reported by the ADA criteria.  The 
glucose concentration was: 70-120 mg/dl for heathy; 150-200 mg/dl for pre-
diabetics and 180-300 mg/dl for diabetics. All studies were approved by Albert 
Einstein (protocol #: 00000140) and Perugia University (protocol #: 366017) ethical 
committee.    
Cell Preparations 
PBMC: All blood samples were collected, in EDTA-treated tubes, between 8 and 
9 am after a 12-h fast.  All subjects gave written informed consent before taking 
part in the study. Whole blood was diluted 1:1 with 1X PBS and PBMC separated 
using Ficoll-Paque gradient centrifugation (catalog # GE17-1440-02, Sigma-
Aldrich).   
Mouse Dendritic Cells: Ob/Ob mice and littermate controls were injected 
subcutaneously with 40x106 B16-FLt3-L-producing melanoma cells (269). Twelve 
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to 14 days after injection spleens were harvested and DCs were purified by 
density-gradient centrifugation using 30% Bovine Albumin solution (Sigma-
Aldrich). The preparation routinely contains 70 to 80% CD11c+ DCs (270).   
Mouse dendritic cell line JAWS II: cells were cultured in complete Dulbecco’s 
modified Eagle’s medium - low glucose (DMEM-low glucose, catalog # D5546 
Sigma-Aldrich) with 10% heat-inactivated fetal bovine serum (FBS) in humidified 
5% CO2 atmosphere at 37 oC. The cultures were also supplemented with 100 U/ml 
penicillin and 100 mg/ml streptomycin. Cellular AGE-formation were induced by 
adding increasing concentrations of sterile glucose solution (5 mM, 7 mM, 15 mM 
and 20 mM) for 72 hours in a humidified 5% CO2 atmosphere at 37 oC. Untreated 
mouse JAWS cells (containing the 5mM low glucose from the DMEM media) were 
cultured under the same conditions and used as control.  After incubation cells 
were harvested, washed three times with sterile PBS (pH 7.4) and pelleted for 
further analysis. 
SDS-PAGE and Western Blot Analysis 
Cells (Human PBMC and mouse Dendritic cells) were lysed in RIPA buffer 
(catalog# R0278, Sigma-Aldrich)  supplemented with 1 × protease inhibitor cocktail 
(catalog# 04693116001, Roche) for 30 minutes, on ice. Lysates were spun twice 
at 20,000 g to collect the soluble proteins present in the supernatant. Protein 
concentrations were determined by a Bradford microassay.  Equal amount (20–
30 g) of proteins were suspended in 2% SDS, 50 mM DTT, 50 mM Tris pH 7.4 at 
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RT before loading SDS-PAGE (Mini-PROTEAN® TGXTM Gels (4–15%, BioRad, 
CA). To confirm equal loading gels were silver stained using the Pierce Color Silver 
Stain Kit (catalog # 24612 Pierce). 
Detection of carbonylated proteins: Cell lysates (10 g total proteins) were 
derivatized using the Oxyblot Protein Oxidation Detection Kit (catalog # S7150 
Millipore, USA), separated on 4–15% SDS-PAGE, and the transferred membranes 
incubated with a rabbit polyclonal anti-DNPH antibody followed by a goat anti-
rabbit IgG–HRP antibody (OxiSelect™ Protein Carbonyl Immunoblot Kit (catalog 
# STA-308) from Cell Bioloabs, Inc). Proteins were visualized by 
chemiluminescence. 
Detection of AGE, HNE and CML-modified proteins: Cell lysates (50-70 g total 
proteins) were separated on a 4–15% SDS-PAGE prior to blotting onto 
nitrocellulose membranes.  Membranes were blocked in 5% nonfat milk in TBST 
for 1 h, at room temperature, and probed with the following primary antibodies: 
polyclonal goat-anti AGE (catalog # AB9890, from EMD-Millipore) and polyclonal 
goat-anti 4-hydroxynonenal (HNE) (catalog #NB100-63093, from Novus 
Biologicals) at 1:200-1:500 dilution, overnight at 4 °C. Odyssey secondary 
antibodies (IRdye 800CW, donkey anti-goat 925-32214) (1:5000-1:3000) were 
added according to the manufacturer's instructions (LI-COR Biosciences, 
Cambridge, UK).  Incubation with secondary antibodies was performed at room 
temperature for 2 h. Blots were imaged using an Odyssey Infrared Imaging System 
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(LI-COR Biosciences, Cambridge, UK).  The ImageJ software 
(https://imagej.nih.gov/ij) was used to perform the densitometry analysis of 
western blot analysis. Data were normalized to the total protein/loaded well after 
Ponceau staining. All western blots were performed in a minimum of triplicate 
experiments. 
Antigen processing assay in primary dendritic cells  
Primary splenic DC from control (C57BL/6J) and Ob/Ob (B6Cg-Lep ob/J) mice 
were purified on a BSA gradient and pulsed at 2x106 cells in presence of 150 g 
of fluorescent Eα-RFP protein for 1 hour (T0).  Cells were then washed in PBS and 
chased for different time points T2 (2 hours), T6 (6 hours) and T12 (12 hours).  
After collection DC were analyzed by FACS to detect processing of Eα-RFP as 
well as MHC class II loading I-Ab/Eα-52-68 at each time point.  
Flow Cytometry 
The purified DC were incubated for 30 minutes on ice with saturating amounts 
of Y-Ae-FITC anti-mouse antibody (eBioscience, Cat # 11-5741-82) in staining 
buffer (PBS, 0.1% BSA, 0.01% NaN3). Following washing in staining buffer, 
samples were analyzed with the FACScan flow cytometer (Becton Dickinson, N.J, 
USA). 
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In vivo/Ex vivo measurement of reactive oxygen species 
To investigate the levels of oxidative stress in different mice groups and specific 
organs, we performed both in vivo and ex vivo imaging.  Briefly, mice were tail-
vein-injected with 50 μL (2.5 mM) of the fluorescent probe CellROX® (oxidative 
stress reagent, excitation 640 nm / emission 664 nm, Molecular Probes, CA, USA). 
Following injection, mice were placed in isofluorane chamber and the whole body 
was imaged.  Next, the animals’ organs namely spleen, small intestines, kidney, 
heart and fat tissue were dissected and placed onto a tray for ex vivo imaging using 
the In Vivo Imaging System (IVIS, Kodak Image Station 400MM PRO, Carestream 
Health, New Haven, CT, USA). The whole body were imaged for 5 minutes and 
specific organs were imaged for 3 minutes at excitation 610 nm/ emission 700 nm 
using build-in cooled CCD camera automated with high precision 10X zoom lens 
in a closed optical path imaging chamber. Images were threshold with respect to 
background intensity and different levels of fluorescence intensity were displayed 
using pseudo rainbow color scheme analyzed using build-in Carestream Molecular 
Imaging Software. Fluorescence intensity scale ranges from pink (lowest level) to 
red (highest level). 
Proteomic Analysis  
Sample preparation:  Equal protein amounts (30-50 g), prepared in technical 
duplicates, were reduced in 25 mM TCEP.HCl (Thermo Scientiﬁc), 50 mM 
ammonium bicarbonate buffer, at pH 8.5 containing 8 M urea for 35 minutes at 
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room temperature. The reduced proteins were alkylated with 100 mM 
iodoacetamide solution, for 50 minutes at room temperature. Three different 
enzymes were used for “in solution” digestion in 50 mM ammonium bicarbonate 
buffer, pH 8.5, for 18 hours, at 37 °C: endoproteinase Lys-C (1:50 enzyme: protein 
ratio); trypsin (1:20 enzyme: protein ratio) and Glu-C (1:10 enzyme: protein ratio) 
(sequencing grade Promega, Madison, WI, USA).  In addition, independent 
proteomics experiments were conducted using “in gel” digestion as previously 
published (271,272).  The gels were stained using a silver-staining kit (Thermo 
Scientific, Rockford, IL USA). 8 gel bands were cut across each sample lane. In 
gel tryptic digestion was carried out at 37°C overnight.  The peptides mixture, 
extracted from all enzymatic digestions, were desalted on C18 Prep clean columns 
before high resolution liquid chromatography tandem mass spectrometry (LC-
MS/MS).  
nanoLC MS/MS: technical duplicates were analyzed on a Q Exactive HF 
quadrupole orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, 
USA) coupled to an Easy nLC 1000 UHPLC (Thermo Fisher Scientific) through a 
nanoelectrospray ion source. After equilibration with 5% acetonitrile, 0.1% formic 
acid, peptides were separated by a 90min and 120 min linear gradients from 4% 
to 30% acetonitrile 0.1% formic acid at 400nL/min (Optima™ LC/MS, Fisher 
Scientific, Pittsburgh, PA).   The mass spectrometer was operated in the positive 
ion mode, in the data–dependent acquisition (DDA) mode. Full MS scans were 
obtained with a range of m/z from 300 to 1600, a mass resolution of 120,000 at 
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m/z 200, and a target value of 1.00E+06 with the maximum injection time of 50 ms. 
HCD collision was performed on the 15 most significant peaks, and tandem mass 
spectra were acquired at a mass resolution of 30,000 at m/z 200 and a target value 
of 1.00E+05. Isolation of precursors was performed with a window of 1.2 Th. The 
dynamic exclusion time was 20s. The normalized collision energy was 32%. We 
excluded precursor ions with single, unassigned, or eight and higher charge states 
from fragmentation selection.  
DR1 expression and purification 
HLA-DR1 (DRA*01:01/DRB1*01:01) extracellular domains were expressed in 
Drosophila S2 cells and purified by immunoaffinity chromatography with LB3.1 
antibody followed by Superdex200 (GE Healthcare) size exclusion 
chromatography as described (181). HLA-DM (DMA*01:01/DMB*01:01) 
extracellular domains were expressed similarly but were purified using a C-
terminal FLAG-tag, as described (273). 
Peptide labeling 
 The HA306-318-derived peptide Ac-PRYVKQNTLRLAT (where Ac represents N-
terminal acetyl) was labeled using the free amino group at position K5. For this 
purpose, the peptide (2 mg) was dissolved in 400 μl of sodium bicarbonate (150 
mM pH 9.8) and mixed with Alexa488-tetrafluorophenyl ester (1 mg) (Molecular 
Probes). After one-hour incubation at room temperature, labeled peptide was 
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purified by reverse HPLC (Agilent) using a C18 column (Jupiter 300A 00G-4053-
E0) and a gradient of acetonitrile in 0.02% trifluoracetic acid.  
DR1 glycation  
DR1 was incubated for 3 or 50 days at 37 °C with CLIP peptide (Ac-
VSKMRMATPLLMQ) in absence or presence of glucose at the indicated 
concentrations (5 mM, 20 mM or 500 mM). The incubation was performed in PBS 
and 0.1% octyl β-D-glucopyranoside. After incubation, the monomeric fraction of 
DR1Clip was purified away from detergent, free peptide, glucose, and aggregated 
protein that formed during the incubation using Superdex200 (GE Healthcare) size 
exclusion chromatography in PBS.  Aggregation did not differ appreciably for 
samples incubated in the presence or absence of glucose and represented less 
than 15% of the total protein. For the samples incubated for 3 days with glucose, 
we used PBS with matching concentration of glucose present in the DR1Clip 
sample.  
DR1 binding with labeled-HA. 
Peptide binding was monitored using a fluorescence polarization assay (172).  
Purified monomeric DR1Clip was added to a black, polystyrene half well area 96 
well plate (Corning) with or without DM in binding buffer (100 mM sodium citrate, 
50 mM sodium chloride, 0.1% octyl β-D-glucopyranoside, 5 mM 
ethylenediaminetetraacetic acid, 0.1% sodium azide, 0.1 μg/ml 
phenylmethanesulfonyl fluoride, 0.2 mM iodoacetic acid, 1 mM dithiothreitol). For 
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the samples incubated for 3 days with glucose, we added matching concentration 
of glucose with the DR1Clip sample. The plate was sealed and incubated at 37 °C 
for 3 minutes. Labeled-HA was diluted in binding buffer in a black tube and 
incubated at 37 °C for 3 minutes. The warmed labeled-HA was added to the 
warmed DR1Clip and DM to have final 100 nM DR1Clip, 0 or 1 μM DM, and 25 nM 
labeled-HA in a final volume of 50 μl. The plate was transferred to a Victor X5 
Multilabel plate reader (PerkinElmer, Shelton, CT) to measure fluorescence 
polarization. With the mp values, a plot of labeled-HA binding to DR1 vs time was 
obtained, and a line was fitted to the initial portion of the binding reaction. The 
slope of the line is the initial peptide binding rate.  
Protein identification 
 In the case of the human PBMC proteome, the raw files from each technical 
and biological replicate were filtered, de novo sequenced and assigned with 
protein ID using Peaks 8.0 software (Bioinformatics Solutions, Waterloo, Canada), 
by searching against the human (Homo Sapiens) Swiss-Prot database (January 
2017; 158,154 entries). In the case of the mouse proteome (JAWS II, Ob/Ob a 
littermate control dendritic cells) the search was performed against the mouse 
(Mus musculus) Swiss-Prot database (March 2017; 91,343 entries). The following 
search parameters were applied for LFQ analysis:  trypsin, Lys-C and GluC 
restriction enzymes and one allowed missed cleaved at one or both peptide end.  
The parent mass tolerance was set to 15 ppm using monoisotopic mass, and 
fragment ion mass tolerance was set to 0.05 Da.  Carbamidomethyl cysteine 
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(+57.0215 on C) was specified in PEAKS 8.0 as a fixed modification.  Methionine, 
lysine, proline, arginine, cysteine and asparagine oxidations (+15.99 on 
CKMNPR), deamidation of asparagine and glutamine (NQ-0.98) and pyro-Glu 
from glutamine (Q-18.01 N-term) were set as variable modifications.   
Post-translational analysis of amide-AGE peptides: The analysis of amide-AGE 
focused on the following PTM on lysine and arginine: Carboxymethylation (CML, 
CMA) (+58.005; K, R);  Carboxyethylation (CEL) (+72.021; K, R);  Fructosylation 
(N-hexosyl lysine) (+162.053; K)  Pyrraline (+108.021; K);  GLAP (+109.029; K);  
Glycerinylation (+88.016; K); Acetylation (+42.011; K);  Formylation (+27.995; K);  
Glarg (+39.995; R);  MG-H (+54.011; R); G-H1 (+39.990; R); Argpyrimidine 
(+79.966; R) Tetrahydropyrimidine (3-deoxyglucosone) (+144.042; R); 
Dihydroxyimidazolidine (CEAMGDHI) (+72.020; R); N-Pentosyl Lysine 
(+132.0575; K); N-tetrosyl Lysine (+102.0317; K) (as reported already in other 
studies of AGE in human or other animal samples (216–219,221).  All AGE PTM 
were added to the list of other variable PTM described above and included in the 
work flow for the protein identification using the de novo algorithm provided by 
PEAKS 8.0 software.   
Post-translational analysis of carbonylated peptides: The following 
posttranslational modifications were specified in PEAKS 8.0 as variable 
modifications for the carbonylation: Lys->Allysine (-1.03; K); Lys->AminoadipicAcid 
(+14.96; K);  Amino (Y) (+15.01, Y); Trp->Oxolactone (W) (+13.98, W);  Pro-
>Pyrrolidone (P) (-27.99; P);  Pro->Pyrrolidinone (P) (-30.01; P); Arg->GluSA (-
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43.05; R); Dehydrated 4-hydroxynonenal (HNE-Delta:H(2)O(H)) (+138.21, C,H,K); 
reduced 4-Hydroxynonenal (HNE+Delta:H(2) (H)) (+158.13, C,H,K);  HNE 
(+156.12, C,H,K); 4-Oxononenal (ONE) (4-ONE) (+154.10, C,H,K); dehydrated 4-
Oxononenal Michael adduct (4-ONE+Delta:H(-2)O(-1)) (+136.09; C,H,K). 
Validation of the posttranslational (PTM) modifications and normalized spectral 
counts  
Data were validated using the false discovery rate (FDR) method built in 
PEAKS 8.0 and protein identifications were accepted if they could be identified 
with a confidence score (-10lgP)>15 for peptides and (-10lgP)>15 for proteins; a 
minimum of 1 peptide per protein after data were filtered for less than 0.5% FDR 
for peptides and less than 1% FDR for proteins identifications (p<0.05).   An 
independent validation of the MS/MS-based peptides and protein identification 
was performed with the Scaffold (version Scaffold_4.6.2, Proteome Software Inc.) 
using the compatible “.mzid” files of all samples exported from PEAKS 8.0.  The 
Scaffold built in option “MuDPIT” was used to combine multiple files from biological 
and/or technical replicates of each patient or Ob/Ob and littermate control mice 
and the JAWS II dendritic cell line.  Peptide identifications were accepted if they 
could be established at greater than 95.0% probability by the Peptide Prophet 
algorithm with Scaffold delta-mass correction. Protein identifications were 
accepted if they could be established at greater than 90.0% probability and 
contained at least 1 identified peptide. The Protein Prophet algorithm assigned 
protein probabilities. Proteins that contained similar peptides and could not be 
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differentiated based on MS/MS analysis alone were grouped to satisfy the 
principles of parsimony. Proteins were annotated with GO terms from NCBI 
(downloaded on March 2016). 
Scaffold PTM 3.1.0 (Proteome Software Inc, Portland Oregon, USA) was used 
to annotate PTM sites derived from MS/MS sequencing using Scaffold (version 
4.7.2).  Using the site localization algorithm developed by Sean A Beausoleil, Judit 
Villen, Scott A Gerber, Josh Rush & Steven P Gygi, (Nature Biotechnology 24, 
1285-1292 (2006)), Scaffold PTM re-analyses MS/MS spectra identified as 
modified peptides and calculates Ascore values and site localization probabilities 
to assess the level of confidence in each PTM localization.  Scaffold PTM then 
combines localization probabilities for all peptides containing each identified PTM 
site to obtain the best estimated probability that a PTM is present at that particular 
site. The AGE-amide modified peptides identified by both PEAKS 8.0 and Scaffold 
PTM software in duplicates out of triplicate MS runs were manually inspected for 
the criteria described already in other recent studies (216–219,221) 1) missed 
cleavage at the modified residue; 2) the accurate mass increase corresponding to 
AGE modification; 3) presence of unmodified peptide with matching fragments for 
each modified peptide; 4) presence of fragment ions retaining modification; 5) if 
modification is at the N terminus, then presence of b-ions retaining modification 
and unmodified y-ions; 6) if modification is at the middle position, then presence of 
b- or y-ions retaining modification; 7) presence of at least a few consecutive b- or 
y-ions; and 8) presence of complementary b- or y-ions.  The total number of unique 
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AGE and carbonylation sites were calculated for each patient, treated as 
independent biological replicate for each “Diabetics” and “Heathy” group.  Each 
patient sample was run in technical duplicates, which were further MuDPIT in one 
single biological sample such that the average AGE and carbonylation unique sites 
were calculated for each “Diabetics” and “Healthy” group of patients.  Selected 
classes of AGE and carbonylation sites were further quantified and reported only 
for proteins with 50% sequence coverage. 
Gene ontology (GO), molecular and cellular pathways enrichment analysis 
Networks, functional analyses, biochemical and cellular pathways were 
generated by employing the ingenuity pathway analysis (IPA; Ingenuity Systems, 
Redwood City, CA, USA) on the list of identified proteins from each healthy and 
pre/diabetic PBMC sample or Ob/Ob and littermate control mice and the JAWS II 
dendritic cell line.  For network generation, datasets containing gene identifiers 
(gene symbols) were uploaded into the IPA application together with their rescaled 
log2 transformation of protein’s area ratios. These molecules were overlaid onto a 
global molecular network contained in the Ingenuity Knowledge Base. The 
networks of network-qualified molecules were then algorithmically generated 
based on their connectivity index using the built-in the IPA algorithm.  The 
probability of having a relationship between each IPA indexed biological function 
and the experimentally determined genes was calculated by a right-tailed Fisher’s 
exact test.  The level of significance was set to a P-value of <0.05.  Accordingly, 
the IPA analysis identified the molecular and cellular pathways from the IPA library 
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of established pathways that were most significant to the dataset (-log (p 
value)>2.0).  For the quantitative analysis of the expression profiles, IPA assigned 
the “z-score” function to all eligible canonical and cellular pathways (where a “z<-
2 represent significant down-regulation while a z>2.0 represent a significant up-
regulation of the selected pathway)  
Statistic  
Statistical analysis was performed using Windows GraphPad Prism 7.0 
(GraphPad Software, La Jolla, California, USA). Numerical results are reported as 
mean +/- SE or +/-SDV when appropriate. Data are derived from a minimum of 
three independent experiments unless stated otherwise. Statistical significance of 
the difference between experimental groups, in instances of multiple means 
comparisons, was determined using one-way ANOVA, followed by the Bonferroni 
post hoc test. In addition, two-tailed unpaired 1-way ANOVA and two-tailed t-test 
were performed for western blot, ELISA and LFQ analyses.  A “p” value less than 
0.05 was considered significant.  Correlation analysis was performed using linear 
regression and Spearman regression (assuming non-Gaussian distribution of the 
data set). Pearson correlation analysis was performed to determine if there is a 
linear relationship between the total numbers of CML modified lysine residues in 
the hemoglobin alpha and beta chains from pre/diabetics patients and the total 
number of CML modified lysine residues in the total proteome from pre/diabetics 
subjects.  A “r” value less than 0.05 for the Pearson coefficient was considered to 
describe a statistically significant correlation between the two variables of interest. 
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CHAPTER IV  
Recognition of Listeria infection by germline elements of the 
Vγ1.1 Vδ6.3 TCR 
The work presented in this chapter corresponds to the following manuscript ready 
for submission: 
Negroni MP, Kang J, Stern LJ. (2018) Recognition of Listeria infection by germline 
elements of the Vγ1.1 Vδ6.3 TCR. 
 
Author contributions 
I performed all the work presented in this chapter except for the γδNKT TCR 
gamma chain sequencing, which was performed in Dr. Joonsoo Kang laboratory. 
 
Abstract 
γδNKT cells are an abundant γδT cell population with restricted Vγ1.1 Vδ6.3 
gene usage and phenotypic and functional similarity to conventional αβ invariant 
NKT cells. The γδNKT population responds to Listeria infections, but specific 
ligands are not known. In this work we studied the CDR3 requirements of the 
γδNKT TCR, Vγ1.1Vδ6.3 for recognizing naïve macrophages and macrophages 
from Listeria infected mice. We expressed four different variants of the Vγ1.1Vδ6.3 
TCR in TCR-deficient hybridomas, one with germline encoded sequences and 
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three with non-germline encoded sequences. All of the hybridomas were activated 
when cultured in the presence of macrophages, and the activation was increased 
when the macrophages were infected with Listeria. This indicates that these TCRs 
can recognize a self-ligand present in macrophages, and suggests that the ligand 
is modified or upregulated when the cells are infected with Listeria. Since the 
different TCRs introduced in the hybridomas share the same delta sequence but 
have different gamma sequences, we can also conclude that the recognition of the 
Listeria-induced ligand is not gamma CDR3-restricted.  
 
Introduction 
More than twenty years ago, γδNKT cells were identified by different groups as 
a γδT population that shares many similarities with αβiNKT cells (274,275). The 
role and function of γδNKT cells are still not clear. By contrast, αβiNKT have been 
well characterized. They are defined by the expression of a semi-invariant T cell 
receptor (TCR) that recognizes CD1d, a non-classical MHC class I protein (MHC 
I), loaded with self and foreign lipids, and are known to have a broad 
immunomodulatory role (50). Although their TCRs are generated in the same way 
as conventional αβT cell TCRs, by somatic rearrangement of V (variable), D 
(diversity) and J (joining) gene segments (1), the αβiNKT TCR has restricted 
diversity. It is formed by the Vα14Jα18 chain paired with a limited Vβ chain 
repertoire (Vβ2, Vβ7, Vβ8.1, Vβ8.2 and Vβ8.3). In a similar way, the γδNKT cells 
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also express a restricted TCR formed by Vγ1.1Jγ4Cγ4 and Vδ6.3Dδ2Jδ1Cδ1 in 
B6 mice (276) or Vδ6.4Dδ2Jδ1Cδ1 in DBA/2 (275,277). γδNKT and αβiNKT 
populations have a highly similar gene expression profile, more similar to each 
other than αβiNKT with conventional αβ subsets (278). γδNKT and αβiNKT cell 
populations express many of the same cell-surface markers, such as NK1.1 and 
NKG2D, and a preactivated phenotype characterized by the high expression level 
of CD44 and low expression level of CD62L (275,276). In more recent work, it was 
shown that Vγ1.1+ Vδ6.3+ γδNKT cells express PLZF (63), the same transcription 
factor that drives differentiation of αβiNKT (65,279). In γδNKT cells, expression of 
PLZF depends on the strong TCR stimulation, and drives the secretion of both 
IFN-γ and IL-4, a characteristic shared with αβNKT cells (63). 
Despite having a well characterized phenotype, the specific ligand for the 
γδNKT TCR has not been identified yet, limiting understanding of the function of 
these cells in the immune system. Several studies have reported that the γδNKT 
cell population can respond to Listeria monocytogenes (Listeria) infection (280–
283). During early γδT cell studies, it was shown that Vδ6.3+ was the major subtype 
of γδT cells present in liver and thymus during Listeria infection (281). The 
Vγ1.1Vδ6.3 T cells adhered on macrophages isolated from Listeria-infected mice, 
and an anti-Vδ6.3 blocking antibody interfered with cell adhesion indicating that 
the interaction between γδT cells and the macrophages depends on the TCR 
(282). In one study, a Vγ1.1Vδ6.3 hybridoma derived from Listeria-infected mice 
spleen was activated and secreted IFN-γ when cultured with peritoneal exudate 
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cells obtained from Listeria-infected mice (280). In the same study, splenocytes 
enriched for γδT cells showed a cytotoxic effect on the peritoneal exudate cells, 
with the effect blocked by an anti-Vδ6.3 TCR blocking antibody(280). These results 
indicate that the interaction of Vγ1.1Vδ6.3 TCR with a ligand present in 
macrophages from Listeria-infected mice can result in a functional response. Using 
fluorescently labeled oligomers of a soluble version of a γδNKT TCR, carrying 
characteristic Vγ1.1 Vδ6.3 chains from clone BTN 19.8 (derived from the thymus 
of newborn B10 mice (284)), Aydintug et al. were able to stain peritoneal-derived 
macrophages, indicating that the macrophages expressed a self-ligand for the 
TCR (283). Staining was enhanced when the mice were infected with Listeria 
(283). However, staining required higher-order oligomerization, with antibody and 
streptavidin used to form approximately octameric staining reagents, and staining 
was not observed with conventional tetramers (283). This suggests a very low 
affinity interaction between the TCR and the putative ligand present in the 
macrophages. Moreover, since the BTN 19.8 clone was isolated from newborn 
mice before induction of the machinery to generate junctional diversity, the BTN 
19.8 TCR carries germ-line sequences, and the role of CDR3 diversity in ligand 
recognition was not investigated. 
In the present study we investigated the CDR3 sequence requirement of the 
Vγ1.1Vδ6.3 TCR to recognize macrophages and macrophages infected with 
Listeria. For this purpose, we expressed 4 different CDR3 gamma variants of 
Vγ1.1Vδ6.3 TCRs in TCR-deficient hybridomas cell lines, and showed that all four 
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variants can induce cell activation measured as IL-2 secretion when cocultured 
with macrophages. The activation was enhanced when the macrophages were 
directly infected in vitro with Listeria. These results indicate that a functionally 
relevant γδNKT TCR self-ligand is present in macrophages, and that when 
macrophages are directly infected with Listeria they become more potent 
activators of the γδNKT TCR+ hybridomas. The four γδTCRs used in this study 
include both germ-line and adult-derived Vγ1.1 sequences, indicating that 
selection of specific CDR3γ sequences is not required for γδNKT recognition of 
Listeria infection. 
 
Results 
Selection of gamma and delta TCR sequences for expression 
We wanted to express different variants of the Vγ1.1Vδ6.3 TCR to test their 
response to macrophages and macrophages infected with Listeria. We used a 
TCR Vδ6.3 sequence previously characterized for γδNKT cells isolated from the 
liver of WT mice (64). The TCR delta sequences observed in that study had 
restricted junctional diversity with only four different sequences observed, all using 
the same Dδ2 open reading frame and limited N nucleotides, all with the same 
overall CDR3 length. Out of the four sequences observed, we used the most highly 
represented one (88%) (Figure 4.1A) and we randomly call it variant 10. To identify 
TCR Vγ1.1 gamma sequences that could pair with the selected Vδ6.3 sequence, 
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we characterized TCR Vγ1.1 sequences from thymus of adult βTCR knock-out 
mice. Adult thymus γδNKT cells derive from fetal progenitors or from adult 
precursors which remain as a thymic resident population (275,285), and so exhibit 
heterogenous junctional diversity allowing us to characterize a range of TCR Vγ1.1 
sequences. We chose five Vγ1.1 sequences, one with germline sequence called 
variant 10, and the other four selected based on differences in the CDR3 region, 
called variants 2, 3, 6 and 13 (Figure 4.1B).   
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Figure 4.1: Selection of gamma and delta sequences for TCR expression. (A) 
Vδ6.3 sequence selected from γδNKT TCR sequences isolated from WT liver. (B) 
Vγ1.1 sequences of five variants selected from γδNKT TCR sequences isolated 
from TCRβ KO thymus.  
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Most gamma and delta sequences paired and form a TCR on the cell surface 
We transfected the five different gamma chains in combination with the delta 
chain in TCR-deficient T cell hybridomas and tested which of these combinations 
could refold and form a TCR on the cell surface. For this purpose we stained the 
transfected cells with fluorescent anti-Vγ1.1 and anti-Vδ6.3 antibodies and 
measured the percentage of cells stained with both antibodies by flow cytometry. 
When T cell hybridomas were transfected only with the delta chain, they did not 
express TCR on the surface (Figure 4.2A, top left panel). When T cell hybridomas 
were co-transfected with the Vδ6.3 variant 10 in combination with Vγ1.1 variants 
2, 3, 6 or 10, most of the transfected cells bound both anti-Vγ1.1 and anti-Vδ6.3 
antibodies, indicating that they express TCR on the surface (Figure 4.2A and 
4.2B). However, when Vδ6.3 variant 10 was cotransfected with Vγ1.1 variant 13 
(Figure 4.2A, bottom right panel), no TCR was detected, indicating that this 
combination could not refold and traffic to the cell surface. These results showed 
that out of all the possible gamma-delta combinations tested, Vγ1.1 variants 2, 3, 
6 and 10 paired with Vδ6.3 variant 10 (called 2-10, 3-10, 6-10, and 10-10 TCR 
variants respectively) to form a TCR on the cell surface of transfected cells, and 
only Vγ1.1 variant 13 could not form a TCR with Vδ6.3 variant 10. 
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Figure 4.2: Several selected gamma and delta chains paired and formed a 
TCR on the cell surface of transfected hybridomas. (A) Flow cytometric 
analysis of TCR-deficient hybridomas transfected with the Vδ6.3 variant 10 alone 
(-) or in combination with Vγ1.1 sequence variants 2, 3, 6, 10 and 13. Dot plots 
show representative data from one experiment. (B) Percentage of Vγ1.1Vδ6.3 
γδTCR+ hybridoma cells detected by flow cytometric analysis in panel A. Each 
point represents an independent experiment, the mean is represented with a 
horizontal bar, and the error bar represents the standard deviation of the mean.  
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The paired Vγ1.1Vδ6.3 TCRs expressed on the hybridomas are capable of 
transducing activation signals  
To test if the Vγ1.1Vδ6.3 TCRs expressed on the T cell hybridomas were 
functional and could trigger TCR signaling, we treated the cells with anti-Vγ1.1 
clone 2.11, that was previously shown to activate the TCR (286). As an indicator 
of cell activation, we measured the level of IL-2 secreted. We used as controls 
hybridomas untransfected with any TCR (no TCR), hybridomas transfected with a 
control αβTCR, or hybridomas transfected with Vγ1.1 variant 13- Vδ6.3 variant 10 
(13-10 TCR) that was shown not to form a TCR on the surface. We observed that 
the hybridomas expressing the four γδTCR variants were activated and secreted 
IL-2 when cultured in presence of the Vγ1.1 antibody (Figure 4.3). But this antibody 
could not activate the hybridoma transfected with 13-10 TCR, control αβTCR, or 
hybridomas with no TCR transfected, (Figure 4.3). We also treated cells with an 
antibody anti-CD3, which should activate cells expressing any type of TCR on the 
surface. As expected, this treatment was able to activate and induce IL-2 secretion 
from all the hybridomas expressing a TCR on the cell surface (2-10, 3-10, 6-10, 
10-10 and αβTCR). These results indicate that the four pairs of Vγ1.1 and Vδ6.3 
variants formed a functional TCR on the surface, all of them with different CDR3 
regions, and one encoding a germline TCR (10-10).  
Once we knew which Vγ1.1 and Vδ6.3 variants could pair and get expressed 
on the cell surface, and that those TCRs were functional, we sorted the cells 
expressing high levels of 2-10, 3-10, 6-10 and 10-10 TCR out of the total T cell 
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hybridoma transfectants. After sorting the cells, they were assayed by flow 
cytometry and more than 90 % of the hybridomas were stained positive with an 
anti-Vδ6.3 antibody. We used the sorted cells for further experiments.  
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Figure 4.3: Vγ1.1Vδ6.3 TCRs transfected in TCR-deficient hybridomas are 
activated by anti-Vγ1.1, triggering IL-2 secretion. TCR-deficient hybridomas 
transfected with the different Vγ1.1Vδ6.3 TCR variants, 2-10, 3-10, 6-10, 10-10 
and 13-10, or untransfected (no TCR) or transfected with an αβTCR, were cultured 
in the absence (No Ab.) or presence of 5 μg/ml of anti-CD3 or 10 μg/ml of anti-
Vγ1.1 antibodies (Ab.). IL-2 secretion levels were measured by ELISA. Bars and 
error bars represent the mean and the standard deviation of three independent 
experiments, respectively. A paired t-test was used to analyze the statistical 
differences between samples treated with antibiotic (anti-CD3 Ab. and anti-Vγ1.1 
Ab.) compared to the control sample not treated with antibiotic (No Ab.). *p<0.05, 
**p<0.005, ***p<0.0005 and ****p<0.00005. 
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All Vγ1.1Vδ6.3 TCR variants recognized a self-ligand on a macrophage line 
In a previous report was shown that a Vγ1.1Vδ6.3 TCR clone, BNT 19-8, 
obtained from newborn murine thymus (287), was able to stain peritoneal cavity 
macrophages when used as a fluorescently-labeled octamer. Furthermore, the 
staining increased if the macrophages were isolated from a mice previously 
infected with Listeria (283,288). Taking these results into account, we wanted to 
test if the Vγ1.1Vδ6.3 TCR variants could also recognize ligands on macrophages. 
For this purpose, we co-cultured the Vγ1.1Vδ6.3 TCR+ hybridomas with 
immortalized macrophages, and assayed TCR activation as the level of secreted 
IL-2. We observed a general increase in the secretion of IL-2 by the Vγ1.1Vδ6.3 
TCR+ hybridomas when they were cultured in presence of uninfected immortalized 
macrophages compared to when they were cultured alone (Figure 4.4A). 
Hybridomas expressing 2-10 TCR exhibited a relatively high basal level of IL-2 
secretion when they were cultured alone, which was similar to the high levels of 
IL-2 in presence of uninfected immortalized macrophages, making these two 
values not significantly different. For all the other hybridomas expressing the 3-10, 
6-10, and 10-10 TCR variants, we observed a significant increase in IL-2 secretion 
when they were cultured in presence of uninfected immortalized macrophages, 
compared to when they were cultured alone (Figure 4.4A).  
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Figure 4.4: Hybridomas expressing the Vγ1.1Vδ6.3 TCRs are activated with 
immortalized macrophages, and the response increases when activated with 
macrophages infected with Listeria. A) Hybridomas transfected with variants 2-
10, 3-10, 6-10 and 10-10 of the Vγ1.1Vδ6.3 TCR were incubated alone (No Mϕ), 
in the presence of uninfected immortalized macrophages (UI) or immortalized 
macrophages infected with Listeria at an MOI of 0.1, 0.5, 1 and 5. After 16 h, IL-2 
levels in the supernatant were assayed by ELISA. The bars represent the mean of 
4 independent experiments, and the error bar represents the standard deviation of 
the mean. Statistical analysis was performed using a paired t-test. The asterisk 
above the bracket shows the statistical difference between the sample with no 
macrophages (No Mϕ) and UI treatment. Asterisks above the bars show statistical 
differences between each treatment and UI. *p<0.05, **p< 0.005 and ***p<0.0005. 
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B) Same as in (A) but using hybridomas transfected with the TCR variant 13-10, 
which does not generate a TCR at the cell surface, or untransfected hybridomas 
(no TCR), or hybridomas transfected and expressing an αβTCR. C) IL-6 secreted 
by uninfected (UI) immortalized macrophages or infected with Listeria with an MOI 
of 0.1, 0.5, 1 and 5 
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Activation of Vγ1.1Vδ6.3 TCR+ hybridomas is increased when immortalized 
macrophages are infected with Listeria  
In order to test if the Vγ1.1Vδ6.3 TCR+ hybridomas would respond to Listeria 
infection, we cultured the hybridomas expressing different TCRs with immortalized 
macrophages previously infected with different doses of Listeria (MOI 0.1, 0.5, 1 
and 5). The hybridomas expressing the four variants of Vγ1.1Vδ6.3 TCR were 
activated significantly more strongly with macrophages infected with Listeria as 
compared to uninfected macrophages, in a dose dependent manner (Figure 4.4A). 
The activation was dependent on the γδTCR expression, since cells not 
expressing TCR (transfected with 13-10 or untransfected) or expressing an 
αβTCR, did not secrete IL-2 when cultured with macrophages either uninfected or 
infected with Listeria (Figure 4.4B). To confirm that the macrophages were infected 
by the Listeria, we monitored macrophage activation after treatment with different 
Listeria doses, using the level of IL-6 secreted as a readout of macrophage 
response to infection. We observed that the levels of secreted cytokine increased 
with increasing doses of Listeria, indicating that the doses we were using were not 
saturating (Figure 4.4C). These results indicate that the Vγ1.1Vδ6.3 TCR+ 
hybridomas could recognize a TCR self-ligand present in macrophages, and that 
ligand was modified or upregulated after Listeria infection.  
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Peritoneal derived macrophages also activate the Vγ1.1Vδ6.3 TCR+ hybridomas  
Previous work on a different γδ T cell receptor (human Vγ4Vδ5 clone) showed 
that it recognized the endothelial protein C receptor (EPCR), but only on 
transformed cells or on cells infected with cytomegalovirus (CMV), indicating that 
in that case the γδ T cell response required a particular cellular environment (80). 
We wanted to investigate whether the Vγ1.1Vδ6.3 TCR+ hybridomas were similarly 
dependent on transformation, or whether they could also be activated by primary 
cells. Thus, we repeated the experiments shown in Figure 4.4, using primary 
macrophages isolated from the peritoneal cavity instead of an immortalized 
macrophage cell line.  
Hybridomas expressing the Vγ1.1Vδ6.3 TCRs secreted higher levels of IL-2 
when cultured in presence of uninfected macrophages isolated from wild type B6 
peritoneal cavity than when cultured alone without macrophages (Figure 4.5A). 
The amount of IL-2 secreted by the hybridomas was even higher when the 
macrophages were previously infected with four different doses of Listeria (Figure 
4.5A). The activation of the hybridomas depended on the γδTCR expression, since 
cells not expressing a TCR or expressing an αβTCR, did not secrete IL-2 when 
cultured with uninfected or infected macrophages from the peritoneal cavity (Figure 
4.5B). Levels of IL-6 secreted by the macrophages treated with the different 
Listeria doses reached a maximum after the second dose of Listeria, indicating 
that the Listeria doses we used had a stronger effect on infecting and/or activating 
the macrophages isolated from the peritoneal cavity than the immortalized 
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macrophages (Figure 4.5 C). From these results we can conclude that Vγ1.1Vδ6.3 
TCR with different CDR3 regions can recognize a ligand present in primary or 
transformed macrophages. 
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Figure 4.5: Hybridomas expressing Vγ1.1Vδ6.3 TCRs also recognize 
macrophages isolated from the peritoneal cavity, and the response 
increases when activated with macrophages infected with Listeria. (A) 
Hybridomas transfected with variants 2-10, 3-10, 6-10 and 10-10 of the 
Vγ1.1Vδ6.3 TCR were incubated alone (No Mϕ), in the presence of uninfected 
macrophages (UI), or in the presence of macrophages infected with Listeria at an 
MOI of 0.1, 0.5, 1 and 5. After 16 h of incubation, IL-2 levels in the supernatant 
were assayed by ELISA. The bars represent the mean of 3 independent 
experiments, and the error bar represents the standard deviation of the mean. 
Statistical analysis was performed using a paired t-test. The asterisk above the 
bracket indicates statistical difference between the sample with no macrophages 
(No Mϕ) and the UI treatment. Asterisks above the bars show statistical differences 
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between each treatment and UI. *p<0.05, **p< 0.005 and ***p<0.0005. (B) Same 
as in (A) but using hybridomas transfected with the TCR variant 13-10, which does 
not generate a TCR at the cell surface, or untransfected hybridomas (no TCR), or 
hybridomas transfected and expressing an αβTCR. (C) IL-6 secreted by uninfected 
(UI) peritoneal cavity macrophages or infected with Listeria at an MOI of 0.1, 0.5, 
1 and 5. 
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Discussion 
In this study we investigated ligand recognition by different variants of the 
Vγ1.1Vδ6.3 TCR from γδNKT cells. All of the γδTCR variants we studied shared 
the same delta sequence and had different gamma junctional regions. We 
observed that TCR-deficient hybridomas transfected with the various Vγ1.1Vδ6.3 
TCR became activated when cultured in presence of macrophages, and that this 
activation increased when the macrophages were previously infected with Listeria. 
Activation was specific to the Vγ1.1Vδ6.3 TCR, since hybridomas not expressing 
any TCR or expressing an αβTCR did not show activation when cultured in 
presence of macrophages. These results expand on aspects of previous work on 
the Vγ1.1+Vδ6.3+ T cell population and its role in recognizing Listeria infection 
(280–283).  
In previous work, it was shown that Vγ1.1Vδ6.3 TCR could recognize 
macrophages from Listeria-infected mice (280,282,283). However it was not clear 
if the macrophages needed to be directly infected or if the Listeria- infected 
environment induced changes in the macrophages that allowed for Vγ1.1Vδ6.3 
TCR recognition. In our studies, we infected the macrophages in vitro with cultured 
Listeria, using the level of IL-6 secretion to monitor the degree of macrophage 
infection. We found that macrophages directly infected with Listeria can activate 
the Vγ1.1Vδ6.3 TCR+ hybridomas more potently than uninfected macrophages.  
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Several potential mechanisms could be envisioned to explain how uninfected 
macrophages could induce activation on the Vγ1.1Vδ6.3 TCR+ hybridomas, with 
activation increased when the macrophages were infected with Listeria. One 
possibility is that the Vγ1.1Vδ6.3 TCR recognizes a self-ligand that is expressed 
at low levels on resting macrophages, with surface expression of the self-ligand 
increased after Listeria infection. This mechanism has been observed for murine 
G8 and KN6 γδTCR clones that recognize T10/T22 (67,68), which are MHC I-like 
molecules that do not bind or present antigens (289). The expression level of T10 
and T22 increases in activated lymphocytes and it has been suggested that this 
modulates the activation of γδT cells expressing the G8 and the KN6 receptors 
(81). A second possibility is that this TCR recognizes a self-ligand that binds a 
Listeria-derived molecule upon infection, causing an increase in the affinity 
between the TCR and the ligand. This type of mechanism has been observed for 
γδT cells recognizing CD1d-lipid complexes, where the TCR affinity for CD1d 
increases when it is presenting a specific lipid derived from bacteria (72–74), and 
it also appears to be the mechanism for a human Vγ9Vδ2 TCR that recognizes an 
allosteric change on the A1 isoform of the butyrophilin-3 (BTN-3) in response to 
intracellular accumulation of phosphoantigens in infected or transformed cells 
(77,78). A third possibility involves both TCR recognition of a self-ligand present in 
uninfected macrophages, and a second ligand induced by Listeria infection that 
either favors TCR recognition of the self-ligand or promotes activation of the 
hybridomas by interacting with a different receptor on these cells. This appears to 
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be the mechanism for the human LES Vγ4Vδ5 TCR, that recognizes the CD1d-
like lipid-binding protein EPCR in certain tumor cell lines and in CMV-infected 
fibroblasts (80). Further studies would be required to determine whether 
Vγ1.1Vδ6.3 TCR recognizes Listeria infection by upregulation or modification of a 
self-ligand, induction of additional ligand(s), or another mechanism.  
Previous work showing that the Vγ1.1Vδ6.3 TCR has a role in recognizing 
Listeria infection (280–283) did not address the role of the junctional regions in 
ligand recognition. Previous studies analyzed only the variable gene usage but not 
CDR3 sequence dependence for γδT cells responding to Listeria infection 
(281,282), or investigated only individual Vγ1.1Vδ6.3 TCR sequences expressed 
on hybridomas or as soluble oligomers (280,283). So, it is still not known if all 
Vγ1.1Vδ6.3 TCRs can recognize macrophages from Listeria infected animals, or 
whether some particular CDR3 sequences are required. Here we showed that the 
four Vγ1.1Vδ6.3 TCR variants were able to recognize macrophages and 
macrophages infected with Listeria. These TCRs were formed by the combination 
of a germline-encoded Vδ6.3-Dδ2-Jδ1 chain in combination with four Vγ1.1-Jγ4 
variants with different junctional regions. Therefore, we can conclude that 
variability on the CDR3γ does not limit the ligand recognition of these cells. 
Furthermore, one of the TCR variants was completely germline derived, 
suggesting that both fetal and adult derived Vγ1.1Vδ6.3 TCRs can recognize the 
same Listeria-modulated ligand.  
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Variability in the CDR3γ region did not affect ligand recognition by Vγ1.1Vδ6.3 
TCRs. Crystal structures determined for three other γδTCRs in complex with their 
ligands similarly show a limited role for the CDR3γ in ligand recognition 
(73,74,140). These γδTCRs dock differently on their ligand, but all sit with a tilted 
angle on top of the ligand resulting in an interaction mode that involves mainly the 
delta chain. This interaction mode is different than the conventional diagonal 
αβTCR-MHC interaction, in which, both CDR3α and CDR3β chains typically 
interact with the MHC-peptide binding surface (125). For the murine G8 γδTCR in 
complex with T22, the main interaction is between CDR3δ loop and the empty cleft 
of the T22 protein followed by the interactions involving residues from the CDR1δ 
and CDR2δ loops. The CDR3γ loop also interacts with T22, but contributes only 
11% of the buried surface area (140). For the Vγ5Vδ1 TCR in complex with CD1d-
αGalCer (73), CDR1δ and the CDR3δ contributed most of the TCR-ligand 
interaction, while only one residue from the gamma chain contacted CD1d. For 
Vγ4Vδ1 TCR in complex with CD1d-sulfatide (74), CDR1δ, CDR2δ, and CDR3δ 
loops were evenly involved in the interactions with CD1d and the sulfatide, while 
the gamma chain did not show any interactions with the ligand. It is possible that 
the Vγ1.1Vδ6.3 TCR recognition also involves a tilted angle between the γδTCR 
and its ligand, using mainly the delta chain to interact.  
The findings in this paper support the idea that γδNKT TCRs formed by a 
Vγ1.1Vδ6.3 TCR recognize a self-ligand present in macrophages that is 
upregulated or modified on macrophages directly infected by Listeria, causing an 
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increase on the γδNKT TCR activation. The TCRs that recognize this ligand can 
be originated from fetal as well as from adult γδT cell development, and most 
probably the recognition involves the delta chain of the TCR or conserved regions 
in the gamma chain but not CDR3γ.  
 
Materials and methods 
TCR gamma sequencing and cloning 
Total RNA was isolated from TCRβ-/- Vγ1.1+Vδ6.3+ thymic γδT cells, and TCR 
gamma sequences were cloned as described by Yin C.C., et al. (64). Briefly, 
reverse transcription was performed with qScript DNA Supermix (Quantabio, 
Beverly, MA). TCR Vγ region sequences were amplified from cDNA by PCR using 
previously described primers (288). Amplified sequences were cloned into the 
pCR2.1-TOPO TA vector using the TOPO TA cloning kit (Invitrogen, Carlsbad, 
CA), and DNA isolated from individual clones was sequenced using both forward 
and reverse primers.  
Transfection of gamma and delta sequences in hybridomas  
Gamma and delta sequences cloned into the pCR2.1-TOPO vector did not 
include the transmembrane domain, and thus for expression of TCR on the cell 
surface, the constant region sequences were fully extended using overlapping 
PCR. Using T4 DNA polymerase, 160 and 140 nucleotides of the missing Cγ4 and 
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Cδ1 sequences, respectively, were synthesized. The following primers, shown 
with the 21-nucleotide overlapping portions underlined, were used (all listed 5’ to 
3’): 
Cγ4 forward:  
CTGGAAGATTGCATGAAAGGAAGAAAGGATATGTTGCAGCTTCAGGTCACC
ACCACCTATGCATTCTACACCTACCTCATCCTGTTCTTC 
Cγ4 reverse: 
GATCATCACAGGACATGGCTGCTCTTCTGAATAGACAGAATACAACGAAGG
CCAAGTGGACCATGCTCTTGAAGAACAGGATGAGGTAGG 
Cδ1 forward: 
CAGAGCCTTGCTATGGCCCAAGAGTCACAGTTCACACTGAGAAGGTAAACA
TGATGTCCCTCACGGTGCTGGGCCTACGACTGC 
Cδ1 reverse: 
TTAAAAGAATAACTTAACAGTCAAGAGAAAATTGATGGCAATGGTCTTGGCA
AACAGCAGTCGTAGGCCCAGCACCG 
Amplification products were run on a 2% agarose gel and purified, and then 
were used in a subsequent overlapping PCR with the pCR2.1-TOPO vector 
expressing each of the gamma and delta chains and the following primers. The 
primers included restriction enzyme sites (shown as underlined) with the enzyme 
indicated in brackets: 
Cγ4 forward (XhoI):  
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CCGCTCGAGATGCTGCTCCTGAGATGGCCCACC  
Cγ4 reverse (NotI): 
TTTTCCTTTTGCGGCCGCTTATGAACGTTGATCATCACAGGACATGGCTGCT
CTTC 
Cδ1 forward (SalI): 
ACGCGTCGACATGCCTCCTCACAGCCTGTTCTGTG 
Cδ1 reverse (NotI): 
TTTTCCTTTTGCGGCCGCTTAAAAGAATAACTTAACAGTCAAGAGAAAATTGA
TGGC 
Amplification products for gamma and delta chains were cloned into murine 
stem cell virus-based vectors with resistance genes for zeocin and neomycin, 
respectively. These retroviral vectors as well as the pCL-Eco accessory plasmid 
were cotransfected using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, 
MA) into Phoenix cells. After 48 h, the transfected Phoenix cell supernatant was 
collected and used to transduced αβTCR-deficient T cell hybridoma 5KC-73.8.20 
(kindly provided by Dr. Eric Huseby, University of Massachusetts Medical School, 
Worcester, MA) by spinfection, at 1800 rpm for 2 h at room temperature (290). T 
cell hybridoma transfectants were selected using 0.5 mg/ml neomycin and 0.5 
mg/ml of zeocin for 5 days.  
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Flow cytometry and cell sorting 
T cell hybridoma transfectants (2x106 to 4x106) were treated with anti-mouse 
CD16/CD32 (2.4G2, BioXCell, Walpole, NH) to block Fc receptors, washed and 
stained with FITC anti-mouse TCR Vγ1.1/Cr4 clone 2.11 (BioLegend, Dedham, 
MA), PE anti-mouse Vδ6.3/2 clone 8F4H7B7 (BD Biosciences, San Jose, CA) and 
Live/Dead violet (Thermo Fisher Scientific) for 20 min at 4°C. Cells were acquired 
on an LSRII (BD Biosciences) flow cytometer, and data were analyzed using 
FlowJo software (Tree Star, version 9.7.5, Ashland, OR). For cell sorting, 7x106 to 
9x106 cells were stained as described above, and FITC and PE double-positive 
cells were sorted on a FACSAria II (BD Biosciences). 
Macrophage infection and T cell hybridoma activation assay  
Immortalized macrophages from wild-type C57BL/6 mice were generated using 
bone marrow-derived macrophages as previously described (291) and then 
immortalized by treatment with supernatant from NIH J2 Leukocyte cells, kindly 
provided by Dr. Kenneth L. Rock (University of Massachusetts Medical School, 
Worcester, MA) (292). Peritoneal cavity macrophages from wild-type C57BL/6 
mice were elicited by injection of 3 ml 1% thioglycollate solution intraperitoneally, 
followed by peritoneal lavage and collection at 72 h.  
Immortalized macrophages or peritoneal cavity macrophages were plated in 
96-well plates at 7x104 or 1x105 cells per well, respectively, in media without 
antibiotic and incubated at 37°C overnight. Listeria monocytogenes (10403s strain) 
 190 
 
was kindly provided by Dr. Katherine Fitzgerald (University of Massachusetts 
Medical School, Worcester, MA). Listeria stock was thawed, and 200 μl was diluted 
in 10 ml of fresh media and incubated for 1.5 h in a shaking incubator at 37°C and 
225 rpm. 1 ml of the bacteria culture was then centrifuged at 10,000 g for 10 min 
at room temperature, and the pellet was resuspended in 1 ml PBS and was used 
to infect preplated macrophages at different MOIs. After addition of bacteria to 
each well, the plate was spun at 400 g for 5 min at room temperature and then 
incubated for 1 h at 37°C. Media was then replaced with media containing 100 
μg/ml of gentamicin. After 3 h of incubation, the media was removed, and 250 
μl/well of media alone or media containing 1x105 T cell hybridomas transfected 
with different γδTCRs (or untransfected or transfected with an αβTCR as controls) 
was added to the infected macrophages. After 16 h, IL-2 and IL-6 levels in the 
supernatant were tested by ELISA (BD Biosciences and Thermo Fisher Scientific, 
respectively).  
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CHAPTER V 
Conclusions and future directions 
The research presented in this thesis examined different aspects of antigen 
presentation and recognition. In Chapter II, I described the design of 
photocleavable peptides in search of a reagent that could generate DR1 empty in 
its active conformation to be used in DR1-peptide binding kinetic studies. In 
Chapter III, I presented work performed in collaboration with Laura Santambrogio’s 
laboratory, in which we studied protein modifications caused by hyperglycemic 
conditions, such as diabetes, and their effect on antigen presentation pathways. In 
Chapter IV, I studied the ligand recognition requirements of a γδTCR from a 
specific γδT cell population that is known to play a role during Listeria infection. 
 
Photocleavable peptide design for MHC II proteins 
In Chapter II, I designed different photocleavable peptides in search of a 
peptide that could efficiently bind DR1, so as to generate fragments that could be 
immediately released after UV treatment and generate DR1 empty in the active 
conformation. This would allow us to perform DR1-peptide binding kinetic studies 
using DR1 fully in the DR1a conformation as starting material, instead of DR1 
empty, which is in equilibrium between the DR1a and DR1i conformations. I found 
that photocleavable peptides that bind DR1 with high affinity generated fragments 
following UV exposure, after which the N-terminal fragment was released from the 
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peptide-binding groove with kinetics sufficiently slow to interfere with binding of 
incoming peptides. I modified the photocleavable peptide sequence to avoid slow 
release of the N-terminal fragment. If the photocleavable peptide sequence was 
modified to weaken the P1 pocket interaction or to impair the formation of N-
terminal hydrogen bonds, these peptides could generate fragments with faster 
release kinetics after UV exposure. However, with these modifications, the affinity 
of these peptides for DR1 decreased to such a degree that they were easily 
exchanged for an incoming peptide even before photocleavage. We concluded 
that these peptides could be used to exchange peptides more efficiently, but that 
they could not be used for controlled generation of DR1a for peptide binding kinetic 
studies, given that the fragments generated can interfere with binding of the 
incoming peptide.  
Successful design of photocleavable peptides to generate fragments that are 
released from the peptide-binding groove with rapid kinetics appears to depend 
upon achieving the appropriate balance between identifying a photocleavable 
peptide sequence that can bind to MHC II strongly enough so that it cannot be 
exchanged easily by other peptides before photocleavage, but at the same time 
weakly enough so as to generate fragments that can be released easily from the 
MHC II peptide-binding groove upon UV exposure. Finding the appropriate 
balance will likely be more challenging for some MHC II alleles than others, 
depending on the distribution of the strength of the interactions between the 
peptide and MHC II along the peptide-binding groove.  
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Taking into account that the pockets of each HLA-DR allele vary in shape and 
size due to their polymorphism, it appears that the photocleavable peptides we 
designed and the results we observed may not be applicable to other HLA-DR 
alleles. In previous work performed by another lab (151), in which a photocleavable 
peptide for a different DR allele was used, the authors designed a photocleavable 
peptide that could stably bind DR2b and could be successfully cleaved and 
released from the peptide-binding groove only after UV exposure. The differences 
in their results and ours could be explained by the differences in the peptide-
binding groove of DR2b compared to DR1. In DR1, the P1 pocket is a large 
hydrophobic pocket that preferably accommodates bulky hydrophobic residues 
such as Tyr, Phe, or Trp and serves as a major determinant of peptide binding, 
whereas in DR2b this pocket is shallower and its interaction with peptide is weaker 
(180,293). This difference in the P1 pocket may explain why the N-terminal 
photocleavable peptide fragment was released with faster kinetics in DR2b than in 
DR1. Thus, we can also consider photocleavable peptides as tools to learn about 
MHC II-peptide interactions, and about the strength distribution of these 
interactions along the peptide-binding groove. 
A further possible application of the photocleavable peptides I designed is the 
generation of a crystal of DR1 empty for structural work. Despite the fact that there 
are more than 170 solved structures of MHC II-peptide complexes in the PDB 
database, a structure for MHC II empty has not yet been solved. Solving the crystal 
structure of MHC II empty, as well as of MHC I empty, has proven difficult due to 
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the fact that these proteins are unstable when they are not bound to a peptide, 
causing aggregation at the high concentrations of protein required for 
crystallography. Using a photocleavable peptide could help to overcome this 
problem. DR1 loaded with a photocleavable peptide could be used to set up 
crystals, helping to keep DR1 stable and soluble at high concentrations, and once 
crystallized could be exposed to UV light to fragment the peptide and allow the 
fragments to be released from the peptide-binding groove. It is possible that if the 
packing of DR1-photocleavable peptide in the crystal structure is very tight, with 
several crystal contacts around the peptide-binding groove, then the fragments 
could remain bound to DR1 and thus prevent acquisition of the DR1 empty 
structure. It is also possible that when the crystal is exposed to UV light and the 
photocleavable peptide is fragmented and released, DR1 becomes so flexible that 
it disrupts the crystal contacts, dissolving the crystal. Despite these potential 
complications, the photocleavable peptides I designed could serve to fill a 
considerable gap in crystallographic analysis of the DR1 molecule, if successful.  
Solving the structure of DR1 empty would represent a significant contribution 
to the MHC II-peptide binding field, as it would provide understanding of the 
conformational changes that DR must undergo to bind peptide. If a crystal of DR1-
photocleavable peptide is attained, I predict that the crystal contacts between DR1 
molecules in the crystal packing will determine what conformation of DR1 empty 
can be obtained after photocleavage. If the crystal contacts are close to the 
peptide-binding pocket, they may constrain the flexibility of that area and disallow 
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freedom of movement, so that the final structure may be similar to the structure of 
DR1-peptide complex, likely reflecting the DR1a conformation. Conversely, if 
crystal contacts between different DR1 molecules in the crystal are made in 
regions far from the peptide-binding groove, this domain will consequently have 
more freedom and, once the peptide fragments are released, the protein may be 
stabilized in a conformation that resembles the DR1i form, likely similar to the 
conformation that was observed in a DR1 empty molecular dynamics simulation 
(136). In this simulation, the DR1 αF54 residue occupied the P1 pocket, and 
adjacent residues occupied the peptide-binding groove from P1 to P4, likely 
stabilizing the DR1 in a conformation that interferes with peptide binding (136).   
Better understanding of the DR1 empty structure may also help to understand 
the DR1 conformation that is recognized by DM. DM catalyzes peptide exchange 
on pre-formed DR1-peptide complexes, and DM also catalyzes peptide 
association to DR1 empty, selecting peptides with higher affinity for DR1 and 
acting as a peptide editor to influence the peptides presented at the cell surface 
for antigen presentation (116,294,295). Understanding the DR1 conformation 
recognized by DM may allow for greater understanding of the basis of DM 
recognition and peptide editing. It is known that DM binds MHC II near the N-
terminus of the peptide-binding groove (115,158,296). However, it remains unclear 
why some DR1-peptide complexes are recognized by DM and others are not. 
Crystal structures of DR1 loaded with peptides that are susceptible to DM (i.e. 
peptides easily exchanged for other peptides in the presence of DM) vs. peptides 
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that are DM-resistant (i.e. those for which the presence of DM does not increase 
the peptide-exchange rate) do not show significant differences (128,174) that 
would explain why one complex is a substrate of DM while the other is not. In the 
crystal structure of the DR1-DM complex, one of the regions where significant 
changes were observed in comparison with the structures of DR1-peptide 
complexes was the DR1 α35-57 region (225,297). Differences included, among 
other changes, flipping out of the αW43 residue and rearrangement of the αF51 
residue to stabilize the empty P1 pocket. The conformation that DR1 adopts in 
complex with DM will disrupt the interactions between DR1 and the N-terminal of 
the peptide, inducing peptide release. NMR experiments showed that a DR1-
peptide complex susceptible to DM had more flexibility in residues located in the 
DM interface, compared with a DM-resistant DR1-peptide complex (174). It is 
possible that this DR1 flexibility is required by DM in order to allow DM to induce 
conformational changes in DR1. If this is the case, the crystal structure of DR1-DM 
may reflect the DR1 structure after the conformational changes occur rather than 
the DR1 structure that was originally recognized by DM. Consequently, the 
structure of DR1 empty may reveal a conformation able to be recognized by DM 
and thus could possibly help predict how DM-susceptible peptides allow DR1 to 
adopt that conformation. 
The conclusion that the N-terminal fragment of the photocleavable peptide I 
designed was being released with slow kinetics from the DR1 peptide-binding 
groove was reached through indirect measurements. However, photocleavable 
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peptide fragment release from the peptide-binding groove can be directly 
measured by adding a fluorophore at either the N- or C-terminus of the 
photocleavable peptide. This allows for direct measurement of each fragment 
released after UV exposure by fluorescence polarization. These type of 
measurements could be used in future photocleavable peptide design experiments 
in order to determine how to weaken the interactions between a fragment and the 
peptide-binding groove when a fragment is retained.  
 
Studies on the effect of glycation on DR1 peptide-binding kinetics and its 
catalysis by DM 
In Chapter III, I presented my results (Figure 3.6) in the context of a 
collaboration with Laura Santambrogio’s laboratory. In this work, Dr. 
Santambrogio’s group found that in patients with hyperglycemic conditions, such 
as diabetes and metabolic syndrome, different proteins involved in the antigen 
presentation pathway display AGE modifications. Using mouse models that cause 
hyperglycemia, they found that I-Ab, and several other components of the antigen 
presentation pathway, were significantly modified and that antigen presentation 
efficiency was affected in these animals compared to normal mice (without 
hyperglycemia). I performed in vitro experiments to study the effect of glycation on 
human MHC II peptide-exchange kinetics and the catalysis of this reaction by DM. 
I observed that glycation of DR1 did not affect the kinetics of DR1-peptide 
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exchange. However, when the peptide exchange reaction was performed in the 
presence of DM, the catalytic effect of DM on this reaction was decreased with 
glycated DR1 compared to control DR1. Mass spectrometry analysis of DR1 
glycated in vitro showed AGE modifications in similar regions of the protein as the 
I-Ab that was glycated in vivo, including at the interface with DM, suggesting that 
AGE modifications can interfere with the DR1-DM interaction. This observation 
explains the reduced DM catalytic effect for glycated DR1. Since DM favors binding 
of peptides with higher kinetic stability (298–302), the repertoire of peptides that 
DR1 will present at the cell surface will be affected if DM activity is impaired.  
The concentrations of glucose I used to glycate DR1 (5 mM and 20 mM) are 
the glucose concentrations in plasma of pre-diabetic and diabetic patients. 
However, the DR1 concentration used during glucose treatments, and the absence 
of other molecules that could interfere with the glycation reactions in this assay, 
suggest that in vitro glycation, even when using physiological glucose 
concentrations, may not cause the same level and types of glycation that DR1 will 
display when glycated in vivo. While the modifications observed in I-Ab glycated in 
vivo did show similar locations and the same type of AGE modifications as the 
modifications observed in DR1 glycated in vitro, the mass spectrometry analysis 
performed on both samples does not address how much of the protein present in 
the sample displays each of the detected modifications, making it difficult to 
compare the levels of modifications in both samples. Further analysis would be 
needed in order to determine if the modifications I induced in DR1 are 
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representative of the modifications that this protein will undergo in physiological 
conditions in a hyperglycemic environment.  
In order to determine whether the observed decrease in DM catalysis of the 
peptide-exchange reaction on glycated DR1 could have an impact on the peptide 
repertoire that MHC II presents at the cell surface, an MHC II peptidome analysis 
could also be performed. For this purpose, DC isolated from Ob/Ob and control 
mice could be used to purify I-Ab and perform mass spectrometry of eluted 
peptides. Comparing the peptide sequences of Ob/Ob vs. control DCs would help 
to understand if the observed in vitro effect of DR1 glycation has an impact on DM 
peptide editing in vivo.  
 
Difficulties in identifying γδT cell ligands 
In Chapter IV, I presented the work I performed to examine γδNKT TCR 
requirements for ligand recognition. I showed that hybridomas expressing different 
γδNKT TCRs, which shared the same delta sequence but differed in their gamma 
chain junctional region, are all activated in the presence of macrophages. Their 
activation was further increased when macrophages were previously infected with 
Listeria. We concluded that ligand recognition by the TCR of the γδNKT cell 
population does not appear to be restricted by a particular CDR3γ sequence. 
Instead, TCRs with differences in their CDR3γ regions, including germline-
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encoded CDR3γ, all seem to recognize the same ligand expressed on 
macrophages.  
I also found that Listeria infection of macrophages is required for activation of 
hybridomas expressing different γδNKT TCRs. In previous work it was shown that 
Vγ1.1Vδ6.3 TCR could recognize macrophages from Listeria-infected mice 
(280,282,283), but it was not clear if the macrophages needed to be directly 
infected or if the Listeria-infected environment induced changes in the 
macrophages that allowed for Vγ1.1Vδ6.3 TCR recognition. In the work presented 
in Chapter IV I showed that macrophages in vitro infected with Listeria could 
activate Vγ1.1Vδ6.3 TCR+ hybridomas. There are two possible mechanisms that 
could lead to this result. One is that the infected macrophages express the 
Vγ1.1Vδ6.3 TCR ligand and directly activate the hybridomas. The second 
possibility is that infected macrophages secrete cytokines that can activate 
uninfected macrophages in the same experimental well, and are these activated 
macrophages that express the TCR ligand that can activate the Vγ1.1Vδ6.3 TCR+ 
hybridomas. I did not address this issue in the research presented in Chapter IV, 
but a supernatant transfer assay could be done to rule out which of the two 
mechanisms is taking place. For this assay, uninfected macrophages can be 
treated with supernatant of Listeria-infected macrophages to test if these infected 
cells secreted some molecule to the supernatant that can confer uninfected 
macrophages the ability to activate the Vγ1.1Vδ6.3 TCR+ hybridomas. With this 
experiment we could understand if macrophages need to be infected to either 
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express the ligand, or to activate other macrophages that will finally express the 
ligand. However, in both situations, Listeria infection of the macrophages is 
required to activate the hybridomas.Originally, the aim of this project was to identify 
the ligand on the Vγ1.1Vδ6.3 γδNKT TCR. Based on preliminary experiments 
performed in Dr. Joonsoo Kang’s lab, we hypothesized that EPCR, an MHC I-like 
molecule that shares high homology with CD1d, could be the ligand of this TCR. I 
attempted to express a soluble version of this γδNKT TCR and EPCR to perform 
SPR assays. We were able to successfully express EPCR, but I was never able to 
obtain soluble TCR despite using different expression systems, different lengths 
of the extracellular domain of the TCR and even introducing cysteines that could 
potentially form disulfide bonds between the gamma and delta chains to stabilize 
the dimer. I then transfected hybridomas with the different γδNKT TCRs, and I 
searched for a system that I could use to test if EPCR was indeed the TCR ligand. 
Based on previous reports (280–283,288), I found that both immortalized 
macrophages and peritoneal-derived macrophages could activate the hybridomas 
expressing the different γδNKT TCR variants, and that activation increased if the 
macrophages were infected with Listeria. However, I could never obtain clear and 
definitive data to confirm that EPCR was the γδNKT TCR ligand present on the 
macrophages.  
Identifying ligands for γδT cells has posed a significant challenge in the γδT 
cell field. γδT cells are not MHC-restricted and, based on the few ligands that have 
been identified thus far, they appear to be able to recognize a broad variety of 
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molecules (52), making it difficult to predict the ligands for additional γδT cell 
populations. A further complication in this field is the fact that these cells can be 
activated via other cell surface receptors in addition to their TCR, such as through 
the natural-killer group 2, member D (NKG2D) receptor. Several molecules that 
were first thought to be TCR ligands because of their ability to activate γδT cells 
were in fact determined to be ligands for other receptors present in γδT cells (57).  
For γδT cells that express the human Vγ9Vδ2 TCR, over 20 years have passed 
since it was determined that these cells can recognize phosphoantigens (303). 
However, it remains unclear how these antigens are detected by this γδTCR. It 
was originally thought that the TCR could directly recognize these molecules, but 
attempts to show their direct interaction have failed (304). Recently, the A1 isoform 
of butyrophilin-3 (BTN3-A1) was shown to be implicated in phosophoantigen 
recognition by the Vγ9Vδ2 TCR (77), but some controversy exists as to how this 
γδTCR senses phosphoantigens through BTN3-A1. One group published data that 
suggests the TCR recognizes conformational changes on the BTN3-A1 
extracellular domain induced by the intracellular accumulation of phosphoantigens 
sensed by the cytoplasmic domain of BTN3-A1 (305,306), while another group 
published biophysical and structural studies indicating that BTN3-A1 binds 
phosphoantigens in a small cleft in the extracellular domain and makes cognate 
interactions with soluble Vγ9Vδ2 (307). Further studies are needed to clarify this 
controversy. This example demonstrates the difficulty in identifying γδT cell ligands 
and in understanding the mechanism by which they are recognized. It is possible 
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that γδNKT TCR ligand recognition involves a complex mechanism that makes 
determining if EPCR is the ligand for this receptor quite difficult.  
 
General remarks on the antigen presentation and recognition field 
In the antigen presentation field, there are outstanding remaining questions 
related to the processes that define the peptides presented on MHC molecules. It 
is important that the MHC-peptide complexes that traffic to the cell surface are 
stable in order to allow for TCR recognition and T cell activation. Peptide selection 
processes also play an important role in T cell selection in the thymus, and defects 
in selection can lead to different autoimmune diseases such as type 1 diabetes 
and rheumatoid arthritis. The photocleavable peptides I generated and described 
in Chapter II could be used as reagents to answer questions related to the 
properties that render select DR1-peptide complexes susceptible to DM, as well 
as help understand the basis of peptide editing by DM and the way in which the 
repertoire of peptides presented by MHC II is consequently affected. I also have 
shown that in pathological conditions such as diabetes, protein modifications can 
be induced in DR1, which can affect the interaction of DR1 with DM and impair DM 
catalysis of peptide exchange. These alterations may cause changes in the 
peptides that are presented by MHC II, potentially explaining facets of diabetic 
pathology. Further studies of the MHC II peptidome in diabetic conditions could 
help understand how the peptide repertoire that binds MHC II can be affected in 
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cases where DM interaction with MHC II is impaired. Such studies may also help 
understand the consequences of a defective peptide selection process.   
Following peptide selection, the MHC-peptide complexes presented on the cell 
surface can be recognized by T cells and activate them to initiate an adaptive 
immune response. The way in which TCRs recognize MHC-peptide complexes as 
well as identification of ligands of non-conventional T cells have been longstanding 
questions in the antigen recognition field. Conventional αβT cells have been 
broadly studied, and a model for their mode of MHC-peptide recognition is 
generally understood and accepted (125). Conversely, for non-conventional γδ T 
cells, which are not MHC-restricted, many questions remain regarding the ligands 
they recognize and the TCR restrictions for ligand recognition. I have shown that 
a population of γδ T cells recognizes their ligand via a mechanism that appears to 
be independent of the gamma-chain junctional region sequence. According to 
these results and based on the few crystal structures that exist of γδ TCRs in 
complex with their ligands, it is possible that γδ T cell ligand recognition is primarily 
dependent on the delta chain, allowing for more variability in the gamma chain. 
However, for the few γδ T cells for which ligands have been identified, significant 
differences have been demonstrated in terms of their molecular structure and 
composition, making it difficult to predict a general mode of γδ TCR-ligand 
recognition, or to conclude that γδ TCRs all share the same sequence and/or 
structural restrictions to recognize a broad variety of ligands. Many γδ T cell 
populations exist for which the ligand has not yet been identified, making it difficult 
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to define a role for these γδ T cells. Further studies to define additional γδ T cell 
ligands and determine the crystal structures of the γδ TCR-ligand complexes are 
necessary to understand some of the remaining questions in the γδ T cell antigen 
recognition field.   
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APPENDIX I 
Mutation of DR1 βF89 residue surrounding the P1 pocket, does 
not affect DR1 susceptibility to DM  
In this Appendix I present the work I did in the context of a collaboration with Corrie 
Painter which was published at PNAS: 
Painter CA, Negroni MP, Kellersberger KA, Zavala-Ruiz Z, Evans JE, Stern LJ. 
(2011) Conformational lability in the class II MHC 310 helix and adjacent extended 
strand dictated HLA-DM susceptibility and peptide exchange. Proc Natl Acad Sci. 
Nov 29;108(48):19329-34 
 
DM facilitates CLIP peptide exchange from MHC II in endosomal compartments 
(116) favoring binding of peptides with high kinetic stability (298–300,302). This 
function of DM defines its role as a peptide editor of MHC II (116,295,308). Despite 
being the focus of many studies (113,135,176,177,224,295,296,308–310), the 
mechanism by which DM catalyzes peptide exchange on MHC II is still not clear.  
To determine the relevance of the DR1 region proximal to the P1 pocket for DM 
catalyzed peptide dissociation, DR1 was mutated at several positions surrounding 
that region. I made the βF89A mutant and studied its rate of peptide dissociation 
(Figure A1.1A and A1.1B). The rate of peptide dissociation from the βF89A mutant 
was monitored using fluorescence polarization of Alexa-488 labeled CLIP peptide 
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in complex with DR1 and exposed to excess concentration of unlabeled HA 
peptide. This experiment was performed in absence or presence of different DM 
concentrations (Figure A1.1B).  βF89A DR1 mutant had similar intrinsic peptide 
dissociation rate as the WT protein (Figure A1.1B). When DM was present during 
the reaction, βF89A showed a small increase, but not significantly different, in the 
peptide-dissociation rate compared to WT protein (Figure A1.1B). In order to test 
if the mutation introduced in DR1 affected the interaction with DM, surface plasmon 
resonance (SPR) experiments were done showing undetectable binding signal for 
both WT and βF89A mutant (Figure A1.1C).  
From these results I concluded that the DR1 βF89 residue does not play a role 
in the interaction with DM, neither in the molecular mechanism by which DM 
mediates peptide exchange.  
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Figure A1.1: DR1 βF89A mutation does not affect the rate of peptide 
exchange catalyzed by DM, neither the binding to DM. (A) Side view of the N-
terminal region of DR1 peptide-binding groove represented as a cartoon. DR1 is 
shown in red with side chains of the mutated residues shown in blue. (B) CLIP 
peptide dissociation from DR1 βF89A (top panel) and WT (bottom panel). DR1 
(150 nM) was incubated with 25 nM of Alexa-488 labeled CLIP (Ac-
VSKMRMATPLLMQ) for 3 days at 37°C in 96 well plates. Intrinsic and DM-
mediated dissociation of labeled-CLIP was monitored by fluorescence polarization 
after addition of a 100-fold excess of unlabeled HA peptide (Ac-
PKFVRQNTLRLAT). Plots show the percentage of CLIP peptide bound to DR1 
over time. Data was fitted to a single phase exponential decay. (C) DR1 binding to 
DM measured by SPR. DR1 βF89A mutant (top panel) and DR1 WT (bottom 
panel) were immobilized on the Chip and 2.5 μM DM was injected in the mobile 
phase. For WT protein, several concentrations of DM were tested, from 0 to 2.5 
μM. 
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APPENDIX II 
Studies on EPCR as a possible ligand for the γδNKT TCR. 
In this Appendix II I present work I did to test if EPCR is the ligand recognized by 
Vγ1.1Vδ6.3 TCR. This work relates to the research presented on Chapter IV.  
 
Preliminary data from Dr. Kang’s lab showed that EPCR-deficient Procr-/- mice 
have altered number of Vγ1.1+ Vδ6.3+ γδNKT cells in the liver, and no effect was 
observed on other γδ T cell populations. These results suggest that EPCR has an 
important role in the development and/or survival of γδNKT cells, which may 
involve TCR activation through recognition of EPCR.  
EPCR is an MHC I-like molecule that shares high similarity with CD1d (311). 
EPCR, as well as CD1d, also binds lipids on a lipid-binding groove located at the 
extracellular domain (312). It was previously shown that EPCR is the ligand of a 
human γδTCR, and it was suggested that the EPCR recognition does not depend 
on the lipid present on the EPCR groove (80). Instead, the EPCR recognition by 
the γδTCR seems to depend on CMV infection or cellular trasnformation of the 
recognized cells, suggesting that EPCR is necessary but not sufficient for TCR 
recognition and activation (80).  
Taking into account that Vγ1.1Vδ6.3 TCR+ hybridomas, described in Chapter 
IV, are activated with immortalized macrophages and the activation increases 
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when the macrophages are previously infected with Listeria, I decided to test if the 
Vγ1.1Vδ6.3 TCR ligand present on the immortalized macrophages is EPCR.  
First, I studied if EPCR is present on immortalized macrophage cell surface, since 
this would be required to be the Vγ1.1Vδ6.3 TCR ligand. For this purpose I stained 
immortalized macrophages using a fluorescently labeled anti-EPCR antibody, and 
measure by flow cytometry the fluorescence intensity on the cells. I observed that 
the staining achieved with the anti-EPCR antibody was similar to the staining 
observed with an isotype control antibody, indicating that the EPCR level on the 
immortalized macrophages surface is low (Figure A2.1 left panel, isotype control 
versus uninfected). Then, we wanted to test if these low levels of EPCR increase 
during Listeria infection, explaining why infected immortalized macrophages can 
induce a stronger activation of the Vγ1.1Vδ6.3 TCR+ hybridomas. It was observed 
that immortalized macrophages infected with Listeria (Listeria-infection protocol 
described in Chapter IV) (Figure A2.1, Listeria infected samples) express low 
levels of EPCR on their cell surface, similar to uninfected macrophages, which 
does not provide a mechanism to explain why infected macrophages cause a 
stronger activation of the  Vγ1.1Vδ6.3 TCR+ hybridomas than uninfected 
macrophages. It is possible that the Listeria infection does not affect the TCR 
ligand expression level on the macrophages, but instead it induces some 
modification on the TCR ligand without affecting the expression level.  
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Figure A2.1: Immortalized macrophages express low levels of EPCR and 
these levels are not affected in Listeria-infected macrophages. Immortalized 
macrophages were cultured in media without antibiotic. PBS with or without 
Listeria was added to each well in order to infect or not the cells with an MOI of 5. 
After 1 hour of incubation at 37 °C, the supernatant was replaced for media with 
gentamicin and the cells were incubated for 4 hours. Then, the cells were 
harvested using 0.48 mM EDTA, treated with anti-FcR and stained using an 
antibody anti-EPCR labeled with PE (Ab αEPCR-PE) (BD Biosciences, cat # 
566337) or an isotype control antibody (PE Rat IgG2b, BD Biosciences, cat # 
555848). On the left panel is shown a histogram representing the result from one 
experiment. On the right panel, each bar represents the average of the mean 
fluorescence intensity (MFI) of two independent experiments with the standard 
deviation. The statistical analysis was done with a paired T-test.   
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Despite the mechanism involved in the ligand recognition by Vγ1.1Vδ6.3 TCR 
before and after Listeria infection of the immortalized macrophages, modification 
of the ligand expression level on the macrophages should cause a difference in 
the activation level of the Vγ1.1Vδ6.3 TCR+ hybridomas. Therefore, to test if EPCR 
is the TCR ligand on the immortalized macrophages, I modified the EPCR 
expression level on these cells.  
First, I tried to knock down the EPCR expression on the immortalized 
macrophages. However, since the EPCR expression level on the immortalized 
macrophages was very low (Figure A2.1), it was not possible to test if the different 
knock down mechanisms I tested were effective on decreasing the expression. It 
was not possible to test if the EPCR level was lower or null compared to the already 
extremely low level that immortalized macrophages express.  
Second, I tried to overexpress EPCR on the immortalized macrophages and 
test if it could induce a stronger activation of the Vγ1.1Vδ6.3 TCR+ hybridomas. I 
transfected the immortalized macrophages with lentivirus carrying the pCDH 
vector either with the EPCR sequence (Figure A2.2 , pCDH-EPCR+, EPCR-HI) or 
with the empty vector as a control (Figure A2.2, pCDH-empty, control) and tested 
the EPCR expression level by flow cytometry using a fluorescent anti-EPCR 
antibody. It was observed that the EPCR expression level on the surface of 
immortalized macrophages transfected with the pCDH-empty vector was not 
affected compared to the EPCR levels on the non-transfected immortalized   
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Figure A2.2: Overexpression of EPCR on immortalized macrophages does 
not induce stronger activation of the Vγ1.1Vδ6.3 TCR+ hybridomas. (A) 
Immortalized macrophages not transfected (blue, Original cells), or transfected 
with pCDH empty vector (red, pCDH-empty) or with pCDH vector carrying the 
EPCR sequence (pCDH-EPCT+) were stained with PE-labeled anti-EPCR 
antibody (Ab αEPCR-PE) and the staining intensity was measured by flow 
cytometry and represented in a histogram. (B) Hybridomas expressing different  
Vγ1.1Vδ6.3 TCR variants (2-10, 3-10, 6-10,10-10 described in Chapter IV) were 
co-cultured with uninfected immortalized macrophages (solid and striped blue 
bars) or Listeria-infected immortalized macrophages (solid or striped orange bars) 
which were previously transfected with the empty pCDH vector (control, solid bars) 
or with the pCDH-EPCR vector (EPCR-HI, striped bars). The activation of the 
hybridomas was measured as the IL-2 level present in the media measured by 
ELISA. (C) Same as in B panel but using hybridomas that do not express a TCR 
on the surface (13-10 and No TCR) or hybridomas that express an αβTCR 
(abTCR). Panel B and C show the average of three independent experiments, and 
the error bars represent the standard deviation of the average. The statistical 
analysis was done with a paired T test.  
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macrophages (Figure A2.2A, pCDH-empty versus Original cells), but there was a 
significant increase on the EPCR level on the immortalized macrophages 
transfected with the pCDH-EPCR vector (Figure A2.2A, pCDH-EPCR). Then. I 
used the transfected immortalized macrophages to test if the EPCR 
overexpression induces a stronger activation of the Vγ1.1Vδ6.3 TCR+ hybridomas. 
I co-cultured the Vγ1.1Vδ6.3 TCR+ hybridomas with uninfected (Figure A2.2B, 
solid and striped blue bars) or Listeria-infected immortalized macrophages (Figure 
A2.2B, solid and striped orange bars) which were transfected with the pCDH-
empty (Figure A2.2B, solid bars, Control) or pCDH-EPCR vector (Figure A2.2B, 
striped bars, EPCR-HI). This experiment showed that uninfected, as well as 
Listeria-infected immortalized macrophages overexpressing EPCR did not induce 
a stronger activation of the Vγ1.1Vδ6.3 TCR+ hybridomas compared to the 
immortalized macrophages transfected with the control vector, pCDH-empty. 
These results indicate that the EPCR expression level on the surface of 
immortalized macrophages does not influence the strength with which these cells 
can activate the Vγ1.1Vδ6.3 TCR+ hybridomas, suggesting that EPCR is not 
involved in the TCR activation.  
Despite the fact that preliminary data suggested that EPCR could be the 
Vγ1.1Vδ6.3 TCR ligand, none of the results presented here support that 
preliminary data. If EPCR were the Vγ1.1Vδ6.3 TCR ligand and the responsible 
for the Vγ1.1Vδ6.3 TCR+ hybridomas activation, I would expect to see a clear 
EPCR expression on the immortalized macrophages, but instead I observed an 
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extremely low level, sometimes undetectable. Even if the low level of EPCR 
present on the immortalized macrophages was the responsible of activating the 
Vγ1.1Vδ6.3 TCR+ hybridomas, increasing its expression levels on the 
macrophages should have cause a stronger activation of the Vγ1.1Vδ6.3 TCR+ 
hybridomas. However, higher levels of EPCR on the immortalized macrophage 
surface did not cause an increase in the activation of the hybridomas. All these 
data together indicate that EPCR is not the ligand of the Vγ1.1Vδ6.3 TCR. 
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